Appendix 17b: Forest plots for clinical evidence reviews on pharmacological interventions

SSRIs (OCD, adults)

Clomipramine (OCD, adults)

TCAs (OCD)

SNRIs (OCD)

MAOIs (OCD)

Anxiolytics (OCD)

Other Pharmacological (OCD)

Augmentation (OCD)

SSRIs (OCD, children)

Clomipramine (OCD, children)


Pharmacological (BDD)

SSRIs (OCD, adults)

Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 01 Adverse events



Comparison: 01 SSRIs vs placebo (acute phase)


Outcome: 02 Serious adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine				
Kamijima 2004	3/95	3/94		0.99 [0.20, 4.78]
Subtotal (95% CI) Total events: 3 (SSRI), 3 (Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.01 (P =		94		0.99 [0.20, 4.78]
Total (95% CI) Total events: 3 (SSRI), 3 (Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.01 (P =		94		0.99 [0.20, 4.78]
		0.:	1 0.2 0.5 1 2 5 10	
			Favours SSRI Favours Placebo	

Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 03 Suicide attempts



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 04 Leaving study early

ubtotal (95% CI) otal events: 46 (SSRI), 17 (Placebo) est for heterogeneity: not applicable est for overall effect: Z = 0.36 (P = 0.72 2 Fluoxetine lenike 1997 Montgomery 1993 ubtotal (95% CI) otal events: 45 (SSRI), 18 (Placebo) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine Goodman 1989	4/23 41/160 183 (P = 0.76), ² = 0%	17/101 101 3/21 15/57 78		0.91 [0.55, 1.51] 0.91 [0.55, 1.51] 1.22 [0.31, 4.82] 0.97 [0.59, 1.62] 1.00 [0.62, 1.62]
Montgomery 2001 ubtotal (95% CI) otal events: 46 (SSRI), 17 (Placebo) est for heterogeneity: not applicable est for overall effect: Z = 0.36 (P = 0.72 2 Fluoxetine lenike 1997 Montgomery 1993 ubtotal (95% CI) otal events: 45 (SSRI), 18 (Placebo) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine Goodman 1989	300 4/23 41/160 183 (P = 0.76), I ² = 0%	101 3/21 15/57		0.91 [0.55, 1.51] 1.22 [0.31, 4.82] 0.97 [0.59, 1.62]
otal events: 46 (SSRI), 17 (Placebo) est for heterogeneity: not applicable est for overall effect: Z = 0.36 (P = 0.72 2 Fluoxetine lenike 1997 Montgomery 1993 ubtotal (95% CI) otal events: 45 (SSRI), 18 (Placebo) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine Goodman 1989	4/23 41/160 183 (P = 0.76), ² = 0%	3/21 15/57		0.91 [0.55, 1.51] 1.22 [0.31, 4.82] 0.97 [0.59, 1.62]
est for heterogeneity: not applicable est for overall effect: Z = 0.36 (P = 0.72 2 Fluoxetine enike 1997 dontgomery 1993 ubtotal (95% CI) otal events: 45 (SSRI), 18 (Placebo) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine Goodman 1989	4/23 41/160 183 (P = 0.76), 2 = 0%	15/57		1.22 [0.31, 4.82] 0.97 [0.59, 1.62]
est for overall effect: Z = 0.36 (P = 0.72 2 Fluoxetine enike 1997 dontgomery 1993 ubtotal (95% CI) otal events: 45 (SSRI), 18 (Placebo) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine ecodman 1989	4/23 41/160 183 (P = 0.76), 2 = 0%	15/57		0.97 [0.59, 1.62]
2 Fluoxetine enike 1997 fortgomery 1993 ubtotal (95% CI) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 8 Fluvoxamine Goodman 1989	4/23 41/160 183 (P=0.76), 2 = 0%	15/57		0.97 [0.59, 1.62]
enike 1997 fontgomery 1993 ubtotal (95% Ct) otal events: 45 (SSRI), 18 (Placebo) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine Goodman 1989	41/160 183 (P = 0.76), ² = 0%)	15/57		0.97 [0.59, 1.62]
Montgomery 1993 ubtotal (95% Cl) otal events: 45 (SSRI), 18 (Placebo) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine Goodman 1989	41/160 183 (P = 0.76), ² = 0%)	15/57		0.97 [0.59, 1.62]
ubtotal (95% CI) otal events: 45 (SSRI), 18 (Placebo) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99) 3 Fluvoxamine Goodman 1989	183 (P = 0.76), l² = 0%)		*	0.97 [0.59, 1.62]
otal events: 45 (SSRI), 18 (Placebo) est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine Goodman 1989	(P = 0.76), I ² = 0%)	78		1.00 [0.62, 1.62]
est for heterogeneity: Chi² = 0.09, df = 1 est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine Goodman 1989)`			
est for overall effect: Z = 0.02 (P = 0.99 3 Fluvoxamine Goodman 1989)`			
3 Fluvoxamine Goodman 1989				
∂oodman 1989	2/22			
	2/22			
	2/23	6/23	← +	0.33 [0.07, 1.48]
Goodman 1996	23/80	17/80	+-	1.35 [0.78, 2.33]
Hollander 2003b	43/127	31/126	 -	1.38 [0.93, 2.03]
lenike 1990a	0/18	0/20		Not estimable
fallya 1992	5/19	6/20		0.88 [0.32, 2.40]
erse 1987	1/10	1/10	+	→ 1.00 [0.07, 13.87]
ubtotal (95% CI)	277	279	◆	1.21 [0.91, 1.62]
otal events: 74 (SSRI), 61 (Placebo)				
est for heterogeneity: Chi² = 3.85, df = 4	l (P = 0.43), l ² = 0%			
est for overall effect: Z = 1.30 (P = 0.19)			
4 Paroxetine				
	28/82	20/77	+-	1.31 [0.81, 2.13]
	53/259	15/89	 	1.21 [0.72, 2.04]
	49/201	39/99	 -∫	0.62 [0.44, 0.87]
ubtotal (95% CI)	542	265	•	0.91 [0.71, 1.16]
otal events: 130 (SSRI), 74 (Placebo)				
est for heterogeneity: Chi² = 8.21 , df = 2 est for overall effect: Z = 0.76 (P = 0.45	, ,,	%		
,	,			
5 Sertraline Chouinard 1990	3/43	7/44		0.44 [0.12, 1.59]
	65/241	24/84		0.94 [0.63, 1.40]
lenike 1990b	0/10	0/9	7	Not estimable
	25/86	25/81		0.94 [0.59, 1.50]
ubtotal (95% CI)	380	23/81	<u> </u>	0.89 [0.67, 1.20]
otal events: 93 (SSRI), 56 (Placebo)	000	210	T	0.05 (0.07, 1.20)
est for heterogeneity: Chi² = 1.30, df = 2	2 (P = 0.52) P = 0%			
est for overall effect: Z = 0.76 (P = 0.44	, ,,			
otal (95% CI)	1682	941		0.98 [0.85, 1.13]
otal events: 388 (SSRI), 226 (Placebo)			Ť	,,
est for heterogeneity: Chi² = 16.94, df =	13 (P = 0.20), I ² = 23	.3%		
est for overall effect: Z = 0.26 (P = 0.79				
			· · · · · · · · · · · · · · · · · · ·	10
			Favours SSRI Favours placeb	

Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 05 Leaving study early due to adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
D1 Citalopram				
Montgomery 2001	14/300	2/101		2.36 [0.54, 10.19]
Subtotal (95% CI)	300	101		2.36 [0.54, 10.19]
otal events: 14 (SSRI), 2 (Plac		101		2:00 (0:04, 10:15)
Test for heterogeneity: not app	-			
Test for overall effect: Z = 1.15				
02 Fluoxetine				
Beasley 1992	59/266	2/89		9.87 [2.46, 39.57]
Montgomery 1993	7/160	2/57		1.25 [0.27, 5.83]
Subtotal (95% CI)	426	146		5.59 [2.06, 15.16]
otal events: 66 (SSRI), 4 (Plac		210		0:05 (2:00, 10:10)
est for heterogeneity: Chi² = 4	•	8%		
est for overall effect: Z = 3.38		0.00		
03 Fluvoxamine				
Goodman 1989	2/23	0/23		<u> </u>
Goodman 1996	15/80	6/80		2.50 [1.02, 6.12]
Hollander 2003b	23/127	8/126	<u> </u>	2.85 [1.33, 6.13]
Subtotal (95% CI)	230	229	👗	2.78 [1.57, 4.92]
otal events: 40 (SSRI), 14 (Pla		223		2.70 [1.57, 4.52]
est for heterogeneity: Chi² = 0	,			
est for neterogeneity. Crif = 0 [est for overall effect: Z = 3.51				
04 Paroxetine				
Burnham 1993	15/82	8/77	+-	1.76 [0.79, 3.92]
Hollander 2003d	29/259	7/89	 -	1.42 [0.65, 3.14]
Kamijima 2004	9/95	9/96		1.01 [0.42, 2.43]
Zohar 1996a	18/201	6/99	 •	1.48 [0.61, 3.61]
Subtotal (95% CI)	637	361	•	1.41 [0.93, 2.14]
iotal events: 71 (SSRI), 30 (Pla	acebo)			
[est for heterogeneity: Chi² = 0).86, df = 3 (P = 0.84), l² = 0%			
Fest for overall effect: Z = 1.62	2 (P = 0.11)			
05 Sertraline				
Chouinard 1990	1/43	0/44	-	— 3.07 [0.13, 73.30]
Greist 1995a	23/241	5/84	 	1.60 [0.63, 4.08]
Kronig 1999	9/86	4/81	+	2.12 [0.68, 6.61]
Subtotal (95% CI)	370	209	-	1.84 [0.91, 3.71]
otal events: 33 (SSRI), 9 (Plac	ebo)		-	
est for heterogeneity: Chi² = 0	0.24, df = 2 (P = 0.89), l ² = 0%			
est for overall effect: Z = 1.70) (P = 0.09)			
Total (95% CI)	1963	1046	•	2.15 [1.62, 2.86]
Total events: 224 (SSRI), 59 (P	lacebo)			
Test for heterogeneity: Chi² = 1 Test for overall effect: Z = 5.30	1.30, df = 12 (P = 0.50), $I^2 = 0$	1%		
		0.01	0.1 1 10	100
		0.01	Favours SSRI Favours placeb	


Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 06 Non-responders (OCD) (CGI or Y-BOCS)

Study SSRI

or sub-cetegory pM



0.90 [0.69, 1.18]

0.90 [0.69, 1.18]

10

18/23

23

20/23

23

0.1 0.2

0.5

Favours SSRI Favours placebo


Goodman 1989

Subtotal (95% CI)

Total events: 18 (SSRI), 20 (Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.77 (P = 0.44)

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 08 Non-remitters



Favours SSRI Favours placebo

Review: Comparison: Outcome: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) 09 Y-BOCS

Test for heterogeneity: not applicable Test for overall effect: Z = 2.77 (P = 0.006 D2 Fluoxetine Beasley 1992 75 Jenike 1997 19 Montgomery 1993 52 Subtotal (95% CI) 146 Test for heterogeneity: Chi² = 2.03, df = 2 ITest for overall effect: Z = 3.66 (P = 0.000 D3 Fluvoxamine Goodman 1989 21 Goodman 1996 78 Hollander 2003b 17 Jenike 1990a 18 Subtotal (95% CI) 234 Test for heterogeneity: Chi² = 5.39, df = 3 ITest for overall effect: Z = 4.88 (P < 0.000 D4 Paroxetine Burnham 1993 79 Kamijima 2004 94 Subtotal (95% CI) 98 Subtotal (95% CI) 98 Subtotal (95% CI) 99 Samijima 2004 94 Subtotal (95% CI) 98 Subtotal (95% CI) 98 Subtotal (95% CI) 98 Subtotal (95% CI) 98 Subtotal (95% CI) 99 Subtotal (95% CI) 971	18.90(8.30) 16.20(6.30) -5.13(6.41) (P = 0.36), P = 1.5% 2) 19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	101 101 76 18 56 150 21 78 120 20 239	-5.60(6.90) 23.60(7.50) 18.70(6.10) -3.70(5.98) 28.00(7.00) -1.71(4.88) -5.60(7.67) 21.80(7.60)	- - -	-0.39 [-0.67, -0.11] -0.39 [-0.67, -0.11] -0.59 [-0.92, -0.27] -0.39 [-1.05, 0.26] -0.23 [-0.61, 0.15] -0.43 [-0.66, -0.20] -1.21 [-1.87, -0.54] -0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12] -0.48 [-1.12, 0.17]
Subtotal (95% CI) 102 Fest for heterogeneity: not applicable Fest for overall effect: Z = 2.77 (P = 0.006) 102 Fluoxetine Beasley 1992 75 Jenike 1997 19 Montgomery 1993 52 Subtotal (95% CI) 146 Fest for heterogeneity: Chi² = 2.03, df = 2.07 Fest for overall effect: Z = 3.66 (P = 0.000) 103 Fluvoxamine Goodman 1989 21 Goodman 1989 21 Goodman 1996 78 Hollander 2003b 117 Jenike 1990a 18 Subtotal (95% CI) 234 Fest for heterogeneity: Chi² = 5.39, df = 3.1 Fest for overall effect: Z = 4.88 (P < 0.000) 104 Paroxetine Burnham 1993 79 Kamijima 2004 94 Subtotal (95% CI) 371	18.90(8.30) 16.20(6.30) -5.13(6.41) (P=0.36), P=1.5% 2) 19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	101 76 18 56 150 21 78 120 20	23.60(7.50) 18.70(6.10) -3.70(5.98) 28.00(7.00) -1.71(4.88) -5.60(7.67)	- - -	-0.39 [-0.67, -0.11] -0.59 [-0.92, -0.27] -0.39 [-1.05, 0.26] -0.23 [-0.61, 0.15] -0.43 [-0.66, -0.20] -1.21 [-1.87, -0.54] -0.40 [-0.71, -0.88] -0.38 [-0.64, -0.12]
Test for heterogeneity: not applicable Test for overall effect: Z = 2.77 (P = 0.006 02 Fluoxetine Beasley 1992 75 Jenike 1997 19 Montgomery 1993 52 Subtotal (95% C) 146 Test for heterogeneity: Chi² = 2.03, df = 2 I Test for overall effect: Z = 3.66 (P = 0.000 03 Fluvoxamine Goodman 1989 21 Goodman 1996 78 Hollander 2003b 117 Jenike 1990a 18 Subtotal (95% C) 234 Test for overall effect: Z = 4.88 (P < 0.000 04 Paroxetine Burnham 1993 79 Kamijima 2004 94 Zohar 1996a 198	18.90(8.30) 16.20(6.30) -5.13(6.41) (P = 0.36), P = 1.5% 2) 19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	76 18 56 150 21 78 120 20	18.70(6.10) -3.70(5.98) 28.00(7.00) -1.71(4.88) -5.60(7.67)	* *	-0.59 [-0.92, -0.27] -0.39 [-1.05, 0.26] -0.23 [-0.61, 0.15] -0.43 [-0.66, -0.20] -1.21 [-1.87, -0.54] -0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
Test for overall effect: Z = 2.77 (P = 0.006 02 Fluoxetine Beasley 1992 75 Jenike 1997 19 Montgomery 1993 52 Subtotal (95% CI) 146 Test for heterogeneity: Chi² = 2.03, df = 21 Test for overall effect: Z = 3.66 (P = 0.000 03 Fluvoxamine Goodman 1989 21 Goodman 1989 21 Goodman 1996 78 Hollander 2003b 117 Jenike 1990a 118 Subtotal (95% CI) 234 Test for heterogeneity: Chi² = 5.39, df = 31 Test for overall effect: Z = 4.86 (P < 0.000 04 Paroxetine Burnham 1993 79 Kantijima 2004 94 Kohart 1996a 198 Subtotal (95% CI) 371	18.90(8.30) 16.20(6.30) -5.13(6.41) (P = 0.36), P = 1.5% 2) 19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	18 56 150 21 78 120 20	18.70(6.10) -3.70(5.98) 28.00(7.00) -1.71(4.88) -5.60(7.67)		-0.39 [-1.05, 0.26] -0.23 [-0.61, 0.15] -0.43 [-0.66, -0.20] -1.21 [-1.87, -0.54] -0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
22 Fluoxetine Beasley 1992 75 Jenike 1997 19 Montgomery 1993 52 Subtotal (95% CI) 146 Test for heterogeneity: Chi² = 2.03, df = 2 i Test for overall effect: Z = 3.66 (P = 0.000 33 Fluoxamine Goodman 1989 21 Goodman 1989 21 Goodman 1996 78 Hollander 2003b 117 Jenike 1990a 18 Subtotal (95% CI) 234 Test for heterogeneity: Chi² = 5.39, df = 3 i Test for overall effect: Z = 4.88 (P < 0.000 44 Paroxetine Burnham 1993 79 Kamijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 9371	18.90(8.30) 16.20(6.30) -5.13(6.41) (P = 0.36), P = 1.5% 2) 19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	18 56 150 21 78 120 20	18.70(6.10) -3.70(5.98) 28.00(7.00) -1.71(4.88) -5.60(7.67)	- -	-0.39 [-1.05, 0.26] -0.23 [-0.61, 0.15] -0.43 [-0.66, -0.20] -1.21 [-1.87, -0.54] -0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
Beasley 1992 75 Jenike 1997 19 19 Montgomery 1993 52 Subtotal (95% CI) 146 Test for heterogeneity: Chi² = 2.03, df = 2 Test for overall effect: Z = 3.66 (P = 0.000 20 Test for overall effect: Z = 3.66 (P = 0.000 20 Test for overall effect: Z = 3.66 (P = 0.000 20 Test for overall effect: Z = 3.66 (P = 0.000 20 Test for heterogeneity: Chi² = 5.39, df = 3 Test for heterogeneity: Chi² = 5.39, df = 3 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000 20 Test for overall effect: Z = 4.88 (P < 0.000	16.20(6.30) -5.13(6.41) (P = 0.36), P = 1.5% 2) 19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	18 56 150 21 78 120 20	18.70(6.10) -3.70(5.98) 28.00(7.00) -1.71(4.88) -5.60(7.67)	- -	-0.39 [-1.05, 0.26] -0.23 [-0.61, 0.15] -0.43 [-0.66, -0.20] -1.21 [-1.87, -0.54] -0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
Jenike 1997 19 Montgomery 1993 52 Subtotal (95% CI) 146 Fest for heterogeneity: Chi² = 2.03, df = 2 Fest for overall effect: Z = 3.66 (P = 0.000 Ja Fluvoxamine 21 Goodman 1998 21 Goodman 1996 78 Hollander 2003b 117 Jenike 1990a 18 Subtotal (95% CI) 234 Fest for heterogeneity: Chi² = 5.39, df = 3 Fest for overall effect: Z = 4.88 (P < 0.000 Ja Paroxetine 21 Burnham 1993 79 Karnijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371	16.20(6.30) -5.13(6.41) (P = 0.36), P = 1.5% 2) 19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	18 56 150 21 78 120 20	18.70(6.10) -3.70(5.98) 28.00(7.00) -1.71(4.88) -5.60(7.67)		-0.39 [-1.05, 0.26] -0.23 [-0.61, 0.15] -0.43 [-0.66, -0.20] -1.21 [-1.87, -0.54] -0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
Montgomery 1993 52 Subtotal (95% CI) 146 Test for heterogeneity: Chi² = 2.03, df = 21 Test for overall effect: Z = 3.66 (P = 0.000 33 Fluvoxamine Goodman 1989 21 Goodman 1989 78 Hollander 2003b 117 Jenike 1990a 18 Subtotal (95% CI) 234 Test for heterogeneity: Chi² = 5.39, df = 31 Test for overall effect: Z = 4.88 (P < 0.000 44 Paroxetine Burnham 1993 79 Kanijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371	-5.13(6.41) (P = 0.36), P = 1.5% 2) 19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	21 78 120 20	-3.70(5.98) 28.00(7.00) -1.71(4.88) -5.60(7.67)	-	-0.23 [-0.61, 0.15] -0.43 [-0.66, -0.20] -1.21 [-1.87, -0.54] -0.40 [-0.71, -0.81] -0.38 [-0.64, -0.12]
Subtotal (95% CI) 146 Test for heterogeneity: Chi² = 2.03, df = 2: Test for overall effect: Z = 3.66 (P = 0.000 D3 Fluvoxamine Goodman 1989 21 Goodman 1989 117 Jenike 1990a 18 Subtotal (95% CI) 234 Test for heterogeneity: Chi² = 5.39, df = 3: Test for overall effect: Z = 4.88 (P < 0.000 D4 Paroxetine Burnham 1993 79 Kamijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 94 Subtotal (95% CI) 97	(P = 0.36), P = 1.5% 2) 19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	150 21 78 120 20	28.00(7.00) -1.71(4.88) -5.60(7.67)	* 	-0.43 [-0.66, -0.20] -1.21 [-1.87, -0.54] -0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
Test for heterogeneity: Chi² = 2.03, df = 2 lest for overall effect: Z = 3.66 (P = 0.000) D3 Fluvoxamine Goodman 1989 21 Goodman 1996 78 Hollander 2003b 117 Jaenike 1990a 18 Subtotal (95% Cl) 234 Test for heterogeneity: Chi² = 5.39, df = 3 in the state for overall effect: Z = 4.88 (P < 0.000)	19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	21 78 120 20	-1.71(4.88) -5.60(7.67)	•	-1.21 [-1.87, -0.54] -0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
Fest for overall effect: Z = 3.66 (P = 0.000) 33 Fluvoxamine Goodman 1989 21 Goodman 1996 78 Hollander 2003b 11.7 Jenike 1990a 18 Subtotal (95% Cl) 234 Fest for heterogeneity: Chi² = 5.39, df = 3 If est for overall effect: Z = 4.88 (P < 0.000) 44 Peroxetine Burnham 1993 79 Karnijima 2004 94 Subtotal (95% Cl) 371	19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	78 120 20	-1.71(4.88) -5.60(7.67)	-	-0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
3 Fluvoxamine Goodman 1989 21 Goodman 1996 78 Hollander 2003b 117 Jenike 1990a 18 Subtotal (95% CI) 234 Test for heterogeneity: Chi² = 5.39, df = 31 Test for overall effect: Z = 4.88 (P < 0.000 4 Paroxetine Burnham 1993 79 Kamijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371	19.40(7.00) -3.95(6.28) -8.50(7.57) 18.80(4.00)	78 120 20	-1.71(4.88) -5.60(7.67)	-	-0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
Goodman 1989 21	-3.95(6.28) -8.50(7.57) 18.80(4.00)	78 120 20	-1.71(4.88) -5.60(7.67)		-0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
Goodman 1996 78 Hollander 2003b 117 Jenike 1990a 18 Subtotal (95% CI) 234 Test for heterogeneity: Chi² = 5.39, df = 3 I Test for overall effect: Z = 4.88 (P < 0.000 04 Paroxetine Burnham 1993 79 Kamijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371	-3.95(6.28) -8.50(7.57) 18.80(4.00)	78 120 20	-1.71(4.88) -5.60(7.67)		-0.40 [-0.71, -0.08] -0.38 [-0.64, -0.12]
Hollander 2003b 117 Jenike 1990a 18 Subtotal (95% CI) 234 Fest for heterogeneity: Chi² = 5.39, df = 31 Fest for overall effect: Z = 4.88 (P < 0.000 04 Paroxetine Burnham 1993 79 Kanijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371	-8.50(7.57) 18.80(4.00)	120 20	-5.60(7.67)	-	-0.38 [-0.64, -0.12]
Jenike 1990a 18 Subtotal (95% CI) 234 lest for heterogeneity: Chi² = 5.39, df = 3 i lest for overall effect: Z = 4.88 (P < 0.000 D4 Paroxetine Burnham 1993 79 Kamijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371	18.80(4.00)	20		*	
Subtotal (95% CI) 234 fest for heterogeneity: Chi² = 5.39, df = 31 fest for overall effect: Z = 4.88 (P < 0.000 4 Paroxetine Burnham 1993 79 Kanijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371			21.80(7.60)		-0 49 (-1 12 0 171
Fest for heterogeneity: Chi² = 5.39, df = 3 i Fest for overall effect: Z = 4.88 (P < 0.000 04 Paroxetine Burnham 1993 79 Kanijima 2004 94 Zohar 1996a 198 Sulstotal (95% CI) 371		220			0.40 [1.12, 0.17]
Fest for overall effect: Z = 4.88 (P < 0.000) 14 Paroxetine Burnham 1993 79 Kanijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371		233		♦	-0.46 [-0.64, -0.27]
04 Paroxetine Burnham 1993 79 Kamijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371	(P = 0.15), I ² = 44.4%			•	
Burnham 1993 79 Kamijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371	01)				
Kamijima 2004 94 Zohar 1996a 198 Subtotal (95% CI) 371					
Zohar 1996a 198 Subtotal (95% Cl) 371	-5.61(7.47)	75	-4.60(7.53)	-	-0.13 [-0.45, 0.18]
Subtotal (95% CI) 371	-8.11(8.00)	94	-3.46(6.10)	-	-0.65 [-0.94, -0.36]
	-8.00(8.00)	99	-5.00(7.90)	-	-0.38 [-0.62, -0.13]
est for heterogeneity: Chi² = 5.56, df = 2 i		268		•	-0.40 [-0.56, -0.23]
	(P = 0.06), I ² = 64.0%			•	
Test for overall effect: $Z = 4.82 (P < 0.000)$	01)				
05 Sertraline					
Jenike 1990b 10	20.60(9.20)	8	22.30(7.80)		-0.19 [-1.12, 0.74]
Subtotal (95% Cl) 10		8			-0.19 [-1.12, 0.74]
Test for heterogeneity: not applicable				1	
est for overall effect: Z = 0.40 (P = 0.69)					
Fotal (95% CI) 863		766		•	-0.42 [-0.52, -0.32]
Test for heterogeneity: Chi² = 13.50, df = 1	1 (P = 0.26), I ² = 18.5%			,	•
「est for overall effect: Z = 8.23 (P < 0.000	01)				

Outcome: 10 NIMH-OC SMD (fixed) SMD (fixed) Study Placebo or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Citalopram Montgomery 2001 102 -2.80(2.50) 101 -1.80(2.30) -0.41 [-0.69, -0.14] Subtotal (95% CI) 102 101 -0.41 [-0.69, -0.14] Test for heterogeneity: not applicable Test for overall effect: Z = 2.92 (P = 0.003) Jenike 1997 19 7.00(1.10) 18 7.20(1.30) -0.16 [-0.81, 0.48] Subtotal (95% CI) 19 18 -0.16 [-0.81, 0.48] Test for heterogeneity: not applicable Test for overall effect: Z = 0.49 (P = 0.62) 03 Fluvoxamine Goodman 1996 78 -1.32(2.25) 78 -0.40(1.78) -0.45 [-0.77, -0.13] Jenike 1990a 20 -0.65 [-1.31, 0.00] 18 8.00(2.20) Subtotal (95% CI) 96 98 -0.49 [-0.78, -0.20] Test for heterogeneity: Chi² = 0.30, df = 1 (P = 0.59), l² = 0% Test for overall effect: Z = 3.36 (P = 0.0008) 04 Paroxetine -0.18 [-0.50, 0.13] 75 Burnham 1993 79 -1.42(2.04)-1.04(2.08)-0.38 [-0.62, -0.14] -0.31 [-0.50, -0.11] Zohar 1996a 198 -2.50(2.90) 99 -1.40(2.90) Subtotal (95% CI) Test for heterogeneity: $Chi^2 = 0.91$, df = 1 (P = 0.34), $I^2 = 0\%$ Test for overall effect: Z = 3.11 (P = 0.002)05 Sertraline Jenike 1990b 8.20(2.00) 9 9.30(2.50) -0.47 [-1.38, 0.45] Subtotal (95% CI) 10 -0.47 [-1.38, 0.45] Test for heterogeneity: not applicable Test for overall effect: Z = 1.00 (P = 0.32)Total (95% CI) 400 -0.37 [-0.50, -0.23] Test for heterogeneity: Chi² = 2.84, df = 6 (P = 0.83), l² = 0% Test for overall effect: Z = 5.39 (P < 0.00001)Favours SSRI Favours placebo OCD adults: SSRIs Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 11 General Rating Scale: compulsions SSRI SMD (fixed) SMD (fixed) Study Placebo or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Fluvoxamine -0.74 [-1.76, 0.29] Perse 1987 3.56(2.00) 5.12(2.00) Subtotal (95% CI) -0.74 [-1.76, 0.29] Test for heterogeneity: not applicable Test for overall effect: Z = 1.41 (P = 0.16) 10 Favours SSRI Favours placebo Review: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) Comparison: Outcome: 12 General Rating Scale: obsessions Study SSRI Placebo SMD (fixed) SMD (fixed) Mean (SD) Ν or sub-category Ν Mean (SD) 95% CI 95% CI 01 Fluvoxamine Perse 1987 3.07(1.98) 8 4.31(2.67) -0.50 [-1.50, 0.50] Subtotal (95% CD) -0.50 [-1.50, 0.50] Test for heterogeneity: not applicable Test for overall effect: Z = 0.98 (P = 0.33) -10 -5 10 Favours SSRI Favours placebo Review: OCD adults: SSRIs Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 13 Maudsley Obsessive Compulsive Inventory SMD (fixed) Study Placebo SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Fluvoxamine Perse 1987 8 13.87(5.32) 8 16.12(4.59) -0.43 [-1.42, 0.57] Subtotal (95% CI) -0.43 [-1.42, 0.57] Test for heterogeneity: not applicable Test for overall effect: Z = 0.84 (P = 0.40)

Favours SSRI Favours placebo

Review:

Comparison:

OCD adults: SSRIs

01 SSRIs vs placebo (acute phase)

Review: OCD adults: SSRIs Comparison: 01 SSRIs vs placebo (acute phase) 14 Obsessive-Compulsive Checklist Outcome: Study or sub-category Ν 01 Fluvoxamine Perse 1987 Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.85 (P = 0.39) Review: OCD adults: SSRIs

Placebo SMD (fixed) SMD (fixed) Mean (SD) Ν Mean (SD) 95% CI 95% CI -0.43 [-1.43, 0.56] -0.43 [-1.43, 0.56] 20.06(12.92) 26.19(13.88) -10 10

Favours SSRI Favours placebo

Favours SSRI Favours placebo

Favours SSRI Favours placebo

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 15 OCD Scale (CPRS)

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Fluoxetine										
Jenike 1997	19	6.70(2.60)	18	5.80(3.30)			=			0.30 [-0.35, 0.95]
Subtotal (95% CI)	19		18				₩.			0.30 [-0.35, 0.95]
Test for heterogeneity: not	: applicable						ľ			
Test for overall effect: Z =	0.90 (P = 0.37)									
					-10	-5	 	5	10	

Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase) 16 Beck Depression Inventory Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		5	SMD (fixed) 95% CI			SMD (fixed) 95% Cl
01 Fluvoxamine										
Perse 1987	8	9.73(7.51)	8	12.37(7.56)			-			-0.33 [-1.32, 0.66]
Subtotal (95% CI)	8		8				•			-0.33 [-1.32, 0.66]
Test for heterogeneity: not	t applicable						7			
Test for overall effect: Z =	0.66 (P = 0.51)									
-					-10	-5	-	5	10	

OCD adults: SSRIs Review:

Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 17 Hamilton Rating Scale for Depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Fluoxetine						
Montgomery 1993	52	-1.85(6.04)	56	-1.34(6.92)	<u> </u>	-0.08 [-0.46, 0.30]
Subtotal (95% CI)	52		56		•	-0.08 [-0.46, 0.30]
Test for heterogeneity: not	applicable				Ţ	,
Test for overall effect: Z =	0.40 (P = 0.69)					
02 Fluvoxamine						
Perse 1987	8	9.47(5.55)	8	12.93(5.02)		-0.62 [-1.63, 0.39]
Subtotal (95% CI)	8		8			-0.62 [-1.63, 0.39]
Test for heterogeneity: not	applicable				_	
Test for overall effect: Z =	1.20 (P = 0.23)					
Total (95% CI)	60		64		•	-0.14 [-0.50, 0.21]
Test for heterogeneity: Chi	2 = 0.96, df = 1 (P	= 0.33), I ² = 0%			٦	
Test for overall effect: Z =		**				
					-4 -2 0 2	4
					Favours SSRI Favours pl	acebo

Review: OCD adults: SSRIs Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 18 Montgomery-Asberg Depression Rating Scale SMD (fixed) SMD (fixed) Study Placebo or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Citalopram -0.32 [-0.60, -0.04] Montgomery 2001 102 -3.40(6.30) 101 -1.30(6.70) Subtotal (95% CI) 102 101 -0.32 [-0.60, -0.04] Test for heterogeneity: not applicable Test for overall effect: Z = 2.28 (P = 0.02) 02 Fluoxetine Montgomery 1993 52 -2.96(8.09) 56 -2.88(9.27) -0.01 [-0.39, 0.37] Subtotal (95% CI) 52 56 -0.01 [-0.39, 0.37] Test for heterogeneity: not applicable Test for overall effect: Z = 0.05 (P = 0.96) 03 Paroxetine Zohar 1996a 198 -3.40(7.90) 99 -0.60(7.90) -0.35 [-0.60, -0.11] -0.35 [-0.60, -0.11] Subtotal (95% CI) 198 Test for heterogeneity: not applicable Test for overall effect: Z = 2.85 (P = 0.004) Total (95% CI) 256 -0.28 [-0.44, -0.11] 352 Test for heterogeneity: $Chi^2 = 2.42$, df = 2 (P = 0.30), $I^2 = 17.2\%$ Test for overall effect: Z = 3.30 (P = 0.0010) 0.5 -0.5 Favours SSRI Favours placebo Review: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) Comparison: Outcome: 19 Hamilton Anxiety Scale Study SSRI Placebo SMD (fixed) SMD (fixed) Mean (SD) N or sub-category Ν Mean (SD) 95% CI 95% CI 01 Fluvoxamine Perse 1987 7.69(3.60) 12.37(7.56) -0.75 [-1.77, 0.28] Subtotal (95% CI) -0.75 [-1.77, 0.28] Test for heterogeneity; not applicable Test for overall effect: Z = 1.43 (P = 0.15) -10 10 Favours SSRI Favours placebo OCD adults: SSRIs Review: Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 20 Clinical Global Impression SSRI SMD (fixed) SMD (fixed) Study Placebo or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 01 Fluoxetine Jenike 1997 19 3.10(1.00) 18 3.20(1.00) -0.10 [-0.74, 0.55] -0.10 [-0.74, 0.55] Subtotal (95% CI) 19 Test for heterogeneity: not applicable Test for overall effect: Z = 0.30 (P = 0.77) -10 10 -5 Favours SSRI Favours placebo Review: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) Comparison: 21 Clinical Global Impressions: severity Outcome: Study SSRI Placebo SMD (fixed) SMD (fixed) Mean (SD) Ν Mean (SD) 95% CI or sub-category 95% CI 01 Paroxetine Zohar 1996a 194 -1.20(1.40) 99 -0.70(1.30) -0.36 [-0.61, -0.12] Subtotal (95% CI) 194 99 -0.36 [-0.61, -0.12] Test for heterogeneity: not applicable Test for overall effect: Z = 2.93 (P = 0.003) -10 -5 0 5 10 Favours SSRI Favours placebo OCD adults: SSRIs Review: Comparison 01 SSRIs vs placebo (acute phase) Outcome: 22 Sheehan Disability Scale: family Study SSRI Placebo SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI

> -0.33 [-0.61, -0.06] -0.33 [-0.61, -0.06]

102

-1.80(2.40)

101

-1.00(2.40)

Favours SSRI Favours placebo

01 Citalopram Montgomery 2001

Test for heterogeneity: not applicable Test for overall effect: Z = 2.35 (P = 0.02)

01 SSRIs vs placebo (acute phase) 23 Sheehan Disability Scale: social Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			SMD (fixe 95% CI			SMD (fixed) 95% Cl
O1 Citalopram Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		-2.00(2.20)	101 101	-1.30(2.00)			•			-0.33 [-0.61, -0.05] -0.33 [-0.61, -0.05]
					-10	-5	ó	5	10	
						Favours	SSRI Fa	vours plac	ebo	

Review: Comparison: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) Outcome: 24 Sheehan Disability Scale: work

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	S	MD (fixed) 95% CI		SMD (fixed) 95% Cl
01 Citalopram								
Montgomery 2001	102	-1.90(2.40)	101	-1.10(2.10)				-0.35 [-0.63, -0.08]
Subtotal (95% CI)	102		101			•		-0.35 [-0.63, -0.08]
Test for heterogeneity: not a	pplicable					Ì		
Test for overall effect: $Z = 2$.50 (P = 0.01)							

Review: OCD adults: SSRIs

01 SSRIs vs placebo (acute phase) Comparison: Outcome: 25 Symptom Checklist-90

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)) (fixed) 5% Cl			SMD (fixed) 95% Cl
01 Paroxetine										
Zohar 1996a	169	-29.00(47.10)	77	-19.50(37.30)						-0.21 [-0.48, 0.06]
Subtotal (95% CI)	169		77				4			-0.21 [-0.48, 0.06]
Test for heterogeneity: not	t applicable						1			
Test for overall effect: Z =	1.55 (P = 0.12)									
					-10	-5	<u> </u>	5	10	

Favours SSRI Favours placebo

Favours SSRI Favours placebo

OCD adults: SSRIs Review:

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 26 Subanalysis: Y-BOCS in patients with comorbid depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
02 Fluoxetine						
Beasley 1992	75	18.90(8.30)	76	23.60(7.50)	-	-0.59 [-0.92, -0.27]
Montgomery 1993	52	-5.13(6.41)	56	-3.70(5.98)	- 	-0.23 [-0.61, 0.15]
Subtotal (95% CI)	127		132		•	-0.44 [-0.68, -0.19]
Test for heterogeneity: Chi² =	= 2.02, df = 1 (P	= 0.16), I ² = 50.4%			*	•
Test for overall effect: $Z = 3$.	47 (P = 0.0005)					
03 Fluvoxamine						
Goodman 1989	21	19.40(7.00)	21	28.00(7.00)		-1.21 [-1.87, -0.54]
Subtotal (95% CI)	21		21		•	-1.21 [-1.87, -0.54]
Test for heterogeneity: not ap	pplicable				-	
Test for overall effect: $Z = 3$.	56 (P = 0.0004)	l				
04 Paroxetine						
Kamijima 2004	94	-8.11(8.00)	94	-3.46(6.10)	-	-0.65 [-0.94, -0.36]
Subtotal (95% CI)	94		94		•	-0.65 [-0.94, -0.36]
Test for heterogeneity: not ap	pplicable				•	
Test for overall effect: $Z = 4$.	35 (P < 0.0001)	l				
Total (95% CI)	242		247		•	-0.58 [-0.76, -0.40]
Test for heterogeneity: Chi ² =	6.94, df = 3 (P	= 0.07), I ² = 56.8%			•	
Test for overall effect: $Z = 6$.	22 (P < 0.00001)				

Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 27 Subanalysis: Non-responders (OCD) (CGI or Y-BOCS) in patients with comorbid depression

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
02 Fluoxetine				
Beasley 1992	190/266	82/89	-	0.78 [0.70, 0.85]
Montgomery 1993	92/160	46/57		0.71 [0.59, 0.86]
Subtotal (95% CI)	426	146	•	0.75 [0.69, 0.82]
Total events: 282 (SSRI), 128	3 (Placebo)		-	
Test for heterogeneity: Chi2 :	$= 0.69$, df $= 1 (P = 0.41)$, $I^2 = 0$?	6		
Test for overall effect: $Z = 6$.18 (P < 0.00001)			
04 Paroxetine				
Kamijima 2004	48/95	74/96		0.66 [0.52, 0.82]
Subtotal (95% CI)	95	96		0.66 [0.52, 0.82]
Total events: 48 (SSRI), 74 (I	Placebo)		_	
Test for heterogeneity: not a	pplicable			
Test for overall effect: $Z = 3$.65 (P = 0.0003)			
Total (95% CI)	521	242	•	0.73 [0.66, 0.79]
Total events: 330 (SSRI), 202			•	,
	= 2.58, df = 2 (P = 0.28), l² = 22	2.4%		
Test for overall effect: Z = 7				
		0.5	0.7 1 1.5	2
			Favours SSRI Favours placel	00

Review: OCD adults: SSRIs

Comparison: OCD adults: SSRIs
Outcome: O1 Adverse events
OCD adults: SSRIs
OUtcome: O1 Adverse events

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
	ram 20mg			
Montgomery 2001	67/98	74/102		0.94 [0.79, 1.13]
Subtotal (95% CI)	98	102	-	0.94 [0.79, 1.13]
Total events: 67 (Dose 1), 74 ((Dose 2)		-	
Test for heterogeneity: not app	plicable			
Test for overall effect: $Z = 0.6$	5 (P = 0.52)			
02 Citalopram 60mg vs Citalopi	ram 20mg			
Montgomery 2001	72/100	74/102		0.99 [0.84, 1.18]
Subtotal (95% CI)	100	102	•	0.99 [0.84, 1.18]
Total events: 72 (Dose 1), 74 ((Dose 2)		T	
Test for heterogeneity: not app	plicable			
Test for overall effect: Z = 0.0	9 (P = 0.93)			
03 Citalopram 60mg vs Citalopi	ram 40mg			
Montgomery 2001	72/100	67/98		1.05 [0.88, 1.26]
Subtotal (95% Cl)	100	98		1.05 [0.88, 1.26]
Total events: 72 (Dose 1), 67 ((Dose 2)		-	
Test for heterogeneity: not app	plicable			
Test for overall effect: $Z = 0.5$	6 (P = 0.58)			
04 Sertraline rapid titration vs :	slow titration			
Bogetto 2002	13/17	11/15		1.04 [0.70, 1.56]
Subtotal (95% CI)	17	15		1.04 [0.70, 1.56]
Total events: 13 (Dose 1), 11 ((Dose 2)		_ 	
Test for heterogeneity: not app				
Test for overall effect: Z = 0.2				


Favours Dose 1 Favours Dose 2

Review: Comparison: Outcome:

OCD adults: SSRIs 02 SSRIs at different doses (acute phase) 02 Leaving study early


Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
D1 Citalopram 40mg vs Citalopr Montgomery 2001 Subtotal (95% CI) fotal events: 15 (Dose 1), 16 (i fest for heterogeneity: not app fest for overall effect: Z = 0.07	15/98 98 Dose 2) Jlicable	16/102 102	+	0.98 [0.51, 1.86] 0.98 [0.51, 1.86]
2 Citalopram 60mg vs Citalopr Montgomery 2001 Subtotal (95% CI) otal events: 15 (Dose 1), 16 (I est for heterogeneity: not app est for overall effect: Z = 0.14	15/100 100 Dose 2) Jlicable	16/102 102	+	0.96 [0.50, 1.83] 0.96 [0.50, 1.83]
3 Citalopram 60mg vs Citalopr Montgomery 2001 Subtotal (95% CI) otal events: 15 (Dose 1), 15 (i est for heterogeneity not app est for overall effect: Z = 0.06	ram 40mg 15/100 100 Dose 2) Jlicable	15/98 98	+	0.98 [0.51, 1.89] 0.98 [0.51, 1.89]
14 Fluoxetine 40mg vs Fluoxeti Montgomery 1993 Subtotal (95% CI) Total events: 13 (Dose 1), 14 (Test for heterogeneity, not app Test for overall effect: Z = 0.17	ine 20mg 13/52 52 Dose 2) Jlicable	14/53 53	+	0.95 [0.49, 1.81] 0.95 [0.49, 1.81]
IS Fluoxetine 60mg vs Fluoxeti Montgomery 1993 Subtotal (95% CI) Total events: 14 (Dose 1), 14 (Test for heterogeneity: not app Test for overall effect: Z = 0.11	ine 20mg 14/55 55 Dose 2) Jlicable	14/53 53	+	0.96 [0.51, 1.82] 0.96 [0.51, 1.82]
06 Fluoxetine 60mg vs Fluoxeti Montgomery 1993 Subtotal (95% CI) fotal events: 14 (Dose 1), 13 (I fest for heterogeneity: not app fest for overall effect: Z = 0.05	ine 40mg 14/55 55 Dose 2) Jlicable	13/52 52	+	1.02 [0.53, 1.96] 1.02 [0.53, 1.96]
17 Paroxetine 40mg vs Paroxel Hollander 2003d Subtotal (95% CI) Sotal events: 20 (Dose 1), 14 (I Sest for heterogeneity: not app Sest for overall effect: Z = 1.21	tine 20mg 20/86 86 Dose 2) Jlicable	14/88 88	-	1.46 [0.79, 2.70] 1.46 [0.79, 2.70]
i8 Paroxetine 60mg vs Paroxet Hollander 2003d Subtotal (95% CI) otal events: 19 (Dose 1), 14 (I est for heterogeneity: not app	tine 20mg 19/85 85 Dose 2) Jicable	14/88 88	-	1.41 [0.75, 2.62] 1.41 [0.75, 2.62]
est for overall effect: Z = 1.07 9 Paroxetine 60mg vs Paroxet Hollander 2003d Hubtotal (95% CI) Otal events: 19 (Dose 1), 20 (I) est for heterogeneity: not app	tine 40mg 19/85 85 Dose 2) Jicable	20/86 86	+	0.96 [0.55, 1.67] 0.96 [0.55, 1.67]
est for overall effect: Z = 0.14 0 Sertraline 100mg vs Sertrali Greist 1995a Subtotal (95% CI) otal events: 27 (Dose 1), 17 (i est for heterogeneity: not app est for overall effect: Z = 1.88	ine 50mg 27/81 81 Dose 2) Jicable	17/80 80	-	1.57 [0.93, 2.64] 1.57 [0.93, 2.64]
est for overall effect. Z = 1, as 1 Sertraline 200mg vs Sertrali 3 September 1995a Subtotal (95% CI) 5 CI) 5 CI) 5 CI) 6 CI) 6 CI) 6 CI) 6 CI) 7 CI) 7 CI) 7 CI) 7 CI) 7 CI) 8 CI) 8 CI) 8 CI) 8 CI) 9 CIII 9 CI) 9 CIII 9 CII	ine 50mg 21/80 80 Dose 2) Jicable	17/80 80	-	1.24 [0.71, 2.16] 1.24 [0.71, 2.16]
est for overall effect: Z = 0.74 2 Sertraline 200mg vs Sertrali Greist 1995a ubtotal (95% Cl) otal events: 21 (Dose 1), 27 (l est for heterogeneity: not app est for overall effect: Z = 0.95	ine 100mg 21/80 80 Dose 2) Jicable	27/81 81	-	0.79 [0.49, 1.27] 0.79 [0.49, 1.27]
3 Sertraline rapid titration vs s Bogetto 2002 Subtotal (95% CI) Total events: 3 (Dose 1), 2 (Do Test for heterogeneity: not app	slow titration 3/17 17 ise 2)	2/15 15		- 1.32 [0.25, 6.88] - 1.32 [0.25, 6.88]

Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 03 Leaving study early due to adverse events



Comparison: 02 SSRIs at different doses (acute phase)

Outcome: 04 Non-responders



02 SSRIs at different doses (acute phase) 05 Y-BOCS Comparison:

Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Citalopram 40mg vs Citaloprar Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 0.49 (98 98 able	-8.90(7.00)	102 102	-8.40(7.30)	‡	-0.07 [-0.35, 0.21] -0.07 [-0.35, 0.21]
02 Citalopram 60mg vs Citaloprar Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 1.98 (100 100 able	-10.40(6.90)	102 102	-8.40(7.30)	₹	-0.28 [-0.56, 0.00] -0.28 [-0.56, 0.00]
03 Citalopram 60mg vs Citaloprar Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 1.51 (100 100 able	-10.40(6.90)	98 98	-8.90(7.00)	₹	-0.22 [-0.49, 0.06] -0.22 [-0.49, 0.06]
04 Fluoxetine 40mg vs Fluoxetine Beasley 1992 Montgomery 1993 Subtotal (95% Cl) Test for heterogeneity: Chi² = 0.3 Test for overall effect: Z = 0.26 (67 52 119 85, df = 1 (F	18.10(7.90) -4.76(6.89) P = 0.55), P = 0%	75 52 127	18.90(8.30) -5.13(6.41)	 	-0.10 [-0.43, 0.23] 0.06 [-0.33, 0.44] -0.03 [-0.28, 0.22]
05 Fluoxetine 60mg vs Fluoxetine Beasley 1992 Montgomery 1993 Subtotal (95% Ct) Test for heterogeneity: Chi² = 0.2 Test for overall effect: Z = 1.63 (68 54 122 21, df = 1 (F	16.80(7.80) -6.07(6.92) P=0.64), P=0%	75 52 127	18.90(8.30) -5.13(6.41)	=	-0.26 [-0.59, 0.07] -0.14 [-0.52, 0.24] -0.21 [-0.46, 0.04]
06 Fluoxetine 60mg vs Fluoxetine Beasley 1992 Montgomery 1993 Subtotal (95% Ct) Test for heterogeneity: Chi² = 0.0 Test for overall effect; Z = 1.36 (68 54 122)1, df = 1 (F	16.80(7.80) -6.07(6.92) P=0.93), 2=0%	67 52 119	18.10(7.90) -4.76(6.89)	-	-0.16 [-0.50, 0.17] -0.19 [-0.57, 0.19] -0.18 [-0.43, 0.08]
07 Sertraline rapid titration vs slo Bogetto 2002 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 0.71 (w titration 14 14 able	12.43(3.78)	13 13	13.54(4.03)	-	-0.28 [-1.03, 0.48] -0.28 [-1.03, 0.48]
		es (acute phase)			-4 -2 0 2 4 Favours Dose 1 Favours Dose 2	
Outcome: 06 NIMH-OC Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Citalopram 40mg vs Citaloprar Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 0.27 (98 98 able	-2.90(2.80)	102 102	-2.80(2.50)	+	-0.04 [-0.31, 0.24] -0.04 [-0.31, 0.24]
02 Citalopram 60mg vs Citalopram Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 0.83 (100 100 able	-3.10(2.60)	102 102	-2.80(2.50)	-	-0.12 [-0.39, 0.16] -0.12 [-0.39, 0.16]

98 98

-2.90(2.80)

-3.10(2.60)

-0.07 [-0.35, 0.20] -0.07 [-0.35, 0.20]

0.5

-0.5

Favours Dose 1 Favours Dose 2

03 Citalopram 60mg vs Citalopram 40mg Montgomery 2001 100 Subtotal (95% CI) 100

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)

02 SSRIs at different doses (acute phase) 07 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
01 Fluoxetine 40mg vs Fluox	etine 20mg					
Montgomery 1993	52	-2.55(6.77)	52	-1.85(6.04)		-0.11 [-0.49, 0.28]
Subtotal (95% CI)	52		52			-0.11 [-0.49, 0.28]
Test for heterogeneity: not a	applicable					
Test for overall effect: $Z = 0$.55 (P = 0.58)					
02 Fluoxetine 60mg vs Fluox	etine 20mg					
Montgomery 1993	54	-3.41(6.23)	52	-1.85(6.04)		-0.25 [-0.63, 0.13]
Subtotal (95% CI)	54		52			-0.25 [-0.63, 0.13]
Test for heterogeneity: not a	pplicable					
Test for overall effect: $Z = 1$.29 (P = 0.20)					
03 Fluoxetine 60mg vs Fluox	etine 40mg					
Montgomery 1993	54	-3.41(6.23)	52	-2.55(6.77)		-0.13 [-0.51, 0.25]
Subtotal (95% CI)	54		52			-0.13 [-0.51, 0.25]
Test for heterogeneity: not a	pplicable					•
Test for overall effect: $Z = 0$.68 (P = 0.50)					
					1 -0.5 0 0.5	1

Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 08 Montgomery-Asberg Depression Rating Scale

Study		Dose 1		Dose 2	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Citalopram 40mg vs Citalopram 2	20mg					
Montgomery 2001	98	-3.90(5.20)	102	-3.40(6.30)		-0.09 [-0.36, 0.19]
Subtotal (95% CI)	98		102			-0.09 [-0.36, 0.19]
Test for heterogeneity: not applicab	ole				-	
Fest for overall effect: Z = 0.61 (P =	= 0.54)					
02 Citalopram 60mg vs Citalopram 2	20ma					
Montgomery 2001	100	-4.00(6.50)	102	-3.40(6.30)	 _	-0.09 [-0.37, 0.18]
Subtotal (95% CI)	100		102			-0.09 [-0.37, 0.18]
Test for heterogeneity: not applicab	ole					
Test for overall effect: Z = 0.66 (P =						
03 Citalopram 60mg vs Citalopram 4	10ma					
Montgomery 2001	100	-4.00(6.50)	98	-3.90(5.20)		-0.02 [-0.30, 0.26]
Subtotal (95% CI)	100	,,	98		_	-0.02 [-0.30, 0.26]
Test for heterogeneity: not applicab	ole					
Test for overall effect: Z = 0.12 (P =						
04 Fluoxetine 40mg vs Fluoxetine 2	!Omq					
Montgomery 1993	52	-5.20(8.19)	52	-2.96(8.09)		-0.27 [-0.66, 0.11]
Subtotal (95% CI)	52		52			-0.27 [-0.66, 0.11]
Test for heterogeneity: not applicab	ole					
est for overall effect: Z = 1.39 (P =						
05 Fluoxetine 60mg vs Fluoxetine 2	!Oma					
Montgomery 1993	54	-5.20(8.73)	52	-2.96(8.09)		-0.26 [-0.65, 0.12]
Subtotal (95% CI)	54		52			-0.26 [-0.65, 0.12]
Test for heterogeneity: not applicab	ole					
Test for overall effect: Z = 1.35 (P =						
06 Fluoxetine 60mg vs Fluoxetine 4	Omg					
Montgomery 1993	54	-5.20(8.73)	52	-5.20(8.19)		0.00 [-0.38, 0.38]
Subtotal (95% CI)	54		52		-	0.00 [-0.38, 0.38]
Test for heterogeneity: not applicab						
Test for overall effect: Z = 0.00 (P =						
				-1	-0.5 0 0.5	1

Favours Dose 1 Favours Dose 2

02 SSRIs at different doses (acute phase) 09 Sheehan Disability Score: family Comparison: Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
	oram 20mg					
Montgomery 2001	98	-2.10(2.30)	102	-1.80(2.40)	 _	-0.13 [-0.40, 0.15]
Subtotal (95% CI)	98		102			-0.13 [-0.40, 0.15]
est for heterogeneity: not ap	plicable				-	
Fest for overall effect: $Z = 0$.	90 (P = 0.37)					
02 Citalopram 60mg vs Citalop	oram 20mg					
Montgomery 2001	100	-2.30(2.40)	102	-1.80(2.40)		-0.21 [-0.48, 0.07]
Subtotal (95% CI)	100		102			-0.21 [-0.48, 0.07]
est for heterogeneity: not ap	plicable				-	
est for overall effect: $Z = 1$.	47 (P = 0.14)					
3 Citalopram 60mg vs Citalo	oram 40mg					
Montgomery 2001	100	-2.30(2.40)	98	-2.10(2.30)		-0.08 [-0.36, 0.19]
Subtotal (95% CI)	100		98			-0.08 [-0.36, 0.19]
est for heterogeneity: not ap	plicable				7	•
Test for overall effect: $Z = 0$.	60 (P = 0.55)					

Favours Dose 1 Favours Dose 2

Favours Dose 1 Favours Dose 2

Favours Dose 1 Favours Dose 2

Review:

OCD adults: SSRIs 02 SSRIs at different doses (acute phase) 10 Sheehan Disability Score: social Comparison: Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Citalopram 40mg vs Citalo	pram 20mg					
Montgomery 2001	98	-1.90(2.30)	102	-2.00(2.20)		0.04 [-0.23, 0.32]
Subtotal (95% CI)	98		102			0.04 [-0.23, 0.32]
est for heterogeneity: not a	pplicable				Γ	
est for overall effect: Z = 0	.31 (P = 0.75)					
) 2 Citalopram 60mg vs Citalo	pram 20mg					
Montgomery 2001	100	-2.40(2.50)	102	-2.00(2.20)		-0.17 [-0.45, 0.11]
Subtotal (95% CI)	100		102			-0.17 [-0.45, 0.11]
est for heterogeneity; not a	pplicable				-	
est for overall effect: Z = 1	.20 (P = 0.23)					
03 Citalopram 60mg vs Citalo	pram 40mg					
Montgomery 2001	100	-2.40(2.50)	98	-1.90(2.30)		-0.21 [-0.49, 0.07]
Subtotal (95% CI)	100		98		-	-0.21 [-0.49, 0.07]
est for heterogeneity; not a	pplicable					
est for overall effect: Z = 1						

Review: OCD adults: SSRIs

02 SSRIs at different doses (acute phase) 11 Sheehan Disability Score: work Comparison: Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
	ram 20mg					
Montgomery 2001	98	-2.10(2.30)	102	-1.90(2.40)		-0.08 [-0.36, 0.19]
Subtotal (95% CI)	98		102			-0.08 [-0.36, 0.19]
Test for heterogeneity: not ap	plicable				-	
Test for overall effect: $Z = 0.6$	60 (P = 0.55)					
02 Citalopram 60mg vs Citalop	ram 20mg					
Montgomery 2001	100	-2.00(2.50)	102	-1.90(2.40)	 _	-0.04 [-0.32, 0.24]
Subtotal (95% CI)	100		102			-0.04 [-0.32, 0.24]
Test for heterogeneity: not ap	plicable				7	
Test for overall effect: $Z = 0.3$						
03 Citalopram 60mg vs Citalop	oram 40mg					
Montgomery 2001	100	-2.00(2.50)	98	-2.10(2.30)		0.04 [-0.24, 0.32]
Subtotal (95% CI)	100		98			0.04 [-0.24, 0.32]
Test for heterogeneity: not ap	plicable				T-	•
Test for overall effect: Z = 0.3						
	` ′					

Comparison: 03 SSRIs vs other SSRIs (acute phase)

Outcome: 01 Leaving study early

Study or sub-category	SSRI1 n/N	SSRI 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Citalopram vs Fluvoxamine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/11	0/10 0		Not estimable Not estimable
02 Citalopram vs Paroxetine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/11 0	0/9 0		Not estimable Not estimable
03 Fluoxetine vs Sertraline Bergeron 2002 Subtotal (95% CI) Total events: 22 (SSRI 1), 22 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: Z = 0.21 (P = 0.8)	22/73 73 33)	22/77 77		1.05 [0.64, 1.73] 1.05 [0.64, 1.73]
04 Fluvoxamine vs Paroxetine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/10 0	0/9		Not estimable Not estimable
		0	5 0.7 1 1.5 Favours SSRI 1 Favours SSRI 2	2

Review: OCD adults: SSRIs

Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 02 Leaving study early due to adverse events

Study or sub-category	SSRI1 n/N	SSRI 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Citalopram vs Fluvoxamine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/11 0	0/10 0		Not estimable Not estimable
02 Citalopram vs Paroxetine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/11 0	0/9		Not estimable Not estimable
03 Fluoxetine vs Sertraline Bergeron 2002 Subtotal (95% CI) Total events: 10 (SSRI 1), 15 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: Z = 0.94 (P = 0.)	10/73 73 35)	15/77 77		0.70 [0.34, 1.46] 0.70 [0.34, 1.46]
04 Fluvoxamine vs Paroxetine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogenety: not applicable Test for overall effect: not applicable	0/10 0	0/9 0		Not estimable Not estimable
		0	.1 0.2 0.5 1 2 5 Favours SSRI1 Favours SSRI	10 2

Comparison: 03 SSRIs vs other SSRIs (acute phase)

Outcome: 03 Non-responders

Study or sub-category	SSRI1 n/N	SSRI 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Citalopram vs Paroxetine				
Mundo 1997a	7/11	5/9		1.15 [0.55, 2.39]
Subtotal (95% CI) Total events: 7 (SSRI 1), 5 (SSRI Test for heterogeneity: not applic		9		1.15 [0.55, 2.39]
Test for overall effect: $Z = 0.36$ (P = 0.72)			
03 Fluvoxamine vs Citalopram				
Mundo 1997a	4/10	7/11		0.63 [0.26, 1.52]
Subtotal (95% CI)	10	11		0.63 [0.26, 1.52]
Total events: 4 (SSRI 1), 7 (SSRI	2)			
Test for heterogeneity: not applic				
Test for overall effect: Z = 1.03 (
04 Fluvoxamine vs Paroxetine				
Mundo 1997a	4/10	5/9		0.72 [0.28, 1.88]
Subtotal (95% CI)	10	9		0.72 [0.28, 1.88]
Total events: 4 (SSRI 1), 5 (SSRI	2)		_	·
Test for heterogeneity: not applic	able			
Test for overall effect: Z = 0.67 (
		0	.1 0.2 0.5 1 2 5	10
			Favours SSRI1 Favours SSRI2	

Review: OCD adults: SSRIs Comparison: 03 SSRIs vs other SSRIs (acute phase)

Outcome: 04 Non-remitters

Study or sub-category	SSRI 1 n/N	SSRI 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine vs Sertraline Bergeron 2002 Subtotal (95% Cl) Total events: 57 (SSRI 1), 50 (Test for heterogeneity: not ap Test for overall effect: Z = 1.7	pplicable	50/77 77	+	1.20 [0.98, 1.47] 1.20 [0.98, 1.47]
		0.5	0.7 1 1.5	2

Favours SSRI1 Favours SSRI2

Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 05 Y-BOCS

Study or sub-category	N	SSRI 1 Mean (SD)	N	SSRI 2 Mean (SD)		SMD (fixed) 95% Cl		1D (fixed) 95% Cl
02 Fluoxetine vs Sertraline at	12 weeks							
Bergeron 2002	72	-6.10(5.40)	76	-8.40(6.20)			0.39 [0.	07, 0.72]
Subtotal (95% CI)	72		76			•	0.39 [0.	07, 0.72]
Test for heterogeneity: not ap	plicable					ľ		
Test for overall effect: $Z = 2.3$	37 (P = 0.02)							
03 Fluvoxamine vs Citalopram	1							
Mundo 1997a	10	16.20(8.90)	11	19.80(10.10)		-	-0.36 [-1	.23, 0.50]
Subtotal (95% CI)	10		11			•	-0.36 [-1	.23, 0.50]
Test for heterogeneity: not ap	plicable							
Test for overall effect: $Z = 0.8$	32 (P = 0.41)							
04 Fluvoxamine vs Paroxetine	•							
Mundo 1997a	10	16.20(8.90)	9	21.60(7.60)		-	-0.62 [-1	.55, 0.31]
Subtotal (95% CI)	10		9			•	-0.62 [-1	.55, 0.31]
Test for heterogeneity: not ap	plicable							
Test for overall effect: $Z = 1.3$	31 (P = 0.19)							
05 Paroxetine vs Citalopram								
Mundo 1997a	9	21.60(7.60)	11	19.80(10.10)		-	0.19 [-0	.69, 1.07]
Subtotal (95% CI)	9		11			•	0.19 [-0	.69, 1.07]
Test for heterogeneity: not ap								
Test for overall effect: $Z = 0.4$	42 (P = 0.67)							
					-10	-5 0	5 10	
					Favo	urs SSRI1 Favou	rs SSRI 2	

03 SSRIs vs other SSRIs (acute phase) 06 NIMH-OC Comparison:

Outcome:

Study or sub-category 1	N	SSRI 1 Mean (SD)	N	SSRI 2 Mean (SD)		SMD (fixe 95% Cl	d)	SMD (fixed) 95% Cl
01 Fluoxetine vs Sertraline								
Bergeron 2002	72	5.70(2.60)	76	5.50(2.80)		-		0.07 [-0.25, 0.40]
Subtotal (95% CI)	72		76			•		0.07 [-0.25, 0.40]
Test for heterogeneity: not applicable	Э					ſ		
Test for overall effect: $Z = 0.45$ (P = 0	0.65)							
02 Fluvoxamine vs Citalopram								
Mundo 1997a	10	6.23(1.81)	11	8.58(1.88)				-1.22 [-2.17, -0.27]
Subtotal (95% CI)	10		11					-1.22 [-2.17, -0.27]
Fest for heterogeneity: not applicable	Э					-		
Test for overall effect: $Z = 2.52$ (P = 1	0.01)							
03 Fluvoxamine vs Paroxetine								
Mundo 1997a	10	6.23(1.81)	9	7.77(2.02)		_		-0.77 [-1.71, 0.17]
Subtotal (95% CI)	10		9					-0.77 [-1.71, 0.17]
est for heterogeneity; not applicable	9					-		
est for overall effect: Z = 1.60 (P = 0	0.11)							
04 Paroxetine vs Citalopram								
Mundo 1997a	9	7.77(2.02)	11	8.58(1.88)				-0.40 [-1.29, 0.49]
Subtotal (95% CI)	9		11			-		-0.40 [-1.29, 0.49]
Fest for heterogeneity: not applicable	9					-		
Test for overall effect: $Z = 0.88$ (P = 0.00)	0.38)							
					-4	-2 0	2	4
					Fo	vours SSRI1 Fa	avours SSRI :	2
					га	YOURS SSINE FR	Modes South	4

Review:

OCD adults: SSRIs 03 SSRIs vs other SSRIs (acute phase) 07 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	SSRI1 Mean (SD)	N	SSRI 2 Mean (SD)		S	SMD (fixed) 95% CI		SMD (fixed) 95% CI	
01 Fluoxetine vs Sertraline Bergeron 2002 Subtotal (95% CI) Test for heterogeneity: not app	72 72	7.10(5.40)	76 76	6.20(4.60)			-	 	0.18 [-0.14, 0.50 0.18 [-0.14, 0.50	
Test for overall effect: Z = 1.0					- ;	-0.5		0.5	-:	

Favours SSRI1 Favours SSRI2

OCD adults: SSRIs Review:


Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 01 Adverse events

tudy r sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
1 Fluvoxamine vs Clomipramine	e			
reeman 1994	30/34	24/30		1.10 [0.89, 1.37]
(oran 1996a	35/37	39/41	-	0.99 [0.90, 1.10]
/Jundo 2001	81/115	84/112		0.94 [0.80, 1.10]
ubtotal (95% CI)	186	183	•	0.98 [0.89, 1.09]
otal events: 146 (SSRI), 147 (0 est for heterogeneity: Chi² = 1. est for overall effect: Z = 0.36	.47, df = $2 (P = 0.48)$, $I^2 = 0$	%		
2 Paroxetine vs Clomipramine				
Burnham 1993	77/82	80/82	-	0.96 [0.90, 1.03]
Zohar 1996a	163/201	85/99		0.94 [0.85, 1.05]
ubtotal (95% CI)	283	181	•	0.95 [0.89, 1.02]
otal events: 240 (SSRI), 165 (0	Clomipramine)		·	
est for heterogeneity: Chi² = 0.	.13, df = 1 (P = 0.72), $I^2 = 0$	%		
est for overall effect: Z = 1.45	(P = 0.15)			
3 Sertraline vs Clomipramine				
Askin 1999	7/18	13/18		0.54 [0.28, 1.03]
Bisserbe 1997	56/86	57/82		0.94 [0.76, 1.16]
ubtotal (95% CI)	104	100	-	0.86 [0.71, 1.06]
otal events: 63 (SSRI), 70 (Cloi	mipramine)			
est for heterogeneity: Chi² = 2.	.62, $df = 1 (P = 0.11), I^2 = 6$	1.8%		
est for overall effect: Z = 1.41	(P = 0.16)			
otal (95% CI)	573	464	•	0.95 [0.89, 1.00]
otal events: 449 (SSRI), 382 (0	Clomipramine)		•	
est for heterogeneity: Chi² = 5. est for overall effect: Z = 1.80		%		

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 02 Attempted suicide



Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 03 Leaving study early

Study or sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine vs Clomipramine				
Lopez-Ibor 1996	5/30	4/25		1 04 (0 0) 0 471
Subtotal (95% CI)	5/30	4/25		1.04 [0.31, 3.47] 1.04 [0.31, 3.47]
Test for heterogeneity: not app	•	4/25		1.04 [0.31, 3.47]
Test for overall effect: Z = 0.07				
02 Fluvoxamine vs Clomipramir	ne			
Freeman 1994	6/34	11/32		0.51 [0.22, 1.23]
Koran 1996a	8/37	15/42		0.61 [0.29, 1.26]
Milanfranchi 1997	0/13	1/13	_	- 0.33 [0.01, 7.50]
Mundo 2001	19/115	26/112		0.71 [0.42, 1.21]
Smeraldi 1992	1/6	1/6 ←	_	1.00 [0.08, 12.56]
Subtotal (95% CI)	34/205	54/205	-	0.64 [0.44, 0.93]
Test for heterogeneity: Chi ² = 0		-	—	0.01 (0.11, 0.50,
Test for overall effect: Z = 2.3				
03 Paroxetine vs Clomipramine	•			
Burnham 1993	28/82	28/82		1.00 [0.65, 1.53]
Zohar 1996a	49/201	34/99		0.71 [0.49, 1.02]
Subtotal (95% CI)	77/283	62/181		0.82 [0.62, 1.08]
Test for heterogeneity: Chi ² = 1	1.44 , df = 1 (P = 0.23), $I^2 = 3$	0.4%	T	
Test for overall effect: Z = 1.4				
04 Sertraline vs Clomipramine				
Askin 1999	2/20	4/22 —	<u> </u>	0.55 [0.11, 2.69]
Bisserbe 1997	23/86	35/82		0.63 [0.41, 0.96]
Subtotal (95% CI)	25/106	39/104	-	0.62 [0.41, 0.94]
Test for heterogeneity: Chi ² = 0	0.02, df = 1 (P = 0.88), l ² = 0	%	-	•
Test for overall effect: Z = 2.29	5 (P = 0.02)			
Total (95% CI)	141/624	159/515	•	0.72 [0.59, 0.88]
Test for heterogeneity: $Chi^2 = 4$ Test for overall effect: $Z = 3.25$		%	-	•
rest for overall effect. Z = 3.23	9 (F = 0.001)	0.1	0.2 0.5 1 2 5	10

Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 04 Leaving study early due to adverse events



Comparison: 04 SSRIs vs Clomipramine (acute phase)

05 Non-responders Outcome:

Study or sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine vs Clomipramine	22.420	11.405	_	1 68 (1 00 0 80)
Lopez-Ibor 1996	22/30	11/25 25		1.67 [1.02, 2.73]
Subtotal (95% CI)	30	25		1.67 [1.02, 2.73]
otal events: 22 (SSRI), 11 (Clomi est for heterogeneity: not applica				
est for neterogeneity, not applicate est for overall effect: Z = 2.03 (F				
)2 Fluvoxamine vs Clomipramine				
Koran 1996a	18/37	21/42		0.97 [0.62, 1.52]
Milanfranchi 1997	2/13	3/13 -		0.67 [0.13, 3.35]
Mundo 2001	46/115	44/112		1.02 [0.74, 1.40]
Subtotal (95% CI)	165	167	•	0.99 [0.76, 1.28]
otal events: 66 (SSRI), 68 (Clomi	pramine)		T	,
est for heterogeneity: Chi ² = 0.27	, ,	%		
est for overall effect: Z = 0.08 (F				
3 Paroxetine vs Clomipramine				
Burnham 1993	47/82	42/82	- - -	1.12 [0.84, 1.48]
Zohar 1996a	92/201	47/99	-	0.96 [0.75, 1.25]
Subtotal (95% CI)	283	181	•	1.03 [0.85, 1.24]
Fotal events: 139 (SSRI), 89 (Clon Fest for heterogeneity: Chi² = 0.58 Fest for overall effect: Z = 0.27 (F	9, df = 1 ($P = 0.44$), $I^2 = 0$	%		
04 Sertraline vs Clomipramine				
Bisserbe 1997	24/86	29/82		0.79 [0.50, 1.24]
Subtotal (95% CI) fotal events: 24 (SSRI), 29 (Clomi fest for heterogeneity: not applica fest for overall effect: Z = 1.04 (F	able	82		0.79 [0.50, 1.24]
fotal (95% Cl) fotal events: 251 (SSRI), 197 (Clo fest for heterogeneity: Chi² = 6.0° fest for overall effect: Z = 0.24 (F	1 , df = 6 (P = 0.42), l² = 0	455	•	1.02 [0.89, 1.17]
		0.1	0.2 0.5 1 2 5	10
OCD Inter-CODI-			Favours SSRI Favours Clomip	ramine

Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 06 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipramine						
Lopez-lbor 1996	30	-7.50(9.29)	24	-8.90(7.13)		0.16 [-0.37, 0.70]
Subtotal (95% CI)	30		24			0.16 [-0.37, 0.70]
Test for heterogeneity: not appli	cable				- -	
Test for overall effect: $Z = 0.60$	(P = 0.55)					
02 Fluvoxamine vs Clomipramine	е					
Koran 1996a	34	17.80(7.70)	39	17.00(8.55)	- •	0.10 [-0.36, 0.56]
Milanfranchi 1997	13	18.40(9.20)	12	16.50(11.00)		- 0.18 [-0.60, 0.97]
Mundo 2001	67	14.70(10.10)	61	12.50(8.00)		0.24 [-0.11, 0.59]
Smeraldi 1992	5	18.20(2.50)	5	15.20(12.40)		→ 0.30 [-0.95, 1.55]
Subtotal (95% CI)	119		117			0.19 [-0.06, 0.45]
Test for heterogeneity: $Chi^2 = 0$.	26, df = 3 (P	= 0.97), I ² = 0%			_	
Test for overall effect: $Z = 1.46$	(P = 0.14)					
03 Paroxetine vs Clomipramine						
Burnham 1993	79	-5.61(7.47)	78	-7.73(7.42)		0.28 [-0.03, 0.60]
Zohar 1996a	198	-8.00(8.00)	94	-8.00(8.20)	- +	0.00 [-0.25, 0.25]
Subtotal (95% CI)	277		172		-	0.11 [-0.09, 0.30]
Test for heterogeneity: Chi² = 1.		= 0.16), I ² = 48.4%				
Test for overall effect: Z = 1.09	(P = 0.28)					
Total (95% CI)	426		313		•	0.14 [-0.01, 0.29]
Test for heterogeneity: Chi² = 2.		= 0.87), I ² = 0%				
Test for overall effect: Z = 1.85	(P = 0.06)					
				-1	-0.5 0 0.5	1

04 SSRIs vs Clomipramine (acute phase) 07 NIMH-OC Comparison:

Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluvoxamine vs Clomiprami	ine					
Mundo 2001	112	5.90(3.10)	105	5.90(2.80)		0.00 [-0.27, 0.27]
Subtotal (95% CI)	112		105			0.00 [-0.27, 0.27]
est for heterogeneity: not ap	plicable				T	
est for overall effect: $Z = 0.0$	00 (P = 1.00)					
2 Paroxetine vs Clomipramine	•					
Burnham 1993	79	-1.42(2.04)	78	-2.06(2.03)		0.31 [0.00, 0.63]
Zohar 1996a	198	-2.50(2.90)	94	-2.50(2.60)		0.00 [-0.25, 0.25]
ubtotal (95% CI)	277		172		-	0.12 [-0.08, 0.31]
est for heterogeneity: Chi² =	2.36, df = 1 (P	= 0.12), I ² = 57.6%			-	
est for overall effect: $Z = 1.2$	0 (P = 0.23)					
otal (95% CI)	389		277		•	0.08 [-0.08, 0.23]
est for heterogeneity: Chi ² =	2.86, df = 2 (P	= 0.24), I ² = 30.0%				
est for overall effect: Z = 0.9	7 (P = 0.33)					

Favours SSRI Favours Clomipramine

Review: Comparison:

OCD adults: SSRIs 04 SSRIs vs Clomipramine (acute phase) 08 Comprehensive Psychopathological Rating Scale: obsessive-compulsive Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipran	nine					
Lopez-lbor 1996	30	-8.10(7.64)	24	-10.90(7.33)		— 0.37 [-0.17, 0.91]
Subtotal (95% CI)	30		24			0.37 [-0.17, 0.91]
Test for heterogeneity: not	: applicable				 -	
Test for overall effect: Z =	1.33 (P = 0.18)					
					1 .05 0 05	

Favours SSRI Favours Clomipramine OCD adults: SSRIs

04 SSRIs vs Clomipramine (acute phase) 09 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipran	nine					
Lopez-lbor 1996	30	-7.50(5.93)	24	-9.40(7.71)		0.28 [-0.26, 0.82]
Subtotal (95% CI)	30		24			0.28 [-0.26, 0.82]
Test for heterogeneity: not	: applicable					
Test for overall effect: Z =	1.00 (P = 0.32)					
02 Fluvoxamine vs Clomipr	amine					
Koran 1996a	34	6.10(3.30)	39	5.80(4.70)		0.07 [-0.39, 0.53]
Mundo 2001	112	7.70(6.00)	105	7.00(4.50)		0.13 [-0.14, 0.40]
Subtotal (95% CI)	146		144		-	0.12 [-0.11, 0.35]
Test for heterogeneity: Chi	$i^2 = 0.05$, $df = 1$ (P	= 0.83), I ² = 0%			-	
Test for overall effect: Z =	0.99 (P = 0.32)					
Total (95% CI)	176		168			0.14 [-0.07, 0.35]
Test for heterogeneity: Chi	P = 0.33, df = 2 (P	= 0.85), I ² = 0%				
Test for overall effect: $Z =$	1.30 (P = 0.19)					
				-1	-0.5 0 0.5	1

Favours SSRI Favours Clomipramine

Comparison: 04 SSRIs vs Clomipramine (acute phase) 10 Montgomery-Asberg Depression Rating Scale Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipram	ine					
Lopez-lbor 1996	30	-10.10(8.20)	24	-13.80(9.09)	+-	0.42 [-0.12, 0.97]
Subtotal (95% CI)	30		24		•	0.42 [-0.12, 0.97]
est for heterogeneity; not	applicable				-	
「est for overall effect: Z = '	1.53 (P = 0.13)					
02 Fluvoxamine vs Clomipra	amine					
Smeraldi 1992	5	11.80(6.80)	5	9.60(10.30)		0.23 [-1.02, 1.47]
Subtotal (95% CI)	5		5			0.23 [-1.02, 1.47]
est for heterogeneity; not	applicable					
est for overall effect: Z = I	0.36 (P = 0.72)					
03 Paroxetine vs Clomipram	nine					
Zohar 1996a	198	-3.40(7.90)	94	-2.40(7.30)	=	-0.13 [-0.38, 0.12]
Subtotal (95% CI)	198		94		₩	-0.13 [-0.38, 0.12]
est for heterogeneity; not	applicable				1	
est for overall effect: Z = 1	1.03 (P = 0.30)					
Total (95% CI)	233		123		•	-0.03 [-0.25, 0.19]
est for heterogeneity: Chi ²	2 = 3.47, df = 2 (P	= 0.18), I ² = 42.4%			Ī	
「est for overall effect: Z = I	0.24 (P = 0.81)					
				-4	-2 0 2	4

Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

OCD adults: SSRIs Review:

Comparison: 04 SSRIs vs Clomipramine (acute phase) Outcome: 11 Depression (HRSD; MADRS)

Study		SSRI		Clomipramine	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Fluvoxamine vs Clomipr	amine					
Koran 1996a	34	6.10(3.30)	39	5.80(4.70)		0.07 [-0.39, 0.53]
Mundo 2001	112	7.70(6.00)	105	7.00(4.50)	 -	0.13 [-0.14, 0.40]
Smeraldi 1992	5	11.80(6.80)	5	9.60(10.30)	 	0.23 [-1.02, 1.47]
Subtotal (95% CI)	151		149		*	0.12 [-0.11, 0.35]
Test for heterogeneity: Chi Test for overall effect: Z =	1.04 (P = 0.30)	= 0.96), I ² = 0%				
02 Paroxetine vs Clomiprar					_	
Zohar 1996a	198	-3.40(7.90)	94	-2.40(7.30)	7	-0.13 [-0.38, 0.12]
Subtotal (95% CI)	198		94		•	-0.13 [-0.38, 0.12]
Test for heterogeneity: not Test for overall effect: Z =	• •					
Total (95% CI) Test for heterogeneity: Chi Test for overall effect: Z =		= 0.53), l² = 0%	243		•	0.01 [-0.16, 0.17]

Review: OCD adults: SSRIs

04 SSRIs vs Clomipramine (acute phase) 12 Clinical Anxiety Scale Comparison:

Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)		S	SMD (fixed) 95% CI)		SMD (fixed) 95% CI	
01 Fluvoxamine vs Clomipr	ramine										
Mundo 2001	112	7.00(4.60)	105	6.70(4.30)			_	_		0.07 [-0.20, 0.33]	
Subtotal (95% CI)	112		105				-	-		0.07 [-0.20, 0.33]	
Test for heterogeneity: not	t applicable						_			,	
Test for overall effect: Z =	0.49 (P = 0.62)										
-						0.5		0.5			
					-1	-0.5	U	0.5	1		

Review: Comparison: OCD adults: SSRIs 04 SSRIs vs Clomipramine (acute phase) 13 Covi Anxiety Scale

Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)		SMD (fi: 95%			SMD (fixed) 95% CI
01 Fluoxetine vs Clomipram	nine								
Lopez-lbor 1996	30	-2.40(3.10)	24	-2.40(3.09)					0.00 [-0.54, 0.54]
Subtotal (95% CI)	30		24						0.00 [-0.54, 0.54]
est for heterogeneity: not	applicable					T			
Test for overall effect: Z = I	0.00 (P = 1.00)								
					-1	-0.5 0	0.5	1	
						Favours SSRI	Favours Clor	ipramine	

Comparison:

04 SSRIs vs Clomipramine (acute phase) 14 Anxiety (Clinical Anxiety Scale; Covi Anxiety Scale) Outcome:

N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
•					
30	-2.40(3.10)	24	-2.40(3.09)		0.00 [-0.54, 0.54]
30		24			0.00 [-0.54, 0.54]
plicable				T	
00 (P = 1.00)					
ine					
112	7.00(4.60)	105	6.70(4.30)		0.07 [-0.20, 0.33]
112		105			0.07 [-0.20, 0.33]
plicable					
19 (P = 0.62)					
142		129			0.05 [-0.18, 0.29]
0.05, $df = 1$ (P :	= 0.83), I ² = 0%			_	
14 (P = 0.66)					
	30 30 30 30 30 30 00 (P = 1.00) ine 112 112 112 142 142	30 -2.40(3.10) 30 pplicable 00 (P = 1.00) ine 112 7.00(4.60) 112 pplicable 49 (P = 0.62) 142 0.05, df = 1 (P = 0.83), P = 0%	30 -2.40(3.10) 24 30 24 pplicable 00 (P = 1.00) ine 112 7.00(4.60) 105 112 105 pplicable 49 (P = 0.62) 142 129 0.05, df = 1 (P = 0.83), P = 0%	N Mean (SD) N Mean (SD) 30	N Mean (SD) N Mean (SD) 95% CI 30 -2.40 (3.10) 24 -2.40 (3.09) 30 24 pplicable 30 (P = 1.00) ine 112 7.00 (4.60) 105 6.70 (4.30) 112 105 uplicable 49 (P = 0.62) 142 0.05, df = 1 (P = 0.83), I² = 0%

Review: OCD adults: SSRIs

04 SSRIs vs Clomipramine (acute phase) 15 Clinical Global Impressions: global improvement Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipramin	ne					
Lopez-Ibor 1996	30	-2.60(1.13)	24	-2.60(1.19)		0.00 [-0.54, 0.54]
Subtotal (95% CI)	30		24			0.00 [-0.54, 0.54]
Test for heterogeneity: not a	pplicable				T	
Test for overall effect: $Z = 0$.00 (P = 1.00)					
02 Fluvoxamine vs Clomipran	mine					
Mundo 2001	112	2.30(1.00)	105	2.30(1.00)		0.00 [-0.27, 0.27]
Subtotal (95% CI)	112		105			0.00 [-0.27, 0.27]
Test for heterogeneity: not a	pplicable				Ī	
Test for overall effect: $Z = 0$.	.00 (P = 1.00)					
Total (95% CI)	142		129		•	0.00 [-0.24, 0.24]
Test for heterogeneity: Chi ² :	= 0.00, df = 1 (P	= 1.00), I ² = 0%				
Test for overall effect: $Z = 0$.00 (P = 1.00)					
					1 -0.5 0 0.5	1

Favours SSRI Favours Clomipramine


Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs Comparison: Outcome: 04 SSRIs vs Clomipramine (acute phase) 16 Clinical Global Impressions: severity of illness

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)		SMD (fix 95% (,		SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipramine									
Lopez-lbor 1996	30	-0.90(1.23)	24	-1.90(1.14)		-	-		0.83 [0.27, 1.39]
Subtotal (95% CI)	30		24			-	•		0.83 [0.27, 1.39]
Test for heterogeneity: not app	licable						_		
Test for overall effect: $Z = 2.89$	9 (P = 0.004)								
02 Fluvoxamine vs Clomipramin	ne								
Mundo 2001	112	3.40(1.30)	105	3.20(1.20)		 -			0.16 [-0.11, 0.43]
Subtotal (95% CI)	112		105						0.16 [-0.11, 0.43]
Test for heterogeneity: not app	licable								
Test for overall effect: $Z = 1.17$	7 (P = 0.24)								
03 Paroxetine vs Clomipramine									
Zohar 1996a	194	-1.20(1.40)	94	-1.10(1.20)		-			-0.07 [-0.32, 0.17]
Subtotal (95% CI)	194		94			•			-0.07 [-0.32, 0.17]
Test for heterogeneity: not app	licable								
Test for overall effect: $Z = 0.59$	9 (P = 0.55)								
Total (95% CI)	336		223						0.11 [-0.06, 0.28]
Test for heterogeneity: Chi² = 8	3.57, df = 2 (P	= 0.01), I ² = 76.7%				ľ			
Test for overall effect: $Z = 1.23$	3 (P = 0.22)								
					-4	-2 0	ż	4	
					Fav	ours SSRI F	avours Clom	inramine	

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 17 Symptom Checklist-90



Review: OCD adults: SSRIs

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 18 Subanalysis: Non-responders in patients with comorbid depression

Study or sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine vs Clomipramine				
Lopez-lbor 1996	22/30	11/25		1.67 [1.02, 2.73]
Subtotal (95% CI)	30	25	-	1.67 [1.02, 2.73]
Total events: 22 (SSRI), 11 (Clomipra	mine)		-	
Test for heterogeneity; not applicable				
Test for overall effect: Z = 2.03 (P =	0.04)			
02 Fluvoxamine vs Clomipramine				
Mundo 2001	46/115	44/112	_ 	1.02 [0.74, 1.40]
Subtotal (95% CI)	115	112	•	1.02 [0.74, 1.40]
Total events: 46 (SSRI), 44 (Clomipra	mine)		Ī	
Test for heterogeneity: not applicable	•			
Test for overall effect: Z = 0.11 (P =	0.91)			
Total (95% CI)	145	137		1.16 [0.88, 1.51]
Total events: 68 (SSRI), 55 (Clomipra	mine)		-	,
Test for heterogeneity: Chi ² = 2.72, d	$f = 1 (P = 0.10), I^2 = 6$	3.3%		
Test for overall effect: Z = 1.06 (P =	0.29)			
		0.1	0.2 0.5 1 2 5	10

Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 19 Subanalysis: Y-BOCS in patients with comorbid depression

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipramin	ie					
Lopez-lbor 1996	30	-7.50(9.29)	24	-8.90(7.13)		0.16 [-0.37, 0.70]
Subtotal (95% CI)	30		24			0.16 [-0.37, 0.70]
Test for heterogeneity: not a	pplicable					
Test for overall effect: $Z = 0$.	.60 (P = 0.55)					
02 Fluvoxamine vs Clomipran	nine					
Mundo 2001	67	14.70(10.10)	61	12.50(8.00)		0.24 [-0.11, 0.59]
Smeraldi 1992	5	18.20(2.50)	5	15.20(12.40)		0.30 [-0.95, 1.55]
Subtotal (95% CI)	72		66			0.24 [-0.09, 0.58]
「est for heterogeneity: Chi² =	= 0.01, df = 1 (P	= 0.92), I ² = 0%			-	
Test for overall effect: $Z = 1$.	.42 (P = 0.16)					
Total (95% CI)	102		90		-	0.22 [-0.06, 0.51]
Test for heterogeneity: Chi² =	= 0.07, df = 2 (P	= 0.97), I ² = 0%			-	
Test for overall effect: $Z = 1$.	52 (P = 0.13)					
					-1 -0.5 0	0.5 1

Comparison:

04 SSRts vs Clomigramine (acute phase)
20 Subanalysis: Hamilton Rating Scale for Depression in patients with comorbid depression Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Fluoxetine vs Clomipran	nine					
Lopez-lbor 1996	30	-7.50(5.93)	24	-9.40(7.71)		0.28 [-0.26, 0.82]
Subtotal (95% CI)	30		24			0.28 [-0.26, 0.82]
Test for heterogeneity: not	t applicable					
Test for overall effect: Z =	1.00 (P = 0.32)					
02 Fluvoxamine vs Clomipr	ramine					
Mundo 2001	112	7.70(6.00)	105	7.00(4.50)	- 	0.13 [-0.14, 0.40]
Subtotal (95% CI)	112		105			0.13 [-0.14, 0.40]
est for heterogeneity; not	t applicable				-	
Test for overall effect: Z =	0.96 (P = 0.34)					
Total (95% CI)	142		129			0.16 [-0.08, 0.40]
Fest for heterogeneity: Chi	i ² = 0.22, df = 1 (P	= 0.64), I ² = 0%			-	
Test for overall effect: Z =	1.31 (P = 0.19)	**				
				-1	-0.5 0 0.5	1

Favours SSRI Favours Clomipramine

Favours SSRI Favours other drug

OCD adults: SSRIs

Comparison: Outcome: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase) 01 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Phenelzine						
Jenike 1997	19	16.20(6.30)	17	16.30(7.00)	-+ -	-0.01 [-0.67, 0.64]
Subtotal (95% CI)	19		17		•	-0.01 [-0.67, 0.64]
est for heterogeneity: not applic est for overall effect: Z = 0.04 (
02 Fluvoxamine vs Desipramine						
Goodman 1990a	21	19.50(9.00)	19	25.80(6.00)		-0.80 [-1.45, -0.15]
Subtotal (95% CI)	21		19		-	-0.80 [-1.45, -0.15]
Test for heterogeneity: not applic	able				-	
est for overall effect: Z = 2.42 (P = 0.02)					
03 Clomipramine vs Buspirone						
Pato 1991	9	17.67(4.97)	9	16.78(6.46)		0.15 [-0.78, 1.07]
Subtotal (95% CI)	9		9			0.15 [-0.78, 1.07]
est for heterogeneity: not applic est for overall effect: Z = 0.31 (
04 Sertraline vs Desipramine						
Hoehn-Saric 2000	79	-8.40(8.00)	85	-6.00(8.30)	-	-0.29 [-0.60, 0.02]
Subtotal (95% CI)	79		85		•	-0.29 [-0.60, 0.02]
est for heterogeneity; not applic	able				T	
est for overall effect: Z = 1.86 (
Total (95% CI)	128		130		•	-0.30 [-0.54, -0.05]
Fest for heterogeneity: Chi² = 3.9 Fest for overall effect: Z = 2.35 (= 0.27), I ² = 23.3%				,


Review:

OCD adults: SSRIs 05 SSRIs/Clomipramine vs Non-SRIs (acute phase) 02 NIMH-OC Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Phenelzina	e					
Jenike 1997	19	7.00(1.10)	17	6.80(1.40)		— 0.16 [-0.50, 0.81]
Subtotal (95% CI)	19		17			- 0.16 [-0.50, 0.81]
Test for heterogeneity: not	applicable				-	
Test for overall effect: Z =	0.47 (P = 0.64)					
02 Sertraline vs Desipramin	ne					
Hoehn-Saric 2000	79	-2.70(2.67)	85	-1.70(2.77)		-0.37 [-0.67, -0.06]
Subtotal (95% CI)	79		85			-0.37 [-0.67, -0.06]
Test for heterogeneity: not	applicable				_	
Test for overall effect: Z =	2.32 (P = 0.02)					
03 Clomipramine vs Buspiro	one					
Pato 1991	9	21.22(5.49)	9	19.22(5.97)		0.33 [-0.60, 1.26]
Subtotal (95% CI)	9		9			0.33 [-0.60, 1.26]
Test for heterogeneity: not	applicable				— _	
Test for overall effect: Z =	0.70 (P = 0.48)					
Total (95% CI)	107		111			-0.22 [-0.49, 0.05]
Test for heterogeneity: Chi ²	2 = 3.47, df = 2 (P	= 0.18), I ² = 42.3%			- - -	·
Test for overall effect: Z =		• •				
				-	1 -0.5 0 0.5	1

Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)

Outcome: 03 Adverse events



Review: OCD adults: SSRIs

Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 04 Leaving study early due to adverse events

Study or sub-category	SSRI n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Sertraline vs Desipramine				
Hoehn-Saric 2000	8/80	22/86	-	0.39 [0.18, 0.83]
Subtotal (95% CI)	80	86	◆	0.39 [0.18, 0.83]
otal events: 8 (SSRI), 22 (Other drug)				
Fest for heterogeneity: not applicable Fest for overall effect: Z = 2.46 (P = 0.01)			
)2 Clomipramine vs Imipramine				
oz Cionipranii le vs inipranii le Volavka 1985	2/11	2/12		1.09 [0.18, 6.48]
Subtotal (95% CI)	11	12		1.09 [0.18, 6.48]
otal events: 2 (SSRI), 2 (Other drug)		12		1:05 (0:10, 0:40)
est for heterogeneity: not applicable				
est for overall effect: Z = 0.10 (P = 0.92)			
3 Fluvoxamine vs Desipramine				
Goodman 1990a	0/21	2/19		0.18 [0.01, 3.56]
Subtotal (95% CI)	21	19		0.18 [0.01, 3.56]
otal events: 0 (SSRI), 2 (Other drug)				
est for heterogeneity: not applicable				
est for overall effect: Z = 1.12 (P = 0.26	0)			
04 Clomipramine vs Buspirone				
Pato 1991	1/10	0/10		3.00 [0.14, 65.90]
Subtotal (95% CI)	10	10	-	3.00 [0.14, 65.90]
otal events: 1 (SSRI), 0 (Other drug) est for heterogeneity: not applicable				
est for overall effect: Z = 0.70 (P = 0.49)			
05 Clomipramine vs Phenelzine				
Vallejo 1992	1/16	0/14		2.65 [0.12, 60.21]
Subtotal (95% CI)	16	14		2.65 [0.12, 60.21]
otal events: 1 (SSRI), 0 (Other drug)				
est for heterogeneity: not applicable				
est for overall effect: Z = 0.61 (P = 0.54)			
otal (95% CI)	138	141	•	0.51 [0.28, 0.95]
otal events: 12 (SSRI), 26 (Other drug)				
est for heterogeneity: Chi² = 3.98, df = 4 est for overall effect: Z = 2.14 (P = 0.03				
	*	0.001	0.01 0.1 1 10 100	1000
		5.55	Favours SSRI Favours other d	

05 SSRIs/Clomipramine vs Non-SRIs (acute phase) 05 Non-responders (OCD) Comparison:

Outcome:

Study or sub-category	SSRI n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
02 Sertraline vs Desipramine				
Hoehn-Saric 2000	42/80	40/86		1.13 [0.83, 1.54]
Subtotal (95% CI)	80	86		1.13 [0.83, 1.54]
Total events: 42 (SSRI), 40 (Other drug)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.77 (P = 0.4	4)			
Total (95% CI)	80	86		1.13 [0.83, 1.54]
Total events: 42 (SSRI), 40 (Other drug)				•
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.77$ (P = 0.4)	4)			
		0.5	0.7 1 1.5	2

Favours SSRI Favours other drug

Favours SSRI Favours placebo

Review: OCD adults: SSRIs

06 SSRIs vs placebo (continuation phase) Comparison:

Outcome: 01 Leaving study early

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
O1 Fluoxetine				
Beasley 1992	3/23	2/6		0.39 [0.08, 1.84]
Montgomery 1993	16/61	2/12	<u> </u>	1.57 [0.41, 5.97]
Romano 2001	16/36	23/35		0.68 [0.44, 1.05]
Subtotal (95% CI)	120	53	<u> </u>	0.75 [0.50, 1.12]
Total events: 35 (SSRI), 27 (Pk		55	T	0.70 (0.00, 1.12)
Test for heterogeneity: Chi ² = 2	•	3%		
Test for overall effect: $Z = 1.41$		3.00		
1001 101 0401411 011001. 2 = 1.44	0 (1 = 0.10)			
02 Paroxetine				
Hollander 2003d	19/53	37/52	-	0.50 [0.34, 0.75]
Subtotal (95% CI)	53	52	•	0.50 [0.34, 0.75]
Total events: 19 (SSRI), 37 (Pk	acebo)		Ť	
Test for heterogeneity; not app				
Test for overall effect: Z = 3.3				
Total (95% CI)	173	105	<u> </u>	0.61 [0.46, 0.81]
Total events: 54 (SSRI), 64 (Pk		105	V	0.61 [0.46, 0.61]
Test for heterogeneity: Chi ² = (•	17%		
Test for overall effect: Z = 3.3		i.r 70		
Test for overall effect. Z = 3.3	a (F = 0.0007)			
		0.01	0.1 1 10	100

Review: OCD adults: SSRIs


06 SSRIs vs placebo (continuation phase) Comparison: Outcome: 02 Leaving study early due to adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
O1 Fluoxetine				
Montgomery 1993	2/61	0/12		1.05 [0.05, 20.58]
Romano 2001	2/36	1/35		1.94 [0.18, 20.49]
Subtotal (95% CI)	97	47		1.54 [0.25, 9.58]
Total events: 4 (SSRI), 1 (Placebo)			-	
Test for heterogeneity: Chi² = 0.10, df =	= 1 (P = 0.75), I ² = 0%	5		
Test for overall effect: $Z = 0.46$ (P = 0.1	64)			
02 Paroxetine				
Hollander 2003d	3/53	20/52		0.15 [0.05, 0.47]
Subtotal (95% CI)	53	52	•	0.15 [0.05, 0.47]
Fotal events: 3 (SSRI), 20 (Placebo)			_	
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 3.26$ (P = 0.1	001)			
Total (95% CI)	150	99	-	0.26 [0.11, 0.63]
Total events: 7 (SSRI), 21 (Placebo)			_	,
Fest for heterogeneity: Chi² = 4.58, df =	= 2 (P = 0.10), I ² = 56	.3%		
Test for overall effect: $Z = 3.00 (P = 0.1)$	003)			
		0	.01 0.1 1 10	100
			Favours SSRI Favours placeb	0

OCD adults: SSRIs Review:

06 SSRIs vs placebo (continuation phase) Comparison:

03 Non-responders Outcome:



Favours SSRI Favours placebo

Favours SSRI Favours placebo

Favours SSRI Favours placebo

Review:

OCD adults: SSRIs 06 SSRIs vs placebo (continuation phase) Comparison: Outcome:

04 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	SMD (fixed) 95% CI			SMD (fixed) 95% Cl
01 Fluoxetine										
Beasley 1992	23	9.80(7.30)	6	8.50(6.70)			-			0.18 [-0.72, 1.08]
Romano 2001	35	1.46(7.08)	34	2.50(6.16)			-			-0.15 [-0.63, 0.32]
Subtotal (95% CI)	58		40				•			-0.08 [-0.50, 0.34]
Test for heterogeneity: Ch	$i^2 = 0.41$, $df = 1$ (P :	= 0.52), I ² = 0%					1			
Test for overall effect: Z =	0.39 (P = 0.70)									
					-4	-2	-	2	4	_

Review: OCD adults: SSRIs

06 SSRIs vs placebo (continuation phase) 05 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			(fixed) 5% Cl	SMD (fixed) 95% CI
01 Fluoxetine								
Romano 2001	35	1.20(5.37)	34	1.79(5.06)			 	-0.11 [-0.58, 0.36]
Subtotal (95% CI)	35		34					-0.11 [-0.58, 0.36]
Test for heterogeneity: not	t applicable					_		
Test for overall effect: Z =	0.46 (P = 0.64)							
					-1	-0.5	0 05	1

OCD adults: SSRIs Review:

Comparison: 06 SSRIs vs placebo (continuation phase)

Outcome: 06 SF-36; social functioning

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		SMD (95%			SMD (fixed) 95% Cl
01 Fluoxetine									
Romano 2001	34	9.56(19.23)	34	5.88(27.22)					0.15 [-0.32, 0.63]
Subtotal (95% CI)	34		34						0.15 [-0.32, 0.63]
Test for heterogeneity: not	applicable						_ _ _		
Test for overall effect: Z =	0.64 (P = 0.53)								
					-1	-0.5	0.5	i	
					F	avours SSRI	Favours placeb	00	

Review: OCD adults: SSRIs


Comparison: 07 SSRIs vs placebo (discontinuation phase)

01 Death Outcome:

Study or sub-category	SSRI n/N	Placebo n/N	RR (fi 95%	,		RR (fixed) 95% Cl
Koran 2002	0/109	1/114			0.35 [0	0.01, 8.46]
Subtotal (95% CI)	109	114			0.35 [0	0.01, 8.46]
Total events: 0 (SSRI), 1 (Plac	ebo)					
Test for heterogeneity: not ap	plicable					
Test for overall effect: $Z = 0.6$	55 (P = 0.52)					
			0.01 0.1 1	10	100	
			Favours SSRI	Favours place	ebo	

Comparison: 07 SSRIs vs placebo (discontinuation phase)

Outcome: 02 Leaving study early



Review: OCD adults: SSRIs

Comparison: 07 SSRIs vs placebo (discontinuation phase) Outcome: 03 Leaving study early due to adverse effects

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Sertraline Koran 2002 Subtotal (95% CI)	5/109 109	12/114 114		0.44 [0.16, 1.20] 0.44 [0.16, 1.20]
Total events: 5 (SSRI), 12 (Placeb Test for heterogeneity: not applica Test for overall effect: Z = 1.61 (F	able			
		0.	.1 0.2 0.5 1 2 5	10

Review: OCD adults: SSRIs

Comparison: 07 SSRIs vs placebo (discontinuation phase)

Outcome: 04 Relapse

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Sertraline				
Koran 2002	4/109	6/114 -		0.70 [0.20, 2.40]
Subtotal (95% CI)	109	114		0.70 [0.20, 2.40]
Total events: 4 (SSRI), 6 (Plac	ebo)			,
Test for heterogeneity: not ap	plicable			
Test for overall effect: Z = 0.5	7 (P = 0.57)			
			3 05 1 3	-

Favours SSRI Favours placebo

Favours SSRI Favours placebo

OCD adults: SSRIs Review:

Comparison: 07 SSRIs vs placebo (discontinuation phase)


05 Y-BOCS Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixe 95% CI	d)	SMD (fixed) 95% Cl
01 Sertraline Koran 2002 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		11.40(7.50)	113 113	14.20(7.70)	+		-0.37 [-0.63, -0.10] -0.37 [-0.63, -0.10]
					-1 -0.5 0	0.5 1	
					Favours SSRI Fa	vours placebo	

Review: OCD adults: SSRIs

07 SSRIs vs placebo (discontinuation phase) Comparison:

06 NIMH-OC Outcome:



Favours SSRI Favours placebo

07 SSRIs vs placebo (discontinuation phase) 07 QoL Enjoyment and Satisfaction Comparison:

Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			(fixed) i% Cl	SMD (fixed) 95% CI
O1 Sertraline Koran 2002 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		-77.30(16.10)	109 109	-67.50(20.30)	-	.		-0.53 [-0.80, -0.26] -0.53 [-0.80, -0.26]
					-1	-0.5	0 0.5	1

Favours SSRI Favours placebo

Favours Dose 1 Favours Dose 2

Review: OCD adults: SSRIs

08 SSRIs at different doses (continuation phase) Comparison:

Outcome: 01 Leaving study early

tudy	Dose 1	Dose 2	RR (fixed)	RR (fixed)
sub-category	n/N	n/N	95% CI	95% CI
I 40mg Fluoxetine v 20mg Fluox	etine			
leasley 1992	6/21	3/23		- 2.19 [0.63, 7.67]
fontgomery 1993	6/20	5/18		1.08 [0.40, 2.94]
ubtotal (95% CI)	41	41	-	1.47 [0.68, 3.19]
otal events: 12 (Dose 1), 8 (Dos	e 2)			
est for heterogeneity: Chi² = 0.7	5, df = 1 (P = 0.39), l ² = 09	6		
est for overall effect: Z = 0.98 (I	P = 0.33)			
2 60mg Fluoxetine v 20mg Fluox	etine			
leasley 1992	3/26	3/23		0.88 [0.20, 3.96]
fontgomery 1993	5/23	5/18		0.78 [0.27, 2.29]
ubtotal (95% CI)	49	41		0.82 [0.34, 1.97]
otal events: 8 (Dose 1), 8 (Dose	2)			
est for heterogeneity: Chi² = 0.0	2, df = 1 (P = 0.90), l ² = 09	6		
est for overall effect: Z = 0.45 (I	P = 0.66)			
3 60mg Fluoxetine v 40mg Fluox	etine			
leasley 1992	3/26	6/21 -		0.40 [0.11, 1.43]
fontgomery 1993	5/23	6/20		0.72 [0.26, 2.02]
ubtotal (95% CI)	49	41		0.56 [0.26, 1.24]
otal events: 8 (Dose 1), 12 (Dos	e 2)		- - -	•
est for heterogeneity: Chi² = 0.5	0, df = 1 (P = 0.48), l ² = 09	6		
est for overall effect: Z = 1.43 (I	P = 0.15)			
<u>.</u>	•			+
·		0.1	0.2 0.5 1 2 5	10

Review: OCD adults: SSRIs

Comparison: 08 SSRIs at different doses (continuation phase) Outcome: 02 Leaving study early due to adverse events

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 40mg Fluoxetine v 20mg Fluoxetine				
Montgomery 1993	1/20	0/18		— 2.71 [0.12, 62.70]
Subtotal (95% CI)	20	18		- 2.71 [0.12, 62.70]
Total events: 1 (Dose 1), 0 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.62$ (P = 0.9)	53)			
02 60mg Fluoxetine v 20mg Fluoxetine				
Montgomery 1993	1/23	0/18		— 2.38 [0.10, 55.06]
Subtotal (95% CI)	23	18		- 2.38 [0.10, 55.06]
Total events: 1 (Dose 1), 0 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.54$ (P = 0.5	59)			
03 60mg Fluoxetine v 40mg Fluoxetine				
Montgomery 1993	1/23	1/20		0.87 [0.06, 13.02]
Subtotal (95% CI)	23	20		0.87 [0.06, 13.02]
Total events: 1 (Dose 1), 1 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.10$ (P = 0.9)	92)			
			0.01 0.1 1 10	100
			Favours Dose 1 Favours Dose	2

OCD adults: SSRIs Review:

08 SSRIs at different doses (continuation phase) Comparison:

03 Non-responders Outcome:

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine 40mg v Fluoxetine 20mg				
Beasley 1992	12/21	14/23		0.94 [0.57, 1.54]
Subtotal (95% CI)	21	23		0.94 [0.57, 1.54]
Total events: 12 (Dose 1), 14 (Dose 2))			
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.25$ (P = 0	.80)			
02 Fluoxetine 60mg v Fluoxetine 20mg				
Beasley 1992	11/26	14/23		0.70 [0.40, 1.21]
Subtotal (95% CI)	26	23		0.70 [0.40, 1.21]
Total events: 11 (Dose 1), 14 (Dose 2))		_	
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 1.28$ (P = 0	.20)			
03 Fluoxetine 60mg v Fluoxetine 40mg				
Beasley 1992	11/26	12/21		0.74 [0.41, 1.32]
Subtotal (95% CI)	26	21		0.74 [0.41, 1.32]
Total events: 11 (Dose 1), 12 (Dose 2))			
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 1.01$ (P = 0	.31)			
			0.2 0.5 1 2	5
			Favours Dose 1 Favours Dose 2	2

OCD adults: SSRIs

08 SSRIs at different doses (continuation phase) 04 Y-BOCS Comparison:

Outcome:


Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Fluoxetine 40mg v Fluoxe	etine 20mg					
Beasley 1992	21	9.40(6.00)	23	9.80(7.30)	_ _	-0.06 [-0.65, 0.53]
Subtotal (95% CI)	21		23		•	-0.06 [-0.65, 0.53]
est for heterogeneity; not a	applicable				Ī	
est for overall effect: Z = 0	0.19 (P = 0.85)					
)2 Fluoxetine 60mg v Fluox	etine 20mg					
Beasley 1992	26	7.00(5.40)	23	9.80(7.30)	-	-0.43 [-1.00, 0.13]
ubtotal (95% CI)	26		23		•	-0.43 [-1.00, 0.13]
est for heterogeneity: not a	applicable				-	
est for overall effect: Z = 1	1.49 (P = 0.14)					
3 Fluoxetine 60mg v Fluox	etine 40ma					
Beasley 1992	26	7.00(5.40)	21	9.40(6.00)	 ■-	-0.42 [-1.00, 0.17]
Subtotal (95% CI)	26	•	21		→	-0.42 [-1.00, 0.17]
est for heterogeneity: not a	applicable				-	
est for overall effect: Z = 1						

Favours Dose 1 Favours Dose 2

OCD adults: SSRIs Review:

Comparison: 09 SSRIs v Clomipramine (continuation phase)

Outcome: 01 Leaving study early



Comparison: 09 SSRIs vs Clomipramine (continuation phase) Outcome: 02 Leaving study early due to adverse events

Study	SSRI	Clomipramine	RR (fixed)	RR (fixed)
or sub-category	n/N	n/N	95% CI	95% CI
01 Fluoxetine 60mg vs Clomipi	ramine 200mg (non-respond	lers)		
Lopez-lbor 1996	2/14	0/8		— 3.00 [0.16, 55.72]
Subtotal (95% CI)	14	8		3.00 [0.16, 55.72]
Total events: 2 (SSRI), 0 (Clori	nipramine)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 0.7$	4 (P = 0.46)			
02 Fluoxetine 20mg vs Clomipi	ramine 100mg (responders)			
Lopez-lbor 1996	1/11	1/13		1.18 [0.08, 16.78]
Subtotal (95% CI)	11	13		1.18 [0.08, 16.78]
Total events: 1 (SSRI), 1 (Clori	nipramine)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 0.1$	2 (P = 0.90)			
		0.0	1 0.1 1 10	100
			Favours SSRI Favours Clor	nipramine

Review: OCD adults: SSRIs

Comparison: Outcome: 09 SSRIs vs Clomipramine (continuation phase) 03 Y-BOCS


Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine 60mg vs Clor	nipramine 200mg ((non-responders)				
Lopez-lbor 1996	11	8.80(5.79)	13	13.70(11.79)		-0.50 [-1.31, 0.32]
Subtotal (95% CI)	11		13			-0.50 [-1.31, 0.32]
Test for heterogeneity: not	applicable				-	
Test for overall effect: Z =	1.19 (P = 0.23)					
02 Fluoxetine 20mg vs Clor	nipramine 100mg ((responders)				
Lopez-lbor 1996	14	24.00(7.54)	8	15.00(9.32)	- 	1.05 [0.12, 1.99]
Subtotal (95% CI)	14		8			1.05 [0.12, 1.99]
Test for heterogeneity: not	applicable					
Test for overall effect: Z =	2.21 (P = 0.03)					
Total (95% CI)	25		21		•	0.18 [-0.44, 0.79]
Test for heterogeneity: Chi	² = 5.99, df = 1 (P	= 0.01), I ² = 83.3%				
Test for overall effect: Z =	0.56 (P = 0.57)	••				
				-4	-2 0 2	4

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 10 Sertraline standard dose vs high dose (non-responders)


Outcome: 01 Leaving study early



Review: OCD adults: SSRIs


Comparison: 10 Sertraline standard dose vs high dose (non-responders)

Outcome: 02 Leaving study early due to adverse events



Comparison: 10 Sertraline standard dose vs high dose (non-responders)

Outcome: 03 Non-responders



Review: OCD adults: SSRIs

Comparison: 11 SSRI vs Placebo (maintenance)

Outcome: 01 Leaving the study early

Study or sub-category	SSRI n/N	Placebo n/N		RR (fi 95%			RR (fixed) 95% Cl
01 Paroxetine				_			
Ansseau 1995	19/51	7/12			-		0.64 [0.35, 1.16]
Subtotal (95% CI)	51	12			-		0.64 [0.35, 1.16]
Total events: 19 (SSRI), 7 (PI	acebo)			_			
Test for heterogeneity: not a	pplicable						
Test for overall effect: Z = 1.							
		0.	1 0.2	0.5 1	2	5 10	

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Review: OCD adults: SSRIs

Comparison: 11 SSRI vs Placebo (maintenance)

Outcome: 02 Leaving the study early due to adverse events

Study or sub-category	SSRI n/N	Placebo n/N			(fixed) 5% Cl			RR (fixed) 95% Cl
01 Paroxetine								
Ansseau 1995	8/51	2/12	_					0.94 [0.23, 3.88]
Subtotal (95% CI)	51	12	-		-	_		0.94 [0.23, 3.88]
Total events: 8 (SSRI), 2 (Plac	ebo)				Т			
Test for heterogeneity: not ap	plicable							
Test for overall effect: Z = 0.0	18 (P = 0.93)							
		0	.1 0.2	0.5	1 :	2 5	10	

Review: OCD adults: SSRIs

Comparison: 11 SSRI vs Placebo (maintenance)

Outcome: 03 Adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine Ansseau 1995 Subtotal (95% Cl) Total events: 42 (SSRI), 8 (Pla		8/12 12	*	1.24 [0.81, 1.88] 1.24 [0.81, 1.88]
Test for overall effect: Z = 0.9	99 (P = 0.32)			
		0.1	0.2 0.5 1 2 5	5 10

Review: OCD adults: SSRIs

Comparison: 11 SSRI vs Placebo (maintenance)


Outcome: 04 Severe adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Ansseau 1995	18/51	3/12		1.41 [0.49, 4.03]
Subtotal (95% CI)	51	12		1.41 [0.49, 4.03]
Total events: 18 (SSRI), 3 (Pk	acebo)			•
Test for heterogeneity: not ap	oplicable			
Test for overall effect: $Z = 0$.	64 (P = 0.52)			
			0.1 0.2 0.5 1 2 5	10
			Favours SSRI Favours Placebo	

OCD adults: SSRIs Review:

11 SSRI vs Placebo (maintenance) Comparison:

05 Non-responders (Y-BOCS 25% reduction) Outcome:



Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Review:

OCD adults: SSRIs 11 SSRI vs Placebo (maintenance) Comparison: Outcome:

06 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	SMD (fixed) 95% CI	ı		SMD (fixed) 95% Cl
01 Paroxetine										
Ansseau 1995	51	-14.70(7.20)	12	-11.00(6.90)						-0.51 [-1.15, 0.12]
Subtotal (95% CI)	51		12				•			-0.51 [-1.15, 0.12]
Test for heterogeneity: not	applicable						Ĭ			
Test for overall effect: Z =	1.58 (P = 0.11)									
					-10	-5	-	5	10	

OCD adults: SSRIs Review:

Comparison: 11 SSRI vs Placebo (maintenance)

Outcome: 07 NIMH-OCS

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		5	SMD (fixed 95% CI)		SMD (fixed) 95% Cl
01 Paroxetine Ansseau 1995		5 0040 601	1.0	0.6040.604						0.61.7.1.05.0.001
Subtotal (95% CI)	51 51	-5.20(2.60)	12 12	-3.60(2.60)			<u>-</u>			-0.61 [-1.25, 0.03] -0.61 [-1.25, 0.03]
Test for heterogeneity: not Test for overall effect: Z =	applicable		12							-0.61 (-1.25, 0.03)
					-10	-5	ó	5	10	

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)

Outcome: 01 Leaving the study early

Study or sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
O1 Paroxetine Ansseau 1995 Subtotal (95% CI) Total events: 19 (SSRI), 8 (C Test for heterogeneity: not a Test for overall effect: Z = 0	pplicable	8/20 20	+	0.93 [0.49, 1.77] 0.93 [0.49, 1.77]
		0.1	0.2 0.5 1 2 5	10

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)

Outcome: 02 Leaving the study early due to adverse events


Study or sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) RR (fixed) 95% Cl 95% Cl
01 Paroxetine			
Ansseau 1995	8/51	6/20	0.52 [0.21, 1.32]
Subtotal (95% CI)	51	20	0.52 [0.21, 1.32]
Total events: 8 (SSRI), 6 (Clorr	nipramine)		
Test for heterogeneity: not app	olicable		
Test for overall effect: Z = 1.3	8 (P = 0.17)		
			0.1 0.2 0.5 1 2 5 10
			Farance CODI - Farance Classical -

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)

Outcome: 03 Adverse events



Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)

Outcome: 04 Severe adverse events

Study or sub-category	SSRI n/N	Clomipramine n <i>i</i> N	RR (fixed) 95% Cl		RR (fixed) 95% Cl
01 Paroxetine					
Ansseau 1995	18/51	2/20		 ;	3.53 [0.90, 13.84]
Subtotal (95% CI)	51	20	-	-	3.53 [0.90, 13.84]
Total events: 18 (SSRI), 2 (C	lomipramine)		-		
Test for heterogeneity: not a	pplicable				
Test for overall effect: $Z = 1$.81 (P = 0.07)				
		0.01	0.1 1	10 100	_

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 05 Responders (Y-BOCS 25% reduction)

Study or sub-category	SSRI n/N	Clomipramine n/N		RR (fi 95%			RR (fixed) 95% Cl
01 Paroxetine							
Ansseau 1995	8/51	3/20				-	1.05 [0.31, 3.55]
Subtotal (95% CI)	51	20				-	1.05 [0.31, 3.55]
Total events: 8 (SSRI), 3 (Clorn	ipramine)			I			
Test for heterogeneity: not app	olicable						
Test for overall effect: Z = 0.07	7 (P = 0.94)						
		0.1	0.2	0.5 1	2	5	10

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)


Outcome: 06 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)		\$	SMD (fixed) 95% CI	ı		(fixed) % Cl
01 Paroxetine										·
Ansseau 1995	51	-14.70(7.20)	20	-14.60(7.10)					-0.01 [-0.5	3, 0.50]
Subtotal (95% CI)	51		20				•		-0.01 [-0.5	3, 0.50]
Test for heterogeneity: not	applicable						I			
Test for overall effect: Z =	0.05 (P = 0.96)									
					40			<u> </u>	40	
					-10	-5	U	5	10	

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)

Outcome: 07 NIMH-OCS



Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 13 SSRI vs Placebo (relapse prevention)

Outcome: 01 Leaving the study early

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 2 months				
Ansseau 1995	0/14	3/18 -		0.18 [0.01, 3.24]
Subtotal (95% CI)	14	18		0.18 [0.01, 3.24]
Total events: 0 (Paroxetine), 3 (P	Placebo)		_	
Test for heterogeneity: not applic	cable			
Test for overall effect: $Z = 1.16$ ((P = 0.25)			
02 Paroxetine at 6 months				
Bailer 1995	9/20	16/24	-	0.68 [0.39, 1.18]
Subtotal (95% CI)	20	24	•	0.68 [0.39, 1.18]
Total events: 9 (Paroxetine), 16 ((Placebo)			
Test for heterogeneity: not applic	cable			
Test for overall effect: Z = 1.37 ((P = 0.17)			
Total (95% CI)	34	42	•	0.59 [0.33, 1.04]
Total events: 9 (Paroxetine), 19 ((Placebo)			
Test for heterogeneity: Chi² = 0.8	37, df = 1 (P = 0.35), l² = 0%	6		
Test for overall effect: Z = 1.83 ((P = 0.07)			
		0.0	01 0.1 1 10	100
		F	Favours Paroxetine Favours Placet	00

Review: OCD adults: SSRIs

Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 02 Leaving the study early due to adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 6 months				
Bailer 1995	0/20	9/24		0.06 [0.00, 1.01]
Subtotal (95% CI)	20	24		0.06 [0.00, 1.01]
Total events: 0 (Paroxetine),	9 (Placebo)			
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 1	.95 (P = 0.05)			
			0.001 0.01 0.1 1 10 100	1000

Favours Paroxetine Favours Placebo

Review: OCD adults: SSRIs

Comparison: 13 SSRI vs Placebo (relapse prevention)

Outcome: 03 Full relapse (Y-BOCS and CGI Severity increase)

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
01 Paroxetine at 6 months				
Bailer 1995	1/20	6/24		0.20 [0.03, 1.53]
Subtotal (95% CI)	20	24		0.20 [0.03, 1.53]
Total events: 1 (Paroxetine),	6 (Placebo)			
Test for heterogeneity; not a	pplicable			
Test for overall effect: Z = 1.	55 (P = 0.12)			
			0.01 0.1 1 10	100
			Favours Paroxetine Favours Pla	acebo

Review: OCD adults: SSRIs

13 SSRI vs Placebo (relapse prevention) Comparison:

04 Partial relapse (Y-BOCS or CGI Severity increase) Outcome:

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 2 months				
Ansseau 1995	2/14	7/18		0.37 [0.09, 1.50]
Subtotal (95% CI)	14	18		0.37 [0.09, 1.50]
Total events: 2 (Paroxetine), Test for heterogeneity: not a Test for overall effect: Z = 1	pplicable			
02 Paroxetine at 6 months				
Bailer 1995	9/20	16/24	-	0.68 [0.39, 1.18]
Subtotal (95% CI)	20	24	→	0.68 [0.39, 1.18]
Total events: 9 (Paroxetine),	16 (Placebo)		7	•
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 1	.37 (P = 0.17)			
		(0.01 0.1 1 10	100
			Favours Paroxetine Favours Placeb	00

Review: OCD adults: SSRIs

Comparison: 13 SSRI vs Placebo (relapse prevention)

Outcome: 05 Adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 2 months				
Ansseau 1995	8/14	9/18		1.14 [0.60, 2.18]
Subtotal (95% CI)	14	18		1.14 [0.60, 2.18]
Total events: 8 (Paroxetine),	, 9 (Placebo)		_	•
Test for heterogeneity: not a	applicable			
Test for overall effect: Z = 0).40 (P = 0.69)			
		0.1	0.2 0.5 1 2	5 10

Favours Paroxetine Favours Placebo Review: OCD adults: SSRIs

Comparison: Outcome: 06 Severe adverse events

13 SSRI vs Placebo (relapse prevention)

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 2 months				
Ansseau 1995	1/14	4/18		0.32 [0.04, 2.57]
Subtotal (95% CI)	14	18		0.32 [0.04, 2.57]
Total events: 1 (Paroxetine),	4 (Placebo)			
Test for heterogeneity: not a	applicable			
Test for overall effect: Z = 1	.07 (P = 0.28)			
			0.01 0.1 1 10	100
			Favours Parovetine Favours Place	eho.

Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 07 Y-BOCS

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Paroxetine at 2 months						
Ansseau 1995	12	0.80(1.60)	12	0.90(3.20)		-0.04 [-0.84, 0.76]
Subtotal (95% CI)	12		12		•	-0.04 [-0.84, 0.76]
Test for heterogeneity: not as	oplicable				Ī	
Test for overall effect: $Z = 0$.	09 (P = 0.93)					
02 Paroxetine at 6 months						
Bailer 1995	12	-3.50(3.60)	8	0.88(3.59)	-	-1.17 [-2.15, -0.19]
Subtotal (95% CI)	12		8		•	-1.17 [-2.15, -0.19]
Test for heterogeneity: not as	oplicable				Ť	·
Test for overall effect: $Z = 2$.	33 (P = 0.02)					
Total (95% CI)	24		20		•	-0.49 [-1.11, 0.13]
Test for heterogeneity: Chi2 =	3.05, df = 1 (P	= 0.08), I ² = 67.2%			1	
Test for overall effect: $Z = 1$:	54 (P = 0.12)	• •				
				-10) -5 0 5	10

Favours Paroxetine Favours Placebo

OCD adults: SSRIs 13 SSRI vs Placebo (relapse prevention) 08 NIMH-OC Review: Comparison: Outcome:


Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Paroxetine at 2 months							
Ansseau 1995	11	0.20(0.90)	9	1.30(2.30)			-0.63 [-1.54, 0.28]
Subtotal (95% CI)	11		9			•	-0.63 [-1.54, 0.28]
Test for heterogeneity: not ap	pplicable					·	
Test for overall effect: $Z = 1$.	36 (P = 0.17)						
02 Paroxetine at 6 months							
Bailer 1995	12	-0.67(1.66)	8	0.38(1.67)		-	-0.60 [-1.52, 0.31]
Subtotal (95% CI)	12		8			•	-0.60 [-1.52, 0.31]
Test for heterogeneity: not ap	pplicable					·	
Test for overall effect: $Z = 1$.	29 (P = 0.20)						
Total (95% CI)	23		17			•	-0.62 [-1.26, 0.03]
Test for heterogeneity: Chi² =	= 0.00, df = 1 (P	= 0.97), I ² = 0%					
Test for overall effect: $Z = 1$.	87 (P = 0.06)						
					-10 -5	0 5	10
					Favours Par	oxetine Favours Place	ebo

Clomipramine (OCD, adults)

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase

Outcome: 01 Adverse events



Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase

Outcome: 02 Leaving study early

Study or sub-category	Clomipramine n/N	Placebo n/N		RR (fixed) 95% Cl	RR (fixed) 95% Cl
Burnham 1993	28/82	20/77		-	1.31 [0.81, 2.13]
CCSG 1991(1)	17/118	13/121			1.34 [0.68, 2.64]
CCSG 1991(2)	14/142	12/139			1.14 [0.55, 2.38]
Stein 1992	7/21	2/23		-	→ 3.83 [0.89, 16.44]
Zohar 1996a	34/99	39/99		-	0.87 [0.60, 1.26]
Total (95% CI) Total events: 100 (Clomipra		459		*	1.15 [0.90, 1.47]
- '	² = 5.32, df = 4 (P = 0.26), l ² = 24.	9%			
Test for overall effect: Z =	1.11 (P = 0.27)				
		0	.1 0.2	0.5 1 2 5	10

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 03 Leaving study early due to adverse events

Study or sub-category	Clomipramine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Burnham 1993	17/82	8/77		2.00 [0.91, 4.36]
Zohar 1996a	17/99	6/99		2.83 [1.17, 6.89]
Total (95% CI)	181	176		2.35 [1.31, 4.22]
Total events: 34 (Clomipram	nine), 14 (Placebo)			
Test for heterogeneity: Chi ^z	$I = 0.34$, df = 1 (P = 0.56), $I^2 = 0\%$			
Test for overall effect: Z = :	2.86 (P = 0.004)			

Favours Clomipramine Favours Placebo

Favours Clomipramine Favours Placebo

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase


Outcome: 04 Non-responders (Y-BOCS)

Study or sub-category	Clomipramine n/N	Placebo n/N	RR (fixed) RR (fixed) 95% Cl 95% Cl
Burnham 1993	42/82	45/77	0.88 [0.66, 1.16]
Zohar 1996a	47/99	64/99	0.73 [0.57, 0.95]
Total (95% CI)	181	176	0.79 [0.66, 0.96]
Total events: 89 (Clomipran			
Test for heterogeneity: Chi ²	² = 0.83, df = 1 (P = 0.36), l ² = 0%		
Test for overall effect: $Z =$	2.40 (P = 0.02)		
-			0.1 0.2 0.5 1 2 5 10
			Favours Clomipramine Favours Placebo

OCD adults: Clomipramine Review:

01 Clomipramine vs placebo: acute phase Comparison:

05 Non-responders (CGI) Outcome:



Favours Clomipramine

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase

Outcome: 06 Non-responders (all)

Study or sub-category	Clomipramine n/N	Placebo n/N			RR (fi: 95%				RR (fixed) 95% Cl	
Burnham 1993	42/82	45/77			_			0.8	8 [0.66, 1.16]	
Stein 1992	14/21	17/23			_	_		0.9	0 [0.61, 1.33]	
Zohar 1996a	47/99	64/99			-			0.7	3 [0.57, 0.95]	
Total (95% CI)	202	199			•			0.8	1 [0.68, 0.96]	
Total events: 103 (Clomipra	mine), 126 (Placebo)				*					
	$= 1.17$, df $= 2$ (P = 0.56), $I^2 = 0\%$									
Test for overall effect: Z = :	2.44 (P = 0.01)									
-			0.1	0.2	0.5 1	2	5 1	0		

Favours Clomipramine Favours placebo

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase

Outcome: 07 Non-remitters

Study or sub-category	Clomipramine n <i>i</i> N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
CCSG 1991 (pooled)	136/260	252/260	=	0.54 [0.48, 0.61]
Total (95% CI) Total events: 136 (Clomipramir Test for heterogeneity: not app Test for overall effect: Z = 10.	plicable	260	•	0.54 [0.48, 0.61]
-			1	5 10

Favours Clomipramine Favours placebo

OCD adults: Clomipramine Review:

01 Clomipramine vs placebo: acute phase 08 Y-BOCS Comparison:

Outcome:


Study or sub-category	N	Clomipramine Mean (SD)	N	Placebo Mean (SD)			0 (fixed) 5% Cl			SMD (fixed) 95% Cl
Burnham 1993	78	-7.73(7.42)	75	-4.60(7.53)		-	-			-0.42 [-0.74, -0.10]
CCSG 1991(1)	118	16.23(7.93)	120	25.11(6.68)		-				-1.21 [-1.48, -0.93]
CCSG 1991(2)	134	14.70(7.87)	129	25.59(6.01)		-				-1.55 [-1.82, -1.27]
Zohar 1996a	94	-8.00(8.20)	99	-5.00(7.90)		+	•			-0.37 [-0.66, -0.09]
Fotal (95% CI)	424		423			•				-0.93 [-1.07, -0.78]
Test for heterogeneity: Ch	$ni^2 = 47.71$, $df = 3$ ($(P < 0.00001), I^2 = 93.7\%$				•				
Test for overall effect: Z :	= 12.62 (P < 0.000)	01)								
					-4	-2	0	2	4	
					Favours	: Clomipramine	e Favo	ours Place	bo	

Review: OCD adults: Clomipramine Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 09 OCD Scale (CPRS) SMD (fixed) SMD (fixed) Study Clomipramine Placebo orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Thoren 1980a 8 6.38(2.75) 8 8.75(3.18) -0.75 [-1.78, 0.27] Total (95% CI) -0.75 [-1.78, 0.27] Test for heterogeneity: not applicable Test for overall effect: Z = 1.44 (P = 0.15) Favours Clomipramine Favours Placebo Review: OCD adults: Clomipramine 01 Clomipramine vs placebo; acute phase Comparison: 10 6-item OCD Scale - amelioration Outcome: Study Clomipramine Placebo SMD (fixed) SMD (fixed) Ν Mean (SD) or sub-category Ν Mean (SD) 95% CI 95% CI Montgomery 1990 -10.00(5.11) 7 -0.71(5.11) -1.70 [-2.99, -0.42] Total (95% CI) 7 -1.70 [-2.99, -0.42] Test for heterogeneity: not applicable Test for overall effect: Z = 2.60 (P = 0.009)Favours Clomipramine Favours placebo OCD adults: Clomipramine Review: Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 11 OCD (OCD-CPRS; 6-item OCD Scale-amelioration) SMD (fixed) Study Clomipramine Placebo SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Montgomery 1990 -0.71(5.11)-10.00(5.11) -1.70 [-2.99, -0.42] Thoren 1980a 8 -0.75 [-1.78, 0.27] 6.38(2.75) 8.75(3.18) Total (95% CI) 15 -1.12 [-1.92, -0.32] Test for heterogeneity: Chi² = 1.28, df = 1 (P = 0.26), l² = 21.8% Test for overall effect: Z = 2.75 (P = 0.006) -10 10 Favours Clomipramine Favours placebo Review: OCD adults: Clomipramine Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 12 Y-BOCS/CPRS Clomipramine Placebo SMD (fixed) SMD (fixed) Study or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Y-BOCS Burnham 1993 78 -7.73(7.42) 75 -4.60(7.53) -0.42 [-0.74, -0.10] CCSG 1991(1) 118 16.23(7.93) 120 -1.21 [-1.48, -0.93] 25.11(6.68) CCSG 1991(2) 134 14.70(7.87) 129 25.59(6.01) -1.55 [-1.82, -1.27] -0.37 [-0.66, -0.09] -0.93 [-1.07, -0.78] Zohar 1996a 94 -8.00(8.20) 99 -5.00(7.90) Subtotal (95% CI) 423 424 Test for heterogeneity: Chi² = 47.71, df = 3 (P < 0.00001), l² = 93.7% Test for overall effect: Z = 12.62 (P < 0.00001)

02 OCD-CPRS Thoren 1980a 6.38(2.75) 8.75(3.18) -0.75 [-1.78, 0.27] Subtotal (95% CI) -0.75 [-1.78, 0.27] Test for heterogeneity: not applicable Test for overall effect: Z = 1.44 (P = 0.15) 03 6-item OCD Scale - amelioration -1.70 [-2.99, -0.42] -1.70 [-2.99, -0.42] Montgomery 1990 -10.00(5.11) -0.71(5.11)Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.60 (P = 0.009)Total (95% CI) -0.93 [-1.07, -0.79] 438 Test for heterogeneity: Chi² = 49.22, df = 5 (P < 0.00001), l² = 89.8% Test for overall effect: Z = 12.91 (P < 0.00001)

Favours Clomipramine Favours Placebo

Removing heterogeneity from Clomipramine v Placebo (Y-BOCS/CPRS): Burnham1993 and Zohar1996a removed because they reported change scores



Favours Clomipramine

Favours placebo

Test for overall effect: Z = 0.97 (P = 0.33)

Review: OCD adults: Clomipramine Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 16 Leyton Obsessional Inventory: resistance SMD (fixed) SMD (fixed) Study Clomipramine Placebo orsub-category N Ν Mean (SD) 95% CI 95% CI Thoren 1980a 8 -13.00(19.60) 8 -4.30(18.60) -0.43 [-1.43, 0.56] Total (95% CI) -0.43 [-1.43, 0.56] Test for heterogeneity: not applicable Test for overall effect: Z = 0.85 (P = 0.40) -10 10 Favours Clomipramine Favours placebo Review: OCD adults: Clomipramine Comparison 01 Clomipramine vs placebo: acute phase Outcome: 17 Leyton Obsessional Inventory: interference Study Clomipramine Placebo SMD (fixed) SMD (fixed) Ν Ν Mean (SD) 95% CI 95% CI or sub-category Mean (SD) Thoren 1980a -12.30(24.00) -8.40(15.90) -0.18 [-1.16, 0.80] Total (95% CI) -0.18 [-1.16, 0.80] Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72) Favours Clomipramine Favours placebo Review: OCD adults: Clomipramine Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 18 Self-Rating Obsessive-Compulsive Personality Inventory Study Clomipramine Placebo SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Stein 1992 21 45.17(7.36) 23 49.31(7.36) -0.55 [-1.16, 0.05] Total (95% CI) 23 -0.55 [-1.16, 0.05] Test for heterogeneity: not applicable Test for overall effect: Z = 1.79 (P = 0.07)-10 10 Favours Clomipramine Favours Placebo OCD adults: Clomipramine Review: 01 Clomipramine vs placebo: acute phase Comparison: Outcome: 19 Montgomery-Asberg Depression Rating Scale Study Clomipramine Placebo SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Mean (SD) 95% CI 95% CI Zohar 1996a -2.40(7.30) 99 -0.60(7.90) -0.24 [-0.52, 0.05] Total (95% CI) 99 -0.24 [-0.52, 0.05] Test for heterogeneity: not applicable Test for overall effect: Z = 1.63 (P = 0.10) -10 -5 0 10 Favours Placebo Favours Clomipramine Review: OCD adults: Clomipramine Comparison 01 Clomipramine vs placebo: acute phase Outcome: 20 Clinical Global Impressions: severity of illness SMD (fixed) Study Placebo SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Zohar 1996a 94 -1.10(1.20) 99 -0.70(1.30) -0.32 [-0.60, -0.03] Total (95% CI) 99 -0.32 [-0.60, -0.03] Test for heterogeneity: not applicable Test for overall effect: Z = 2.20 (P = 0.03)-10 -5 10 Favours Clomipramine Favours Placebo Review: OCD adults: Clomipramine 01 Clomipramine vs placebo: acute phase Comparison: Outcome 21 Symptom Checklist-90 SMD (fixed) SMD (fixed) Study Clomipramine Placebo or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI Zohar 1996a 74 -31.90(39.90) 77 -19.50(37.30) -0.32 [-0.64, 0.00] Total (95% CI) 77 -0.32 [-0.64, 0.00] Test for heterogeneity: not applicable Test for overall effect: Z = 1.95 (P = 0.05) -5 5 10

Favours Placebo


Favours Clomipramine

Review: OCD adults: Clomipramine

Test for overall effect: Z = 1.00 (P = 0.32)

Comparison: 02 Clomipramine vs SSRIs: acute phase

Outcome: 01 Adverse events



0.01

0.1

Favours Clomipramine Favours SSRI

10

100

Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 03 Leaving study early

Study	Clomipramine	SSRI	RR (fixed)	RR (fixed)
or sub-category	n/N	n/N	95% CI	95% CI
01 Clomipramine vs Fluoxetine				
Lopez-lbor 1996	4/25	5/30		0.96 [0.29, 3.20]
Subtotal (95% CI)	25	30		0.96 [0.29, 3.20]
otal events: 4 (Clomipramine),	5 (SSRI)		Т	
est for heterogeneity: not appl	licable			
est for overall effect: Z = 0.07	' (P = 0.95)			
02 Clomipramine vs Fluvoxamin	ie			
Freeman 1994	11/32	6/34	 •	1.95 [0.82, 4.65]
Koran 1996a	15/42	8/37	+-	1.65 [0.79, 3.45]
Milanfranchi 1997	1/13	0/13		— 3.00 [0.13, 67.51]
Mundo 2001	26/112	19/115	+	1.41 [0.83, 2.39]
Smeraldi 1992	1/6	1/6	+	1.00 [0.08, 12.56]
Subtotal (95% CI)	205	205	•	1.57 [1.07, 2.29]
Fotal events: 54 (Clomipramine)), 34 (SSRI)		'	
Test for heterogeneity: Chi² = 0	i.71, df = 4 (P = 0.95), i ² = 0%			
Test for overall effect: $Z = 2.34$	(P = 0.02)			
03 Clomipramine vs Paroxetine				
Burnham 1993	28/82	28/82	+	1.00 [0.65, 1.53]
Zohar 1996a	34/99	49/201	 •	1.41 [0.98, 2.03]
Subtotal (95% CI)	181	283	♦	1.22 [0.92, 1.61]
'otal events: 62 (Clomipramine)				
est for heterogeneity: Chi² = 1		4%		
est for overall effect: Z = 1.41	(P = 0.16)			
04 Clomipramine vs Sertraline				
Askin 1999	4/22	2/20	- •	1.82 [0.37, 8.88]
Bisserbe 1997	35/82	23/86	 • -	1.60 [1.04, 2.45]
Subtotal (95% CI)	104	106	•	1.61 [1.06, 2.45]
otal events: 39 (Clomipramine)), 25 (SSRI)			
est for heterogeneity: Chi² = 0				
est for overall effect: Z = 2.25	5 (P = 0.02)			
otal (95% CI)	515	624	*	1.39 [1.14, 1.68]
otal events: 159 (Clomipramine				
est for heterogeneity: Chi² = 4				
Test for overall effect: $Z = 3.29$	9 (P = 0.001)			
		0.01	0.1 1 10	100
		Favo	urs Clomipramine Favours SSRI	

Outcome: 04 Leaving study early due to adverse events SSRI RR (fixed) RR (fixed) Study Clomipramine or sub-category nΝ n/N 95% CI 95% CI 01 Clomipramine vs Fluoxetine Lopez-Ibor 1996 1/25 1/30 1.20 [0.08, 18.23] Subtotal (95% CI) 25 30 1.20 [0.08, 18.23] Total events: 1 (Clomipramine), 1 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.13 (P = 0.90) 02 Clomipramine vs Fluvoxamine Freeman 1994 4/30 5/34 0.91 [0.27, 3.07] Koran 1996a 7/42 5/37 1.23 [0.43, 3.56] Milanfranchi 1997 0/13 0/13 Not estimable 2.05 [0.96, 4.38] 0.33 [0.02, 6.86] Mundo 2001 9/115 18/112 Smeraldi 1992 0/6 1/6 Subtotal (95% CI) 203 205 1.45 [0.85, 2.46] Total events: 29 (Clomipramine), 20 (SSRI) Test for heterogeneity: Chi² = 2.38, df = 3 (P = 0.50), l² = 0% Test for overall effect: Z = 1.38 (P = 0.17) 03 Clomipramine vs Paroxetine 1.13 [0.61, 2.11] Burnham 1993 17/82 15/82 Zohar 1996a 17/99 18/201 1.92 [1.03, 3.56] Subtotal (95% CI) 181 283 1.48 [0.96, 2.29] Total events: 34 (Clomipramine), 33 (SSRI) Test for heterogeneity: $Chi^2 = 1.38$, df = 1 (P = 0.24), $I^2 = 27.5\%$ Test for overall effect: Z = 1.77 (P = 0.08) 04 Clomipramine vs Sertraline Bisserbe 1997 21/82 9/86 2.45 [1.19, 5.03] Subtotal (95% CI) 2.45 [1.19, 5.03] Total events: 21 (Clomipramine), 9 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.44 (P = 0.01) Total (95% CI) 491 604 1.61 [1.19, 2.18] Total events: 85 (Clomipramine), 63 (SSRI) Test for heterogeneity: $Chi^2 = 5.41$, df = 7 (P = 0.61), $I^2 = 0\%$ Test for overall effect: Z = 3.11 (P = 0.002) 0.01 0.1 10 100 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine 02 Clomipramine vs SSRIs; acute phase Comparison: Outcome: 05 Non-responders (25% Y-BOCS) SSRI RR (fixed) RR (fixed) Study Clomipramine or sub-category n/N nΝ 95% CI 95% CI 01 Clomipramine vs Fluvoxamine Koran 1996a 21/42 18/37 1.03 [0.66, 1.61] Subtotal (95% CI) 1.03 [0.66, 1.61] 42 37 Total events: 21 (Clomipramine), 18 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.12 (P = 0.90) 02 Clomipramine vs Paroxetine Zohar 1996a 47/99 92/201 1.04 [0.80, 1.34] Subtotal (95% CI) 99 201 1.04 [0.80, 1.34] Total events: 47 (Clomipramine), 92 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) Total (95% Ch. 238 1.03 [0.83, 1.29] Total events: 68 (Clomipramine), 110 (SSRI) Test for heterogeneity: $Chi^2 = 0.00$, df = 1 (P = 0.97), $I^2 = 0\%$ Test for overall effect: Z = 0.30 (P = 0.76)0.2 0.5 10 5

Favours Clomipramine Favours SSRI

Review:

Comparison:

OCD adults: Clomipramine

02 Clomipramine vs SSRIst acute phase

Review: OCD adults: Clomipramine 02 Clomipramine vs SSRIs; acute phase Comparison: Outcome: 06 Non-responders (35% Y-BOCS) SSRI RR (fixed) RR (fixed) Study Clomipramine or sub-category n/Ν n/Ν 95% CI 95% CI 01 Clomipramine vs Fluvoxamine Mundo 2001 44/112 46/115 0.98 [0.71, 1.35] Subtotal (95% CI) 112 115 0.98 [0.71, 1.35] Total events: 44 (Clomipramine), 46 (SSRI) Test for heterogeneity; not applicable Test for overall effect: Z = 0.11 (P = 0.91) 0.1 0.2 0.5 5 10 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine Comparison: 02 Clomipramine vs SSRIs: acute phase 07 Non-responders (CGI; 25% Y-BOCS) Outcome: SSRL RR (fixed) Study Clomipramine RR (fixed) or sub-category nΝ n/N 95% CI 95% CI 01 Clomipramine vs Fluoxetine 0.60 [0.37, 0.98] Lopez-lbor 1996 11/25 22/30 Subtotal (95% CI) 25 30 0.60 [0.37, 0.98] Total events: 11 (Clomipramine), 22 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.03 (P = 0.04) 02 Clomipramine vs Paroxetine Burnham 1993 42/82 47/82 0.89 [0.67, 1.18] Subtotal (95% CI) 82 0.89 [0.67, 1.18] Total events: 42 (Clomipramine), 47 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.78 (P = 0.43) Total (95% Ch. 0.81 [0.63, 1.03] 107 112 Total events: 53 (Clomipramine), 69 (SSRI) Test for heterogeneity: Chi² = 1.90, df = 1 (P = 0.17), l² = 47.3% Test for overall effect: Z = 1.73 (P = 0.08) 0.2 0.5 10 Favours SSRI Favours Clomipramine Review: OCD adults: Clomipramine Comparison: 02 Clomipramine vs SSRIs; acute phase Outcome: 09 Non-responders (CGI-I) Study SSRI RR (fixed) RR (fixed) Clomipramine or sub-category 95% CL 95% CL n/N n/Ν 01 Clomipramine vs Fluvoxamine Milanfranchi 1997 3/13 2/13 1.50 [0.30, 7.55] Subtotal (95% CI) 1.50 [0.30, 7.55] 13 13 Total events: 3 (Clomipramine), 2 (SSRI) Test for heterogeneity; not applicable Test for overall effect: Z = 0.49 (P = 0.62) 02 Clomipramine vs Sertraline 1.27 [0.81, 1.98] 1.27 [0.81, 1.98] Bisserbe 1997 29/82 24/86

82

86

99

0.2

Favours Clomipramine

0.5

5 10

Favours SSRI

1.29 [0.83, 1.98]

Subtotal (95% CI)

Total (95% CI)

Total events: 29 (Clomipramine), 24 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 1.04 (P = 0.30)

Total events: 32 (Clomipramine), 26 (SSRI)

Test for overall effect: Z = 1.14 (P = 0.25)

Test for heterogeneity: $Chi^2 = 0.04$, df = 1 (P = 0.84), $I^2 = 0\%$

Review: OCD adults: Clomipramine

Comparison: 02 Clomipramine vs SSRIs: acute phase

Outcome: 10 Non-responders (all)

Study	Clomipramine	SSRI	RR (fixed)	RR (fixed)
r sub-category	n/N	n/N	95% CI	95% CI
1 Clomipramine vs Fluoxetine	•			
.opez-lbor 1996	11/25	22/30		0.60 [0.37, 0.98]
ubtotal (95% CI)	25	30	-	0.60 [0.37, 0.98]
otal events: 11 (Clomipramine	e), 22 (SSRI)		-	
est for heterogeneity: not ap	plicable			
est for overall effect: $Z = 2.0$	03 (P = 0.04)			
2 Clomipramine vs Fluvoxami	ine			
(oran 1996a	21/42	18/37		1.03 [0.66, 1.61]
filanfranchi 1997	3/13	2/13		- 1.50 [0.30, 7.55]
Mundo 2001	44/112	46/115	-	0.98 [0.71, 1.35]
ubtotal (95% CI)	167	165	•	1.01 [0.78, 1.31]
otal events: 68 (Clomipramine	e), 66 (SSRI)		Ţ	•
est for heterogeneity: Chi² =	0.27 , df = 2 (P = 0.88), $I^2 = 0\%$			
est for overall effect: Z = 0.0	08 (P = 0.93)			
3 Clomipramine vs Paroxetine	e			
lurnham 1993	42/82	47/82	_ _	0.89 [0.67, 1.18]
ohar 1996a	47/99	92/201	+	1.04 [0.80, 1.34]
ubtotal (95% CI)	181	283	•	0.97 [0.81, 1.18]
otal events: 89 (Clomipramine	e), 139 (SSRI)		Ţ	
est for heterogeneity: Chi² =	0.59 , df = 1 (P = 0.44), I^2 = 0%			
est for overall effect: Z = 0.2	27 (P = 0.79)			
4 Clomipramine vs Sertraline				
isserbe 1997	29/82	24/86	+-	1.27 [0.81, 1.98]
ubtotal (95% CI)	82	86	-	1.27 [0.81, 1.98]
otal events: 29 (Clomipramine	e), 24 (SSRI)		-	
est for heterogeneity: not ap	plicable			
est for overall effect: Z = 1.0	04 (P = 0.30)			
otal (95% CI)	455	564	•	0.98 [0.85, 1.13]
otal events: 197 (Clomipramir	ne), 251 (SSRI)			
est for heterogeneity: Chi² =	6.01 , $df = 6$ (P = 0.42), $I^2 = 0.1$	%		
est for overall effect: Z = 0.2	24 (P = 0.81)			
		(0.1 0.2 0.5 1 2 5	10
		F8	avours Clomipramine Favours SSRI	
outour OCD adulta: Clare	nioromino			

Review:

OCD adults: Clomipramine 02 Clomipramine vs SSRIs: acute phase 11 Y-BOCS Comparison: Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Clomipramine vs Fluoxetine						
Lopez-lbor 1996	24	-8.90(7.13)	30	-7.50(9.29)		-0.16 [-0.70, 0.37]
Subtotal (95% CI)	24		30			-0.16 [-0.70, 0.37]
Test for heterogeneity: not ap	plicable					
Test for overall effect: $Z = 0.6$	60 (P = 0.55)					
02 Clomipramine vs Fluvoxam	ine					
Koran 1996a	39	17.00(8.55)	34	17.80(7.70)		-0.10 [-0.56, 0.36]
Milanfranchi 1997	12	16.50(11.00)	13	18.40(9.20)		-0.18 [-0.97, 0.60]
Mundo 2001	61	12.50(8.00)	67	14.70(10.10)		-0.24 [-0.59, 0.11]
Smeraldi 1992	5	15.20(12.40)	5	18.20(2.50)	•	-0.30 [-1.55, 0.95]
Subtotal (95% CI)	117		119			-0.19 [-0.45, 0.06]
Test for heterogeneity: Chi² = Test for overall effect: Z = 1.4		= 0.97), I ² = 0%				
03 Clomipramine vs Paroxetin	e					
Burnham 1993	78	-7.73(7.42)	79	-5.61(7.47)		-0.28 [-0.60, 0.03]
Zohar 1996a	94	-8.00(8.20)	198	-8.00(8.00)	- + -	0.00 [-0.25, 0.25]
Subtotal (95% CI)	172		277		-	-0.11 [-0.30, 0.09]
Test for heterogeneity: Chi² = Test for overall effect: Z = 1.0		= 0.16), I ² = 48.4%				
Total (95% CI)	313		426			-0.14 [-0.29, 0.01]
Test for heterogeneity: Chi² =		= 0.87), I ² = 0%			~	
Test for overall effect: $Z = 1.8$,,,				
					-1 -0.5 0 0.5	1
					Favours Clomipramine Favours St	PDI

Review: OCD adults: Clomipramine

02 Clomipramine vs SSRIs: acute phase 12 NIMH-OC Comparison:

Outcome:

N	Clomipramine Mean (SD)	N	SSRI Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI	
e						
105	5.90(2.80)	112	5.90(3.10)		0.00 [-0.27, 0.27]	
105		112			0.00 [-0.27, 0.27]	
licable				T		
(P = 1.00)						
78	-2.06(2.03)	79	-1.42(2.04)		-0.31 [-0.63, 0.00]	
94	-2.50(2.60)	198	-2.50(2.90)		0.00 [-0.25, 0.25]	
172		277		-	-0.12 [-0.31, 0.08]	
.36, df = 1 (P	⁹ = 0.12), I ² = 57.6%			-		
(P = 0.23)						
277		389		•	-0.08 [-0.23, 0.08]	
.86, df = 2 (P	P = 0.24), $P = 30.0$ %			<u> </u>		
(P = 0.33)						
	105 105 dicable 0 (P = 1.00) 78 94 172 2.36, df = 1 (F 0 (P = 0.23)	N Mean (SD) 105 105 105 105 ilicable 0 (P = 1.00) 78 -2.06 (2.03) 94 -2.50 (2.60) 172 2.36, df = 1 (P = 0.12), ² = 57.6% 0 (P = 0.23) 277 2.86, df = 2 (P = 0.24), ² = 30.0%	N Mean (SD) N 108 109 105 105 112 105 112 112 112 112 112 112 112 112 112 11	N Mean (SD) N Mean (SD) 105 105 105 112 105 112 112 112 112 112 112 112 112 112 11	N Mean (SD) N Mean (SD) 95% CI 108 105 5.90 (2.80) 112 5.90 (3.10) 105 112 106 112 107 108 -2.06 (2.03) 79 -1.42 (2.04) 94 -2.50 (2.60) 198 -2.50 (2.90) 172 277 2.36, df = 1 (P = 0.12), P = 57.6% 10 (P = 0.23) 277 2.86, df = 2 (P = 0.24), P = 30.0%	

Review:

Comparison:

OCD adults: Clomipramine
02 Clomipramine vs SSRIs: acute phase
13 Comprehensive Psychopathological Rating Scale: obsessive-compulsive Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)		\$	SMD (fixed 95% CI	ł)	SMD (fixed) 95% Cl
01 Clomipramine vs Fluoxe	tine								
Lopez-lbor 1996	24	-10.90(7.33)	30	-8.10(7.64)	_				-0.37 [-0.91, 0.17]
Subtotal (95% CI)	24		30		-				-0.37 [-0.91, 0.17]
Test for heterogeneity: not	applicable					_			
Test for overall effect: Z =	1.33 (P = 0.18)								
					-1	-0.5	_	0.5	1

Favours Clomipramine Favours SSRI

Favours Clomipramine Favours SSRI

Review: OCD adults: Clomipramine

02 Clomipramine vs SSRIs: acute phase 14 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Clomipramine vs Fluoxe	etine					
Lopez-lbor 1996	24	-9.40(7.71)	30	-7.50(5.93)		-0.28 [-0.82, 0.26]
Subtotal (95% CI)	24		30			-0.28 [-0.82, 0.26]
est for heterogeneity: no	t applicable				- -	·
Test for overall effect: Z =	= 1.00 (P = 0.32)					
02 Clomipramine vs Fluvo:	xamine					
Koran 1996a	39	5.80(4.70)	34	6.10(3.30)		-0.07 [-0.53, 0.39]
Mundo 2001	105	7.00(4.50)	112	7.70(6.00)		-0.13 [-0.40, 0.14]
Subtotal (95% CI)	144		146			-0.12 [-0.35, 0.11]
est for heterogeneity: Ch	$ni^2 = 0.05$, $df = 1$ (P = 0.83), I ² = 0%			-	
Test for overall effect: Z =	= 0.99 (P = 0.32)					
Total (95% CI)	168		176			-0.14 [-0.35, 0.07]
Test for heterogeneity: Ch	$ni^2 = 0.33$, $df = 2$ (P = 0.85), I ² = 0%			-	•
「est for overall effect: Z ≕	= 1.30 (P = 0.19)					
					-1 -0.5 0 0.5	- i

Favours Clomipramine Favours SSRI

Comparison: 02 Clomipramine vs SSRIs: acute phase Outcome: 15 Montgomery-Asberg Depression Rating Scale SMD (fixed) SMD (fixed) Study SSRI Clomipramine or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Fluoxetine Lopez-lbor 1996 24 -13.80(9.09) 30 -10.10(8.20) -0.42 [-0.97, 0.12] Subtotal (95% CI) 24 30 -0.42 [-0.97, 0.12] Test for heterogeneity: not applicable Test for overall effect: Z = 1.53 (P = 0.13) Smeraldi 1992 5 9.60(10.30) 5 11.80(6.80) -0.23 [-1.47, 1.02] Subtotal (95% CI) 5 -0.23 [-1.47, 1.02] Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72) 03 Clomipramine vs Paroxetine Zohar 1996a 94 -2.40(7.30) 198 -3.40(7.90)0.13 [-0.12, 0.38] Subtotal (95% CI) 198 0.13 [-0.12, 0.38] Test for heterogeneity: not applicable Test for overall effect: Z = 1.03 (P = 0.30) Total (95% CI) 233 0.03 [-0.19, 0.25] Test for heterogeneity: $Chi^2 = 3.47$, df = 2 (P = 0.18), $I^2 = 42.4\%$ Test for overall effect: Z = 0.24 (P = 0.81) Favours Clomipramine Favours SSRI Review OCD adults: Clomipramine 02 Clomipramine vs SSRIs; acute phase Comparison: 16 Depression (HRSD; MADRS) Outcome: Study Clomipramine SSRI SMD (fixed) SMD (fixed) Ν Mean (SD) or sub-category Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Fluvoxamine Koran 1996a 39 5.80(4.70) 34 6.10(3.30) -0.07 [-0.53, 0.39] Mundo 2001 105 7.00(4.50) 112 7,70(6,00) -0.13 [-0.40, 0.14] Smeraldi 1992 -0.23 [-1.47, 1.02] 5 11.80(6.80) 9.60(10.30) 5 Subtotal (95% CI) -0.12 [-0.35, 0.11] Test for heterogeneity: Chi² = 0.08, df = 2 (P = 0.96), l² = 0% Test for overall effect: Z = 1.04 (P = 0.30) 02 Clomipramine vs Paroxetine Zohar 1996a -2.40(7.30) 198 -3.40(7.90) 0.13 [-0.12, 0.38] Subtotal (95% CI) 94 198 0.13 [-0.12, 0.38] Test for heterogeneity: not applicable Test for overall effect: Z = 1.03 (P = 0.30) Total (95% CI) 349 -0.01 [-0.17, 0.16] Test for heterogeneity: Chi² = 2.21, df = 3 (P = 0.53), l² = 0% Test for overall effect: Z = 0.06 (P = 0.95) -2 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine Comparison: 02 Clomipramine vs SSRIs; acute phase Outcome: 17 Clinical Anxiety Scale SSRI SMD (fixed) SMD (fixed) Study Clomipramine N Mean (SD) 95% CI or sub-category Mean (SD) 01 Clomipramine vs Fluvoxamine Mundo 2001 6.70(4.30) 7.00(4.60) -0.07 [-0.33, 0.20] 105 112 Subtotal (95% CI) 105 112 -0.07 [-0.33, 0.20] Test for heterogeneity: not applicable Test for overall effect: Z = 0.49 (P = 0.62) -0.5 0.5 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine 02 Clomipramine vs SSRIs; acute phase Comparison: 18 Covi Anxiety Scale Outcome: Study Clomipramine SSRI SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Fluoxetine Lopez-lbor 1996 -2.40(3.09) 30 -2.40(3.10) 0.00 [-0.54, 0.54] Subtotal (95% CI) 24 30 0.00 [-0.54, 0.54]

-5

Favours Clomipramine Favours SSRI

10

Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)

Review:

OCD adults: Clomipramine

Review: OCD adults: Clomipramine

Comparison: 02 Clomipramine vs SSRIs; acute phase

19 Anxiety (Clinical Anxiety Scale; Covi Anxiety Scale) Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Clomipramine vs Fluvox	amine					
Mundo 2001	105	6.70(4.30)	112	7.00(4.60)	 _	-0.07 [-0.33, 0.20]
Subtotal (95% CI)	105		112			-0.07 [-0.33, 0.20]
Test for heterogeneity: not	t applicable				٦	
Test for overall effect: Z =	0.49 (P = 0.62)					
02 Clomipramine vs Fluoxe	tine					
Lopez-lbor 1996	24	-2.40(3.09)	30	-2.40(3.10)		0.00 [-0.54, 0.54]
Subtotal (95% CI)	24		30			0.00 [-0.54, 0.54]
Test for heterogeneity: not	t applicable				T	·
Test for overall effect: Z =	0.00 (P = 1.00)					
Total (95% CI)	129		142			-0.05 [-0.29, 0.18]
Test for heterogeneity: Chi	$i^2 = 0.05$, $df = 1$ (F	P = 0.83), I ² = 0%			\neg	
Test for overall effect: Z =						
					-1 -0.5 0 0.5	1

Review: OCD adults: Clomipramine

Comparison: 02 Clomipramine vs SSRIs; acute phase 20 Clinical Global Impressions: global improvement Outcome:

Study SSRI SMD (fixed) SMD (fixed) Clomipramine or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Fluoxetine Lopez-lbor 1996 -2.60(1.19) 30 -2.60(1.13) 0.00 [-0.54, 0.54] 24 Subtotal (95% CI) 30 0.00 [-0.54, 0.54] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) 02 Clomipramine vs Fluvoxamine Mundo 2001 Subtotal (95% CI) 0.00 [-0.27, 0.27] 0.00 [-0.27, 0.27] 105 2.30(1.00) 112 2.30(1.00) 105 112 Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) Total (95% CI) 0.00 [-0.24, 0.24] Total (95% CI) 129 Test for heterogeneity: $Chi^2 = 0.00$, df = 1 (P = 1.00), $I^2 = 0\%$ 142 Test for overall effect: Z = 0.00 (P = 1.00)

> -0.5 Favours Clomipramine Favours SSRI

0.5

Favours Clomipramine Favours SSRI

Review: OCD adults: Clomipramine

02 Clomipramine vs SSRIs; acute phase 21 Clinical Global Impressions; severity of illness Comparison: Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)			(fixed) 5% Cl		SMD (fixed) 95% CI
01 Clomipramine vs Fluoxetine									
Lopez-lbor 1996	24	-1.90(1.14)	30	-0.90(1.23)		-			-0.83 [-1.39, -0.27]
Subtotal (95% CI)	24		30			•			-0.83 [-1.39, -0.27]
Test for heterogeneity: not app	licable								
Test for overall effect: Z = 2.89	9 (P = 0.004)								
02 Clomipramine vs Fluvoxamin	ne								
Mundo 2001	105	3.20(1.20)	112	3.40(1.30)			=		-0.16 [-0.43, 0.11]
Subtotal (95% CI)	105		112				•		-0.16 [-0.43, 0.11]
Test for heterogeneity: not app	licable								
Test for overall effect: $Z = 1.17$	7 (P = 0.24)								
03 Clomipramine vs Paroxetine									
Zohar 1996a	94	-1.10(1.20)	194	-1.20(1.40)			-		0.07 [-0.17, 0.32]
Subtotal (95% CI)	94		194				*		0.07 [-0.17, 0.32]
Test for heterogeneity: not app	licable								
Test for overall effect: $Z = 0.59$	9 (P = 0.55)								
Total (95% CI)	223		336				•		-0.11 [-0.28, 0.06]
Test for heterogeneity: Chi² = 8	3.57, $df = 2$ (F	P = 0.01), I ² = 76.7%					1		·
Test for overall effect: Z = 1.23	3 (P = 0.22)	• •							
					-4	-2	0 2	4	
					Favours Cl	lominramine	Favours SS	21	

Outcome: 22 Symptom Checklist-90 SMD (fixed) SMD (fixed) Study SSRI Clomipramine orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Paroxetine Zohar 1996a -31.90(39.90) 169 -29.00(47.10) -0.06 [-0.34, 0.21] Subtotal (95% CI) 169 -0.06 [-0.34, 0.21] Test for heterogeneity: not applicable Test for overall effect: Z = 0.46 (P = 0.65)0.5 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs 01 Leaving study early Outcome: Clomipramine TCA RR (fixed) RR (fixed) Study 95% CI 95% CI or sub-category n/N nΝ 01 Clomipramine vs Imipramine 0.82 [0.23, 2.87] Volavka 1985 3/11 4/12 Subtotal (95% CI) 12 0.82 [0.23, 2.87] 11 Total events: 3 (Clomipramine), 4 (TCA) Test for heterogeneity: not applicable Test for overall effect: Z = 0.31 (P = 0.75) 02 Clomipramine vs Amitriptyline Ananth 1981 1/10 2/10 0.50 [0.05, 4.67] 0.50 [0.05, 4.67] Subtotal (95% CI) 10 10 Total events: 1 (Clomipramine), 2 (TCA) Test for heterogeneity: not applicable Test for overall effect: Z = 0.61 (P = 0.54) Total (95% CI) 22 0.71 [0.24, 2.12] 21 Total events: 4 (Clomipramine), 6 (TCA) Test for heterogeneity: $Chi^2 = 0.14$, df = 1 (P = 0.70), $I^2 = 0\%$ Test for overall effect: Z = 0.62 (P = 0.54) 0.01 0.1 10 100 Favours Clomipramine Favours TCA Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 02 Leaving study early due to adverse effects Clomipramine TCA RR (fixed) RR (fixed) Study or sub-category nΝ n/Ν 95% CI 95% CI 01 Clomipramine vs Imipramine Volavka 1985 2/11 2/12 1.09 [0.18, 6.48] Subtotal (95% CI) 12 1.09 [0.18, 6.48] 11 Total events: 2 (Clomipramine), 2 (TCA) Test for heterogeneity: not applicable Test for overall effect: Z = 0.10 (P = 0.92) 0.2 0.1 0.5 5 10 Favours Clomipramine Favours TCA Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 03 Levton Obsessional Inventory: symptom Study TCA SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Nortriptyline -3.00(3.10) -4.40(9.60) -0.19 [-1.17, 0.80]

-0.19 [-1.17, 0.80]

Favours Clomipramine Favours TCA

Subtotal (95% CI)

Test for heterogeneity: not applicable Test for overall effect: Z = 0.37 (P = 0.71)

OCD adults: Clomipramine

02 Clomipramine vs SSRIs; acute phase

Review: Comparison:

Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 04 Leyton Obsessional Inventory: trait TCA SMD (fixed) SMD (fixed) Study Clomipramine or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Nortriptyline Thoren 1980a -1.90(2.30) -1.50(1.10) -0.21 [-1.19, 0.77] Subtotal (95% CI) -0.21 [-1.19, 0.77] Test for heterogeneity: not applicable Test for overall effect: Z = 0.42 (P = 0.68) Favours Clomipramine Favours TCA Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 05 Leyton Obsessional Inventory: resistance Study Clomipramine TCA SMD (fixed) SMD (fixed) Ν Ν Mean (SD) 95% CI 95% CI or sub-category Mean (SD) 01 Clomipramine vs Nortriptyline Thoren 1980a -13.00(19.60) 8 -4.60(15.90) -0.45 [-1.44, 0.55] Subtotal (95% CI) -0.45 [-1.44, 0.55] Test for heterogeneity: not applicable Test for overall effect: Z = 0.88 (P = 0.38) Favours TCA Favours Clomipramine Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 06 Leyton Obsessional Inventory: interference Study Clomipramine SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Nortriptyline Thoren 1980a 8 -12.30(24.00) 8 -19.00(15.90) 0.31 [-0.68, 1.30] Subtotal (95% CI) 0.31 [-0.68, 1.30] Test for heterogeneity: not applicable Test for overall effect: Z = 0.62 (P = 0.54) Favours Clomipramine Favours TCA OCD adults: Clomipramine Review: Comparison: 03 Clomipramine vs TCAs Outcome Study Clomipramine TCA SMD (fixed) SMD (fixed) Mean (SD) or sub-category N Mean (SD) 95% CI 95% CI 01 Clomipramine vs Nortriptyline Thoren 1980a 6.38(2.75) 8 7.31(2.89) -0.31 [-1.30, 0.68] Subtotal (95% CI) -0.31 [-1.30, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.62 (P = 0.54) Favours Clomipramine Favours TCA OCD adults: Clomipramine Review: Comparison 03 Clomipramine vs TCAs Outcome: 08 Self-Rating Obsessive Compulsive Personality Inventory SMD (fixed) Study TCA SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Imipramine Volavka 1985 47.90(14.40) 68.70(12.90) -1.44 [-2.57, -0.30] Subtotal (95% CI) -1.44 [-2.57, -0.30] Test for heterogeneity: not applicable Test for overall effect: Z = 2.48 (P = 0.01)Favours Clomipramine Favours TCA Review: OCD adults: Clomipramine 03 Clomipramine vs TCAs Comparison: 09 Self-Rating Obsessional Neurotic Scale SMD (fixed) SMD (fixed) Study Clomipramine TCA or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI 01 Clomipramine vs Imipramine -1.17 [-2.26, -0.09] -1.17 [-2.26, -0.09] Volavka 1985 8 41.90(13.90) 8 63.60(20.50) Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.11 (P = 0.03) 0

Favours Clomipramine Favours TCA

Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 10 Hamilton Rating Scale for Depression Study or sub-category N 01 Clomipramine vs Imipramine Volavka 1985 Subtotal (95% CI)

TCA SMD (fixed) SMD (fixed) Clomipramine Mean (SD) N Mean (SD) 95% CI 95% CI 2.01(2.20) 6.20(4.90) -1.04 [-2.11, 0.02] 8 -1.04 [-2.11, 0.02] Test for heterogeneity: not applicable Test for overall effect: Z = 1.92 (P = 0.05)

Favours Clomipramine Favours TCA

Favours Clomipramine Favours TCA

OCD adults: Clomipramine Review: Comparison: 03 Clomipramine vs TCAs Outcome: 11 Global Evaluation of Efficacy

Study or sub-category	N	Clomipramine Mean (SD)	N	TCA Mean (SD)			MD (fixed) 95% Cl)		SMD (fixed) 95% Cl
01 Clomipramine vs Imiprar Volavka 1985 Subtotal (95% Cl) Test for heterogeneity: not Test for overall effect: Z =	8 8 t applicable	1.75(0.89)	8 8	2.88(1.13)		4				-1.05 [-2.12, 0.02] -1.05 [-2.12, 0.02]
					-4	-2	Ó	2	4	

OCD adults: Clomipramine Review: Comparison: 04 Clomipramine vs other drugs 01 Adverse effects Outcome:

Study Clomipramine Other drug RR (fixed) RR (fixed) or sub-category n/Ν nN95% CI 95% CI 01 Clomipramine vs Venlafaxine Albert 2002 43/47 16/26 1.49 [1.08, 2.04] Subtotal (95% CI) 47 26 1.49 [1.08, 2.04] Total events: 43 (Clomipramine), 16 (Other drug) Test for heterogeneity: not applicable Test for overall effect: Z = 2.46 (P = 0.01) 0.2 0.5 5

Favours Clomipramine Favours other drug

Favours Clomipramine Favours other drug

ż

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs Outcome: 02 Leaving study early

Study or sub-category	Clomipramine n <i>i</i> N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clomipramine vs Buspirone				
Pato 1991	1/10	1/10	<u>-</u>	1.00 [0.07, 13.87]
Subtotal (95% CI)	10	10		1.00 [0.07, 13.87]
Total events: 1 (Clomipramine), 1 (9	Other drug)		T	
Fest for heterogeneity: not applical	ble -			
Test for overall effect: Z = 0.00 (P	= 1.00)			
02 Clomipramine vs Phenelzine				
Vallejo 1992	2/16	2/14		0.88 [0.14, 5.42]
Subtotal (95% CI)	16	14		0.88 [0.14, 5.42]
Total events: 2 (Clomipramine), 2 (G	Other drug)		T	
Test for heterogeneity: not applical	ble			
Test for overall effect: Z = 0.14 (P	= 0.89)			
03 Clomipramine vs Venlafaxine				
Albert 2002	7/47	1/26		3.87 [0.50, 29.77]
Subtotal (95% CI)	47	26		3.87 [0.50, 29.77]
otal events: 7 (Clomipramine), 1 (Other drug)			,
Test for heterogeneity: not applical				
Test for overall effect: Z = 1.30 (P				
		0.01	0.1 1 10	100

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs

Outcome: 03 Leaving study early due to adverse effects

RR (fixed) 95% Cl
[0.14, 65.90]
[0.14, 65.90]
[0.12, 60.21]
[0.12, 60.21]
•
[0.36, 107.66]
[0.36, 107.66]
_

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs

Outcome: 04 Non-responders

Study or sub-category	Clomipramine n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clomipramine vs Venlafa	xine			
Albert 2002	27/47	17/26		0.88 [0.61, 1.28]
Subtotal (95% CI)	47	26		0.88 [0.61, 1.28]
Total events: 27 (Clomipram	ine), 17 (Other drug)		_	
Test for heterogeneity: not a	applicable			
Test for overall effect: Z = 0	0.68 (P = 0.50)			
			0.5 0.7 1 1.5	2

Favours Clomipramine Favours other drug

Favours Clomipramine Favours other drug

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs

Outcome: 05 Y-BOCS

Study or sub-category	N	Clomipramine Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Clomipramine vs Buspiron	ie					
Pato 1991	9	17.67(4.97)	9	16.78(6.46)		0.15 [-0.78, 1.07]
Subtotal (95% CI)	9		9			0.15 [-0.78, 1.07]
est for heterogeneity; not a	pplicable					
est for overall effect: $Z = 0$.	31 (P = 0.76)					
02 Clomipramine vs Venlafax	tine					
Albert 2002	47	17.30(6.15)	26	18.36(7.11)	-	-0.16 [-0.64, 0.32]
Subtotal (95% CI)	47		26		-	-0.16 [-0.64, 0.32]
est for heterogeneity; not a	pplicable				1	,
Test for overall effect: $Z = 0$.	.66 (P = 0.51)					

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs

Outcome: 06 NIMH-OC

SMD (fixed) 95% Cl SMD (fixed) 95% CI Other drug Study Clomipramine Mean (SD) or sub-category Ν Mean (SD) N 01 Clomipramine vs Buspirone 0.08 [-0.84, 1.01] 0.08 [-0.84, 1.01] 9 9 5.11(1.27) Pato 1991 5.22(1.20) Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.18 (P = 0.86) -2 Favours Clomipramine Favours other drug


Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs Outcome: 07 Maudsley Obsessive-Compulsive Inventory SMD (fixed) SMD (fixed) Study Clomipramine Other drug orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Phenelzine Vallejo 1992 12.10(4.70) 10.10(6.90) 0.33 [-0.44, 1.11] 12 14 Subtotal (95% CI) 14 12 0.33 [-0.44, 1.11] Test for heterogeneity: not applicable Test for overall effect: Z = 0.84 (P = 0.40) Favours Clomipramine Favours other drug OCD adults: Clomipramine Review: Comparison 04 Clomipramine vs other drugs 08 Hamilton Rating Scale for Depression Outcome SMD (fixed) SMD (fixed) Study Clomipramine Other drug Ν or sub-category Ν Mean (SD) Mean (SD) 95% CI 95% CI 01 Clomipramine vs Buspirone Pato 1991 9 9.33(4.58) 9 9.89(6.75) -0.09 [-1.02, 0.83] Subtotal (95% CI) -0.09 [-1.02. 0.83] Test for heterogeneity: not applicable Test for overall effect: Z = 0.20 (P = 0.84) 02 Clomipramine vs Phenelzine Vallejo 1992 11.50(6.90) 12 7.00(5.70) 0.68 [-0.11, 1.48] Subtotal (95% CI) 0.68 [-0.11, 1.48] Test for heterogeneity: not applicable Test for overall effect: Z = 1.68 (P = 0.09)Favours Clomipramine Favours other drug OCD adults: Clomipramine Review: Comparison: 04 Clomipramine vs other drugs 09 Hamilton Rating Scale for Anxiety SMD (fixed) SMD (fixed) Study Clomipramine Other drug N Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category 01 Clomipramine vs Phenelzine 0.88 [0.07, 1.69] 0.88 [0.07, 1.69] Vallein 1992 14 14.10(8.70) 12 7.00(6.60) Subtotal (95% CI) 12 14 Test for heterogeneity: not applicable Test for overall effect: Z = 2.12 (P = 0.03) -2 Favours Clomipramine Favours other drug Review: OCD adults: Clomipramine 05 Intravenous Clomipramine vs IV placebo Comparison: 01 Leaving study early Outcome: Study IV Clomipramine IV Placebo RR (fixed) RR (fixed) or sub-category nΝ n/Ν 95% CI 95% CI Fallon 1998 2/25 0.43 [0.04, 4.48] 1/29 Total (95% CI) 29 25 0.43 [0.04, 4.48] Total events: 1 (IV Clomipramine), 2 (IV Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.70 (P = 0.48) 0.01 100 0.1 10 Favours Clomipramine Favours Placebo Review: OCD adults: Clomipramine Comparison: 05 Intravenous Clomipramine vs IV placebo Outcome: 02 Non-responders

IV Placebo RR (fixed) RR (fixed) Study IV Clomipramine or sub-category nΝ n/N 95% CI 95% CI Fallon 1998 23/29 25/25 0.79 [0.66, 0.96] Total (95% CI) 29 0.79 [0.66, 0.96] 25 Total events: 23 (IV Clomipramine), 25 (IV Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 2.44 (P = 0.01) 0.5 1.5 ż Favours Placebo Favours Clomipramine

Review: OCD adults: Clomipramine

Comparison: 05 Intravenous Clomipramine vs IV placebo

Outcome: 03 Y-BOCS



Review: OCD adults: Clomipramine

Comparison: 05 Intravenous Clomipramine vs IV placebo

Outcome: 04 NIMH-OC

Study or sub-category	Ν '	IV Clomipramine Mean (SD)	N	IV Placebo Mean (SD)	D (fixed) 95% Cl	SMD (fixed) 95% Cl
Fallon 1998	28	10.40(2.00)	23	10.80(1.00)		-0.24 [-0.80, 0.31]
Total (95% Cl) Test for heterogeneity: not app Test for overall effect: Z = 0.8			23			-0.24 [-0.80, 0.31]

Favours Clomipramine Favours Placebo

Favours Clomipramine Favours Placebo

Favours Clomipramine Favours Placebo

Review: OCD adults: Clomipramine

Comparison: 05 Intravenous Clomipramine vs IV placebo Outcome: 05 Clinical Global Impressions: severity

Study or sub-category	N I	V Clomipramine Mean (SD)	N	IV Placebo Mean (SD)			(fixed) % Cl	SMD (fixed) 95% Cl
Fallon 1998	28	5.30(1.00)	23	5.70(5.00)		-		-0.11 [-0.67, 0.44]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			23					-0.11 [-0.67, 0.44]
					-1	-0.5	0 0.5	1

Review: OCD adults: Clomipramine


Comparison: 05 Intravenous Clomipramine vs IV placebo Outcome: 06 Hamilton Rating Scale for Depression

Study or sub-category	N	IV Clomipramine Mean (SD)	N	IV Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
Fallon 1998	28	12.00(6.00)	23	12.70(7.00)	-	-0.11 [-0.66, 0.45]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			23			-0.11 [-0.66, 0.45]
					-1 -0.5 0 0.5	1

Review: OCD adults: Clomipramine

Comparison: 06 Intravenous Clomipramine vs oral Clomipramine


Outcome: 01 Adverse effects



Review: OCD adults: Clomipramine

Comparison: 06 Intravenous Clomipramine vs oral Clomipramine

Outcome: 02 Leaving study early



Review: OCD adults: Clomipramine

Comparison: 06 Intravenous Clomipramine vs oral Clomipramine

Outcome: 03 Non-responders

Study or sub-category	IV Clomipramine n/N	Oral Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
Koran 1997	1/7	7/8		0.16 [0.03, 1.02]
Total (95% CI) Total events: 1 (IV Clomipre Test for heterogeneity: not Test for overall effect: Z =		8		0.16 [0.03, 1.02]
		0	.01 0.1 1 10	100

Favours IV Favours Oral

Favours IV Favours Oral

Favours Placebo

Review: OCD adults: Clomipramine

Comparison: 06 Intravenous Clomipramine vs oral Clomipramine

Outcome: 04 Y-BOCS

Study or sub-category	N I	V Clomipramine Mean (SD)	Or N	al Clomipramine Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% Cl
Koran 1997	7	16.71(3.30)	8	25.00(7.86)		-	_			-1.26 [-2.40, -0.12]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 2			8			-	-			-1.26 [-2.40, -0.12]
					-4	-2	ò	2	4	

Review: OCD adults: Clomipramine

Comparison: 07 Clomipramine vs placebo: continuation phase

Outcome: 01 Adverse effects

Study or sub-category	Clomipramine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
Katz 1990	108/110	9/14	_	1.53 [1.03, 2.26]
Total (95% CI) Total events: 108 (Clomipra Test for heterogeneity: not Test for overall effect: Z =	applicable	14		1.53 [1.03, 2.26]
		0.2	0.5 1 2	5

Favours Clomipramine

Review: OCD adults: Clomipramine


Comparison: 07 Clomipramine vs placebo: continuation phase Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Clomipramine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Katz 1990	17/110	0/14	-	4.73 [0.30, 74.65]
Total (95% CI) Total events: 17 (Clomipran Test for heterogeneity: not Test for overall effect: Z =	applicable	14	-	4.73 [0.30, 74.65]
		0.01	0.1 1 10	100
		Favo	ours Clomipramine Favours Placebo	

Review: OCD adults: Clomipramine

Comparison: 07 Clomipramine vs placebo: continuation phase

03 NIMH-OC Outcome:



Review: Comparison: OCD adults: Clomipramine 07 Clomipramine vs placebo: continuation phase

Outcome: 04 Physician's Global Evaluation

Study or sub-category	N	Clomipramine Mean (SD)	N	Placebo Mean (SD)			(fixed) % Cl		SMD (fixed) 95% Cl
Katz 1990	101	1.89(0.94)	12	3.33(0.89)		-			-1.53 [-2.16, -0.90]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =)	12			•			-1.53 [-2.16, -0.90]
					-4	-2	0 2	4	

Favours Clomipramine Favours Placebo

Favours SSRI

OCD adults: Clomipramine Review:

08 Clomipramine vs SSRIs: continuation phase Comparison:

Outcome: 01 Leaving study early

Study or sub-category	Clomipramine n/N	SSRI n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clomipramine 200mg vs F	luoxetine 60mg (non-responders)		
Lopez-Ibor 1996	3/8	6/14		0.88 [0.30, 2.58]
Subtotal (95% CI)	8	14		0.88 [0.30, 2.58]
Total events: 3 (Clomipramin	e), 6 (SSRI)			,
Test for heterogeneity: not a				
Test for overall effect: Z = 0	.24 (P = 0.81)			
02 Clomipramine 100mg vs F	luoxetine 20mg (responders)			
Lopez-lbor 1996	6/13	3/11		1.69 [0.55, 5.24]
Subtotal (95% CI)	13	11		1.69 [0.55, 5.24]
Total events: 6 (Ćlomipramin	e), 3 (SSRI)			,
Test for heterogeneity: not a				
Test for overall effect: Z = 0	• •			
		0.1	0.2 0.5 1 2 5	10

Favours Clomipramine

Review: OCD adults: Clomipramine

Comparison: 08 Clomipramine vs SSRIs: continuation phase Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Clomipramine n <i>i</i> N	SSRI n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clomipramine 200mg vs F	luoxetine 60mg (non-responders)		
Lopez-lbor 1996	0/8	2/14		0.33 [0.02, 6.19]
Subtotal (95% CI)	8	14		0.33 [0.02, 6.19]
Total events: 0 (Clomipramine	e), 2 (SSRI)			,
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 0	.74 (P = 0.46)			
02 Clomipramine 100mg vs F	luoxetine 20mg (responders)			
Lopez-Ibor 1996	1/13	1/11		- 0.85 [0.06, 12.01]
Subtotal (95% CI)	13	11		- 0.85 [0.06, 12.01]
Total events: 1 (Clomipramine	e), 1 (SSRI)			•
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 0	.12 (P = 0.90)			
			0.01 0.1 1 1	0 100
			Favours Clomipramine Favours	SSRI

Review: OCD adults: Clomipramine

Comparison: 09 Clomipramine same dose vs half dose vs none: continuation/discontinuation

Outcome: 01 Leaving study early

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Same dose (150mg) vs half dose (7	'5mg)			
Ravizza 1996a	2/14	0/15	- - - - - - - - - - 	5.33 [0.28, 102.26]
Subtotal (95% CI)	14	15		5.33 [0.28, 102.26]
Total events: 2 (Dose 1), 0 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 1.11 (P = 0.)	27)			
02 Same dose (150mg) vs none				
Ravizza 1996a	2/14	1/14	- - 	2.00 [0.20, 19.62]
Subtotal (95% CI)	14	14	-	2.00 [0.20, 19.62]
Total events: 2 (Dose 1), 1 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.59 (P = 0.	55)			
03 Half dose (75mg) vs none				
Ravizza 1996a	0/15	1/14		0.31 [0.01, 7.09]
Subtotal (95% CI)	15	14		0.31 [0.01, 7.09]
Total events: 0 (Dose 1), 1 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.73$ (P = 0.	47)			
		0.0	01 0.01 0.1 1 10 100 1	000

Favours Dose 1 Favours Dose 2

Favours Dose 1 Favours Dose 2


Review: OCD adults: Clomipramine

Comparison: 09 Clomipramine same dose vs half dose vs none: continuation/discontinuation

Outcome: 02 Relapse (CGI; 25% Y-BOCS)

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Same dose (150mg) vs half dose (75ma)			
Ravizza 1996a	5/14	4/15		1.34 [0.45, 4.00]
Subtotal (95% CI)	14	15		1.34 [0.45, 4.00]
Total events: 5 (Dose 1), 4 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.52$ (P = 0	1.60)			
02 Same dose (150mg) vs none				
Ravizza 1996a	5/14	11/14		0.45 [0.21, 0.97]
Subtotal (95% CI)	14	14		0.45 [0.21, 0.97]
Total events: 5 (Dose 1), 11 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 2.05 (P = 0	1.04)			
03 Half dose (75mg) vs none				
Ravizza 1996a	4/15	11/14		0.34 [0.14, 0.82]
Subtotal (95% CI)	15	14		0.34 [0.14, 0.82]
Total events: 4 (Dose 1), 11 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 2.40 (P = 0	1.02)			
04 Continuation v discontinuation				
Ravizza 1996a	9/29	11/14		0.39 [0.22, 0.73]
Subtotal (95% CI)	29	14		0.39 [0.22, 0.73]
Total events: 9 (Dose 1), 11 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 3.00$ (P = 0	1.003)			
		0.1	0.2 0.5 1 2 5	10


TCAs (OCD)



Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)

Outcome: 01 Adverse effects



Favours TCA Favours other drug

Favours TCA Favours other drug

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)

Outcome: 02 Leaving study early

Study or sub-category	TCA n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
01 Amitriptyline vs Clomipramine			_	
Ananth 1981	2/10	1/10		2.00 [0.21, 18.69]
Subtotal (95% CI)	10	10		2.00 [0.21, 18.69]
Total events: 2 (TCA), 1 (Other drug) Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.61 (P = 0.5	54)			
02 Desipramine vs Fluvoxamine				
Goodman 1990a	6/19	2/21	+	3.32 [0.76, 14.49]
Subtotal (95% CI)	19	21	-	3.32 [0.76, 14.49]
Total events: 6 (TCA), 2 (Other drug)				
Test for heterogeneity: not applicable	445			
Test for overall effect: Z = 1.59 (P = 0.1	11)			
03 Desipramine vs Sertraline				
Hoehn-Saric 2000	33/86	14/80		2.19 [1.27, 3.79]
Subtotal (95% CI)	86	80	◆	2.19 [1.27, 3.79]
Total events: 33 (TCA), 14 (Other drug))			
Test for heterogeneity: not applicable	005)			
Test for overall effect: $Z = 2.82$ (P = 0.0	005)			
04 Imipramine vs Clomipramine				
Volavka 1985	4/12	3/11		1.22 [0.35, 4.28]
Subtotal (95% CI)	12	11		1.22 [0.35, 4.28]
Total events: 4 (TCA), 3 (Other drug)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.31$ (P = 0.3)	75)			
		0.01	0.1 1 10	100

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)

Outcome: 03 Leaving study early due to adverse effects

2/19 19	0/21 21		5.50 [0.28, 107.78]
			E EO (O 20 107 701
19	21		3.30 [0.20, 107.78]
	Z.1	-	5.50 [0.28, 107.78]
		- -	
3/86	9/80		2.38 [1.17, 4.83]
86	80	-	2.38 [1.17, 4.83]
		-	·
2/12	2/11		0.92 [0.15, 5.44]
12	11		0.92 [0.15, 5.44]
		T	
	0.001	0.01 0.1 1 10 100	1000
		Favours TCA Favours other dr	210
	86	86 80 2/12 2/11 12 11	2/12 2/11 12 11 0.001 0.01 0.1 1 10 100

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)
Outcome: 04 Non-responders (OCD)

Study or sub-category	TCA n/N	Other drug n/N		(fixed) 5% Cl		RR (fixed) 95% Cl
01 Desipramine vs Sertraline Hoehn-Saric 2000 Subtotal (95% Cl) Total events: 40 (TCA), 42 (Of Test for heterogeneity: not ap Test for overall effect: Z = 0.7	plicable	42/80 80		-		.89 [0.65, 1.21] .89 [0.65, 1.21]
		0.	5 0.7	1 1.5	2	

Favours TCA Favours other drug

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)
Outcome: 05 Non-responders (MDD)

Study or sub-category	TCA n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
01 Desipramine vs Sertraline						
Hoehn-Saric 2000	43/86	29/80		- 1.38 [0.96, 1.98]		
Subtotal (95% CI)	86	80		- 1.38 [0.96, 1.98]		
Total events: 43 (TCA), 29 (Other	drug)		- -	,		
Test for heterogeneity: not application						
Test for overall effect: Z = 1.75 (F	P = 0.08)					
		0.5	0.7 1 1.5	2		
			Favours TCA Favours other dru	ıg		

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)
Outcome: 06 Non-remitters (HRSD>17)

Study or sub-category	TCA n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Desipramine vs Sertraline				
Hoehn-Saric 2000	56/86	41/80		1.27 [0.98, 1.65]
Subtotal (95% CI)	86	80	-	1.27 [0.98, 1.65]
Total events: 56 (TCA), 41 (C	ther drug)			·
Test for heterogeneity: not ap	oplicable			
Test for overall effect: $Z = 1$.	78 (P = 0.08)			
		0.5	0.7 1 1.5 2	!
			Favours TCA Favours other drug	

Comparison: 02 TCAs vs other drugs (adults) Outcome: 07 Y-BOCS SMD (fixed) SMD (fixed) Study TCA Other drug or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Designamine vs Fluvoxamine Goodman 1990a 19 25.80(6.00) 21 19.50(9.00) 0.80 [0.15, 1.45] Subtotal (95% CI) 19 21 0.80 [0.15, 1.45] Test for heterogeneity: not applicable Test for overall effect: Z = 2.42 (P = 0.02) 02 Desipramine vs Sertraline Hoehn-Saric 2000 85 -6.00(8.30) 79 -8.40(8.00) 0.29 [-0.02, 0.60] Subtotal (95% CI) 85 79 0.29 [-0.02, 0.60] Test for heterogeneity: not applicable Test for overall effect: Z = 1.86 (P = 0.06) Total (95% CI) 0.39 [0.11, 0.66] 100 Test for heterogeneity: $Chi^2 = 1.92$, df = 1 (P = 0.17), $I^2 = 47.8\%$ Test for overall effect: Z = 2.72 (P = 0.006) Favours TCA Favours other drug Review: OCD: TCAs Comparison: 02 TCAs vs other drugs (adults) Outcome: 08 NIMH-OC SMD (fixed) Study TCA Other drug SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Desipramine vs Sertraline Hoehn-Saric 2000 85 -1.70(2.77) 79 -2.70(2.67) 0.37 [0.06, 0.67] Subtotal (95% CI) 0.37 [0.06, 0.67] Test for heterogeneity: not applicable Test for overall effect: Z = 2.32 (P = 0.02)-0.5 0.5 Favours TCA Favours other drug OCD: TCAs Review: 02 TCAs vs other drugs (adults) Comparison: 09 Leyton Obsessional Inventory: symptom Outcome: Study TCA Other drug SMD (fixed) SMD (fixed) Mean (SD) N Mean (SD) or sub-category Ν 95% CI 95% CI 01 Nortriptyline vs Clomipramine Thoren 1980a -3.00(3.10) -4.40(9.60) 0.19 [-0.80, 1.17] Subtotal (95% CI) 8 0.19 [-0.80, 1.17] Test for heterogeneity: not applicable Test for overall effect: Z = 0.37 (P = 0.71) Favours TCA Favours other drug OCD: TCAs Review: Comparison: 02 TCAs vs other drugs (adults) Outcome: 10 Leyton Obsessional Inventory: trait SMD (fixed) SMD (fixed) Study Other drug or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Nortriptyline vs Clomipramine Thoren 1980a -1.50(1.10) -1.90(2.30) 0.21 [-0.77, 1.19] Subtotal (95% CI) 0.21 [-0.77, 1.19] Test for heterogeneity: not applicable Test for overall effect: Z = 0.42 (P = 0.68) ż Favours TCA Favours other drug OCD: TCAs Review: Comparison: 02 TCAs vs other drugs (adults) 11 Leyton Obsessional Inventory: resistance Outcome: Study TCA Other drug SMD (fixed) SMD (fixed) Mean (SD) or sub-category Ν Ν Mean (SD) 95% CI 95% CI 01 Nortriptyline vs Clomipramine

-4.60(15.90)

8

-13.00(19.60)

Favours TCA

Favours other drug

0.45 [-0.55, 1.44]

0.45 [-0.55, 1.44]

Thoren 1980a

Subtotal (95% CI)

Test for heterogeneity: not applicable Test for overall effect: Z = 0.88 (P = 0.38)

OCD: TCAs

Review:

OCD: TCAs Review: Comparison: 02 TCAs vs other drugs (adults) Outcome: 12 Leyton Obsessional Inventory: interference TCA Other drug SMD (fixed) SMD (fixed) Study orsub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Nortriptyline vs Clomipramine Thoren 1980a -19.00(15.90) -12.30(24.00) -0.31 [-1.30, 0.68] Subtotal (95% CI) -0.31 [-1.30, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.62 (P = 0.54) Favours TCA Favours other drug OCD: TCAs Review: 02 TCAs vs other drugs (adults) Comparison: 13 CPRS: obsessive-compulsive Outcome: Study TCA Other drug SMD (fixed) SMD (fixed) Mean (SD) or sub-category Ν Ν Mean (SD) 95% CI 95% CI 01 Nortriptyline vs Clomipramine Thoren 1980a 8 7.31(2.89) 8 6.38(2.75) 0.31 [-0.68, 1.30] Subtotal (95% CI) 8 0.31 [-0.68, 1.30] Test for heterogeneity: not applicable Test for overall effect: Z = 0.62 (P = 0.54) Favours TCA Favours other drug Review: OCD: TCAs Comparison: 02 TCAs vs other drugs (adults) Outcome: 14 Self-Rating Obsessive Compulsive Personality Inventory SMD (fixed) Study Other drug SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Imipramine vs Clomipramine Volavka 1985 8 68.70(12.90) 8 47.90(14.40) 1.44 [0.30, 2.57] Subtotal (95% CI) 1.44 [0.30, 2.57] Test for heterogeneity: not applicable Test for overall effect: Z = 2.48 (P = 0.01)Favours TCA Favours other drug Review: OCD: TCAs 02 TCAs vs other drugs (adults) Comparison: 15 Self-Rating Obsessional Neurotic Scale Outcome SMD (fixed) Study TCA Other drug SMD (fixed) Mean (SD) N Mean (SD) or sub-category 95% CI 95% CI 01 Imipramine vs Clomipramine Volavka 1985 63.60(20.50) 8 41.90(13.90) 1.17 [0.09, 2.26] Subtotal (95% CI) 1.17 [0.09, 2.26] Test for heterogeneity: not applicable Test for overall effect: Z = 2.11 (P = 0.03) Favours TCA Favours other drug Review: OCD: TCAs Comparison: 02 TCAs vs other drugs (adults) 16 Hamilton Rating Scale for Depression Outcome: Study Other drug SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Desipramine vs Fluvoxamine Goodman 1990a 17.70(15.00) 0.32 [-0.30, 0.94] 22.30(13.00) Subtotal (95% CI) 19 21 0.32 [-0.30, 0.94] Test for heterogeneity: not applicable Test for overall effect: Z = 1.00 (P = 0.32) 02 Desipramine vs Sertraline Hoehn-Saric 2000 85 -11.50(10.14) 79 -14.80(9.78) 0.33 [0.02, 0.64] Subtotal (95% CI) 85 0.33 [0.02, 0.64] Test for heterogeneity: not applicable

2.01(2.20)

-2

Favours TCA Favours other drug

1.04 [-0.02, 2.11]

1.04 [-0.02, 2.11]

6.20(4.90)

Test for overall effect: Z = 2.09 (P = 0.04)


Test for heterogeneity: not applicable Test for overall effect: Z = 1.92 (P = 0.05)

03 Imipramine vs Clomipramine Volavka 1985

Subtotal (95% CI)

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)
Outcome: 17 Global Evaluation of Efficacy



Review: OCD: TCAs

Comparison: 03 Designamine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 01 Leaving the study early (only during the 2-month substitution period)

Study or sub-category	Desipramine n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Leonard 1991a	1/10	0/11		3.27 [0.15, 72.23]
Total (95% CI) Total events: 1 (Desipramin Test for heterogeneity: not Test for overall effect: Z = I	applicable	11		3.27 [0.15, 72.23]
		0.01	0.1 1 10	100

Favours Desipramine Favours Clomipramine

Review: OCD: TCAs

Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)

Outcome: 02 Relapse (Physician's Relapse Scale)

Study or sub-category	Desipramine n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Leonard 1991a	8/9	2/11	-	4.89 [1.37, 17.49]
Total (95% CI) Total events: 8 (Desipramin Test for heterogeneity: not a Test for overall effect: Z = 2	applicable	11		4.89 [1.37, 17.49]
		0.01	0.1 1 10	100

Favours Desipramine

Review: OCD: TCAs

Comparison: 03 Designamine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 03 Comprehensive Psychopathological Rating Scale: obsessive-compulsive

Study or sub-category	N	Desipramine Mean (SD)	N	Clomipramine Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
Leonard 1991a	9	6.30(3.30)	11	5.20(4.00)			-		0.28	3 [-0.60, 1.17]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			11				+		0.28	3 [-0.60, 1.17]
Test for overall effect. Z =	0.63 (P = 0.53)				-4	-2	0	2	4	


Favours Desipramine Favours Clomipramine

Favours Clomipramine

Review: OCD: TCAs

Comparison: 03 Designamine substitution vs Clomipramine continuation (child/adolescent)

Outcome: 04 NIMH-OC



SNRIs (OCD)

Review: OCD: SNRIs

Comparison: 01 SNRIs vs other drugs Outcome: 01 Adverse effects

Study or sub-category	SNRI n/N	Other drug n/N		RR (fixed) 95% Cl			RR (fixed) 95% Cl
01 Venlafaxine vs Clomipram	nine						
Albert 2002	16/26	43/47	_	_			0.67 [0.49, 0.92]
Subtotal (95% CI)	26	47	-	-			0.67 [0.49, 0.92]
Total events: 16 (SNRI), 43 (Other drug)			-			
Test for heterogeneity: not a	pplicable						
Test for overall effect: $Z = 2$.	46 (P = 0.01)						
		0.2	0.5	1	- <u>;</u>	5	

Favours SNRI Favours other drug

Review: OCD: SNRIs

Comparison: 01 SNRIs vs other drugs Outcome: 02 Leaving study early

Study or sub-category	SNRI n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Venlafaxine vs Clomiprami	ne			
Albert 2002	1/26	7/47		0.26 [0.03, 1.99]
Subtotal (95% CI)	26	47		0.26 [0.03, 1.99]
Total events: 1 (SNRI), 7 (Oth	er drug)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 1.3$	30 (P = 0.19)			
		0.01	0.1 1 10	100

Favours SNRI Favours other drug

Review: OCD: SNRIs


Comparison: 01 SNRIs vs other drugs

Outcome: 03 Leaving study early due to adverse effects

Study or sub-category	SNRI n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Venlafaxine vs Paroxetine				
Denys 2003a	2/75	6/75		0.33 [0.07, 1.60]
Subtotal (95% CI)	75	75		0.33 [0.07, 1.60]
Total events: 2 (SNRI), 6 (Other	er drug)		-	
Test for heterogeneity: not ap				
Test for overall effect: Z = 1.3	37 (P = 0.17)			
02 Venlafaxine vs Clomiprami	ne			
Albert 2002	0/26	5/47		0.16 [0.01, 2.81]
Subtotal (95% CI)	26	47		0.16 [0.01, 2.81]
Total events: 0 (SNRI), 5 (Other	er drug)			,
Test for heterogeneity; not ap	plicable			
Test for overall effect: Z = 1.2	25 (P = 0.21)			
		0.001	0.01 0.1 1 10 100	1000

OCD: SNRIs Review:

Comparison: 01 SNRIs vs other drugs 04 Non-responders Outcome:



Review: OCD: SNRIs

Comparison: Outcome: 01 SNRIs vs other drugs 05 Y-BOCS

Study or sub-category	N	SNRI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
11 Venlafaxine vs Paroxetine	•						
Denys 2003a	73	-7.20(7.50)	72	-7.80(5.40)		0.09 [-0.23, 0.42]	
Subtotal (95% CI)	73		72			0.09 [-0.23, 0.42]	
est for heterogeneity: not ap	oplicable				_		
est for overall effect: $Z = 0$.	55 (P = 0.58)						
2 Venlafaxine vs Clomipram	ine						
Albert 2002	26	18.36(7.11)	47	17.30(6.15)		0.16 [-0.32, 0.64]	
ubtotal (95% CI)	26		47			0.16 [-0.32, 0.64]	
est for heterogeneity: not a	oplicable				-		
est for overall effect: $Z = 0$.	66 (P = 0.51)						

Favours SNRI Favours other drug

OCD: SNRIs Review:

Comparison:

01 SNRIs vs other drugs 06 Hamilton Rating Scale for Depression Outcome:

Study or sub-category	N	SNRI Mean (SD)	N	Other drug Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% Cl	
01 Venlafaxine vs Paroxeti	ine									
Denys 2003a	73	-2.80(5.60)	72	-3.50(4.60)		_		_		0.14 [-0.19, 0.46]
Subtotal (95% CI)	73		72			-		<u> </u>	_	0.14 [-0.19, 0.46]
Test for heterogeneity: not	applicable							_		·
Test for overall effect: Z =	0.82 (P = 0.41)									
					-0.5	-0.25	_	0.25	0.5	

Favours SNRI Favours other drug


Favours SNRI Favours other drug

Review:

Comparison: 01 SNRIs vs other drugs 07 Hamilton Anxiety Scale Outcome:

Study or sub-category	N	SNRI Mean (SD)	N	Other drug Mean (SD)		SMD (fixed) 95% Cl				SMD (fixed) 95% Cl	
01 Venlafaxine vs Paroxeti	ine										
Denys 2003a	73	-4.90(5.00)	72	-4.70(7.00)						-0.03 [-0.36, 0.29]	
Subtotal (95% CI)	73		72							-0.03 [-0.36, 0.29]	
Test for heterogeneity: not	applicable										
Test for overall effect: Z =	0.20 (P = 0.84)										
					-0.5	-0.25	-	0.25	0.5		

MAOIs (OCD)



Favours MAOI Favours placebo

Review: OCD: MAOIs

02 MAOIs vs other drugs Comparison: Outcome: 01 Leaving study early

Study or sub-category	MAOI n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Phenelzine vs Clomipramin	e			
Vallejo 1992	2/14	2/16		1.14 [0.18, 7.08]
Subtotal (95% CI)	14	16		1.14 [0.18, 7.08]
Total events: 2 (MAOI), 2 (Oth	er drug)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 0.1$	4 (P = 0.89)			
02 Phenelzine vs Fluoxetine				
Jenike 1997	3/20	4/23		0.86 [0.22, 3.40]
Subtotal (95% CI)	20	23		0.86 [0.22, 3.40]
Total events: 3 (MAOI), 4 (Oth	er drug)			•
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 0.2$	21 (P = 0.83)			
				10
		0.1	0.2 0.5 1 2 5	10

Review: OCD: MAOIs

02 MAOIs vs other drugs Comparison:

02 Leaving study early due to adverse effects Outcome:

Study or sub-category	MAOI n/N	Other drug n/N	,	fixed) % Cl	RR (fixed) 95% Cl
01 Phenelzine vs Clomipramine					
Vallejo 1992	0/14	1/16			0.38 [0.02, 8.59]
Subtotal (95% CI)	14	16			0.38 [0.02, 8.59]
Total events: 0 (MAOI), 1 (Other	drug)		_ _ _		
Test for heterogeneity: not applic	cable				
Test for overall effect: Z = 0.61 ((P = 0.54)				
			0.01 0.1		100

Favours MAOI Favours other drug

Favours MAOI Favours other drug

OCD: MAOIs Review: 02 MAOIs vs other drugs Comparison:

Outcome: 03 Y-BOCS

SMD (fixed) 95% Cl SMD (fixed) 95% Cl MAOI Mean (SD) Study Other drug N N Mean (SD) or sub-category 01 Phenelzine vs Fluoxetine 0.01 [-0.64, 0.67] 0.01 [-0.64, 0.67] Jenike 1997 17 16.30(7.00) 19 19 16.20(6.30) Subtotal (95% CI) 17 Test for heterogeneity: not applicable Test for overall effect: Z = 0.04 (P = 0.96) -0.5 0.5

OCD: MAOIs

02 MAOIs vs other drugs 04 NIMH-OC Comparison:

Outcome:

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)		5	SMD (fixed 95% CI	,	SMD (fixed) 95% CI
01 Phenelzine vs Fluoxetin	B								
Jenike 1997	17	6.80(1.40)	19	7.00(1.10)	-		-		-0.16 [-0.81, 0.50]
Subtotal (95% CI)	17		19		-			_	-0.16 [-0.81, 0.50]
Test for heterogeneity: not	applicable						_		
Test for overall effect: Z =	0.47 (P = 0.64)								
					-1	-0.5		0.5	1

Favours MAOI Favours other drug

Favours MAOI Favours other drug

OCD: MAOIs Review: Comparison:

02 MAOIs vs other drugs Outcome: 05 Maudsley Obsessive-Compulsive Inventory

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)) (fixed) 5% Cl		SMD (fixed) 95% Cl
01 Phenelzine vs Clomiprai Vallejo 1992 Subtotal (95% Cl) Test for heterogeneity: not	12 12 applicable	10.10(6.90)	14 14	12.10(4.70)		7	-		-0.33 [-1.11, 0.44] -0.33 [-1.11, 0.44]
Test for overall effect: Z =	0.84 (P = 0.40)				-4 Fa	-2 avours MAOI	0 Favour	2 s other dru	4

Review: OCD: MAOIs

02 MAOIs vs other drugs 06 OCD Scale (CPRS) Comparison: Outcome:

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% Cl	
01 Phenelzine vs Fluoxetin	ne									
Jenike 1997	17	6.50(3.80)	19	6.70(2.60)			_		-0.06 [-0.72, 0.59]
Subtotal (95% CI)	17		19				دوقو		-0.06 [-0.72, 0.59]
Test for heterogeneity: not	t applicable									
Test for overall effect: Z =	0.18 (P = 0.86)									
							<u> </u>		-:	
					-1	-0.5	U	0.5	1	

Review: Comparison:

OCD: MAOIs 02 MAOIs vs other drugs 07 Hamilton Rating Scale for Depression Outcome:

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)	SMD (fi:		SMD (fixed) 95% Cl
01 Phenelzine vs Clomipramir Vallejo 1992 Subtotal (95% Cl) Test for heterogeneity: not ap Test for overall effect: Z = 1.1	12 12 oplicable	7.00(5.70)	14 14	11.50(6.90)	+		-0.68 [-1.48, 0.11] -0.68 [-1.48, 0.11]

Review: OCD: MAOIs

Comparison:

02 MAOIs vs other drugs 08 Hamilton Rating Scale for Anxiety Outcome:

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% CI
01 Phenelzine vs Clomipra Vallejo 1992 Subtotal (95% CI)	12 12	7.00(6.60)	14 14	14.10(8.70)		4	-			-0.88 [-1.69, -0.07] -0.88 [-1.69, -0.07]
Test for heterogeneity: not Test for overall effect: Z =										
					-4	-2	0	2	4	

OCD: MAOIs Review:

02 MAOIs vs other drugs 09 Clinical Global Impression Comparison: Outcome:

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)		S	MD (fixed) 95% CI)		SMD (fixed) 95% Cl
01 Phenelzine vs Fluoxetine	e									
Jenike 1997	17	3.20(1.00)	19	3.10(1.00)			_			0.10 [-0.56, 0.75]
Subtotal (95% CI)	17		19							0.10 [-0.56, 0.75]
Test for heterogeneity: not	applicable									
Test for overall effect: Z =	0.29 (P = 0.77)									
					-1	-0.5	-	0.5	1	

Favours MAOI Favours other drug

Favours MAOI Favours other drug

Favours MAOI Favours other drug

Anxiolytics (OCD)

Review: OCD: anxiolytics Comparison: 01 Anxiolytics vs placebo Outcome: 01 Leaving study early

Study or sub-category	Anxiolytic n/N	Placebo n/N		RR (fixed) 95% CI				RR (fixed) 95% Cl
01 Clonazepam								
Hollander 2003c	5/17	4/10	_		\vdash			0.74 [0.26, 2.12]
Subtotal (95% CI)	17	10				_		0.74 [0.26, 2.12]
Total events: 5 (Anxiolytic),	4 (Placebo)							
Test for heterogeneity: not a	pplicable							
Test for overall effect: Z = 0	.57 (P = 0.57)							
			0.2	0.5	1	2	5	

Favours anxiolytic Favours placebo

OCD: anxiolytics Review: Comparison: 01 Anxiolytics vs placebo

Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Anxiolytic n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clonazepam				
Hollander 2003c	3/17	2/10		0.88 [0.18, 4.41]
Subtotal (95% CI)	17	10		0.88 [0.18, 4.41]
Total events: 3 (Anxiolytic),	2 (Placebo)			·
Test for heterogeneity: not a	applicable			
Test for overall effect: Z = 0	0.15 (P = 0.88)			
			0.1 0.2 0.5 1 2 5	1 10

Favours anxiolytic Favours placebo

OCD: anxiolytics Review: 01 Anxiolytics vs placebo Comparison: 03 Non-responders Outcome:

Study or sub-category	Anxiolytic n/N	Placebo n/N		RR (fixed) 95% Cl		RR (fixed) 95% Cl
01 Clonazepam						
Hollander 2003c	16/17	8/10			-	1.18 [0.84, 1.64]
Subtotal (95% CI)	17	10			-	1.18 [0.84, 1.64]
Total events: 16 (Anxiolytic)	, 8 (Placebo)					
Test for heterogeneity: not a	pplicable					
Test for overall effect: $Z = 0$.96 (P = 0.34)					
		0.5	0.7	1 1.5	2	

Favours anxiolytic Favours placebo

Review: OCD: anxiolytics 01 Anxiolytics vs placebo 04 Y-BOCS Comparison:

Outcome:

Study or sub-category	N	Anxiolytic Mean (SD)	N	Placebo Mean (SD)		SMD (1 95%		SMD (fixed) 95% CI
01 Clonazepam Hollander 2003c	16	-1.70(4.30)	9	-0.67(5.10)		-		-0.22 [-1.04, 0.60]
Subtotal (95% CI)	16		9			•	•	-0.22 [-1.04, 0.60]
Test for heterogeneity: not	t applicable]		
Test for overall effect: Z =	0.52 (P = 0.60)							
					-10	-5 0	5	10

Favours anxiolytic Favours placebo

OCD: anxiolytics Comparison: 01 Anxiolytics vs placebo


05 NIMH-ÓC

Review:

Study or sub-category	N	Anxiolytic Mean (SD)	N	Placebo Mean (SD)		:	SMD (fixed 95% Cl)		SMD (fixed) 95% Cl
01 Clonazepam										
Hollander 2003c	16	0.13(2.40)	9	0.00(2.50)			_			0.05 [-0.77, 0.87]
Subtotal (95% CI)	16		9				•			0.05 [-0.77, 0.87]
Test for heterogeneity: not	: applicable						Γ			
Test for overall effect: Z =	0.12 (P = 0.90)									
					-4	-2	-	- <u> </u>	4	
					Fav	ours anxio	lvtic Fav	ours placeb	00	

Review: OCD: anxiolytics Comparison: 01 Anxiolytics vs placebo

Outcome: 06 Hamilton Rating Scale for Depression



Review: OCD: anxiolytics
Comparison: 01 Anxiolytics vs placebo
Outcome: 07 Hamilton Anxiety Scale

Study or sub-category	N	Anxiolytic Mean (SD)	N	Placebo Mean (SD)		S	MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Clonazepam										
Hollander 2003c	16	-1.10(7.70)	9	0.33(9.80)			-			-0.16 [-0.98, 0.66]
Subtotal (95% CI)	16		9				•			-0.16 [-0.98, 0.66]
Test for heterogeneity: no	t applicable						1			
Test for overall effect: Z =	0.39 (P = 0.70)									
					-10	-5	-	5	10	

Review: OCD: anxiolytics
Comparison: 02 Anxiolytics vs.

Comparison: 02 Anxiolytics vs other drugs Outcome: 01 Leaving study early

Study Anxiolytic Other drug RR (fixed) RR (fixed) or sub-category n/Ν nN95% CI 95% CI 01 Buspirone vs Clomipramine Pato 1991 1/10 1.00 [0.07, 13.87] 1/10 Subtotal (95% CI) 10 10 1.00 [0.07, 13.87] Total events: 1 (Anxiolytic), 1 (Other drug) Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) 0.01 0.1 10 100

Favours anxiolytic Favours other drug

Favours anxiolytic Favours placebo

Review: OCD: anxiolytics

Comparison: 02 Anxiolytics vs other drugs


Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Anxiolytic n/N	Other drug n/N	_					RR (fixed) 95% Cl
01 Buspirone vs Clomipramin	e							
Pato 1991	0/10	1/10						0.33 [0.02, 7.32]
Subtotal (95% CI)	10	10				_		0.33 [0.02, 7.32]
Total events: 0 (Anxiolytic), 1	l (Other drug)							
Test for heterogeneity; not as								
Test for overall effect: $Z = 0$.	•							
				-				
			0.01	0.1	1	10	100	
			Favou	rs anxioly	/tic Fa√	ours othe	r drug	

Review: OCD: anxiolytics

Comparison: 02 Anxiolytics vs other drugs


Outcome: 03 Y-BOCS



Review: OCD: anxiolytics


02 Anxiolytics vs other drugs 04 NIMH-OC Comparison:

Outcome:




OCD: anxiolytics Review:

02 Anxiolytics vs other drugs 05 Hamilton Rating Scale for Depression Comparison: Outcome:



Other Pharmacological (OCD)

Review: OCD: other pharmacological Comparison: 01 Inositol vs placebo Outcome: 01 Y-BOCS



Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 01 Adverse effects

Study or sub-category	Oxytocin n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Den Boer 1992	6/6	1/6	-	6.00 [1.00, 35.91]
Total (95% CI) Total events: 6 (Oxytocin), 1 Test for heterogeneity: not ay Test for overall effect: Z = 1.	pplicable	6		6.00 [1.00, 35.91]
		0.01	0.1 1 10	100

Favours Oxytocin Favours Placebo

Favours Oxytocin Favours Placebo

Favours Oxytocin Favours Placebo

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 02 Leaving study early

Study or sub-category	Oxytocin n/N	Placebo n/N	,	iixed) 6 Cl	RR (fixed) 95% Cl
Den Boer 1992	0/6	0/6			Not estimable
Total (95% CI) Total events: 0 (Oxytocin), 0 (Placebo Test for heterogeneity: not applicable Test for overall effect: not applicable	0	0			Not estimable
		0.1	1 0.2 0.5 1	1 2 5	10

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 03 Hamilton Depression Scale

Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)		5	SMD (fixed) 95% Cl			SMD (fixed) 95% Cl
Den Boer 1992	6	8.20(3.10)	6	7.00(2.80)			-	_		0.38 [-0.77, 1.52]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0.			6				-	-		0.38 [-0.77, 1.52]
•					-4	-2	Ó	2	4	

Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 04 Self Rating Depression Scale

Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)		s	MD (fixed 95% CI)		SMD (fixed) 95% Cl
Den Boer 1992	6	50.80(6.90)	6	50.80(6.00)		_	+	-		0.00 [-1.13, 1.13]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			6			-	+	•		0.00 [-1.13, 1.13]
					-4	-2	Ó	2	4	
					Favo	urs Oxyto	cin Fav	ours Place	ebo	

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 05 Hamilton Anxiety Scale

Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)			MD (fixed) 95% CI			SMD (fixed) 95% Cl
Den Boer 1992	6	12.20(5.10)	6	11.20(3.10)		_	-	-		0.22 [-0.92, 1.36]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			6			-	+	•		0.22 [-0.92, 1.36]
					-4	-2	0	2	4	

Favours Oxytocin Favours Placebo

Favours Oxytocin Favours Placebo

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 06 State Anxiety Inventory


Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)			D (fixed) 5% Cl			SMD (fixed) 95% Cl
Den Boer 1992	6	48.70(13.40)	6	61.20(7.90)		-	+			-1.05 [-2.29, 0.19]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			6			-				-1.05 [-2.29, 0.19]
					-4	-2	-	2	4	

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 07 General Symptom Index

Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)			MD (fixed 95% CI)		SMD (fixed) 95% Cl
Den Boer 1992	6	1.50(0.70)	6	1.50(0.40)		_	•	-		0.00 [-1.13, 1.13]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 0.0			6				+			0.00 [-1.13, 1.13]
					-4	-2	Ó	2	4	
					Favo	ours Oxytoo	cin Fav	ours Place	ebo	

Augmentation (OCD)

Review: OCD: augmentation strategies Comparison: 01 Buspirone vs placebo Outcome: 01 Non-responders



Review: OCD: augmentation strategies Comparison: 01 Buspirone vs placebo

Outcome: 02 Y-BOCS

Study or sub-category	N	FLV+Buspirone Mean (SD)	N	FLV+Placebo Mean (SD)		S	SMD (fixed) 95% CI		SMD (fixed) 95% Cl
01 FLV+Buspirone v FLV+	-Placebo								
McDougle 1993a	19	24.90(6.60)	14	21.00(9.10)			+		0.49 [-0.21, 1.19]
Subtotal (95% CI)	19		14				-		0.49 [-0.21, 1.19]
Test for heterogeneity: not	t applicable						-		
Test for overall effect: Z =	1.37 (P = 0.17)								
-					4	-	\rightarrow	-	1

Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

Review: OCD: augmentation strategies
Comparison: 01 Buspirone vs placebo
Outcome: 03 Hamilton Depression Rating Scale

Study FLV+Buspirone FLV+Placebo SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 FLV+Buspirone v FLV+Placebo McDougle 1993a 17.90(10.70) 11.70(7.40) 0.64 [-0.07, 1.35] 14 Subtotal (95% CI) 0.64 [-0.07, 1.35] Test for heterogeneity: not applicable Test for overall effect: Z = 1.77 (P = 0.08)

Review: OCD: augmentation strategies Comparison: 01 Buspirone vs placebo Outcome: 04 Hamilton Anxiety Scale

Study or sub-category	N	FLV+Buspirone Mean (SD)	N	FLV+Placebo Mean (SD)		S	MD (fixed) 95% CI			SMD (fixed) 95% Cl
01 FLV+Buspirone v FLV+F		11 5045 001	1.4	0.6044.001						0.40.7.0.00.1.101
McDougle 1993a Subtotal (95% CI)	19 19	11.60(6.80)	14 14	8.60(4.90)			-			0.48 [-0.22, 1.18] 0.48 [-0.22, 1.18]
Test for heterogeneity: not	applicable									
Test for overall effect: $Z = 1$	1.35 (P = 0.18)									
					-4	-2	- 6	2	4	
					Favours	augmentat	tion Favo	ours non-a	aug	

Review: OCD: augmentation strategies
Comparison: 02 Citalopram+Clomipramine vs Citalopram
Outcome: 01 Non-responders (Y-BOCS 35%)

Study or sub-category	Citalopram+CMI n/N	Citalopram n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Pallanti 1999	0/9	6/7		0.06 [0.00, 0.94]
Total (95% CI) Total events: 0 (Citalopram+ Test for heterogeneity: not a Test for overall effect: Z = 2	applicable	7		0.06 [0.00, 0.94]
			0.001 0.01 0.1 1 10 100 100 Favours augmentation Favours non-aug	00

Review: OCD: augmentation strategies Comparison: 02 Citalopram+Clomipramine vs Citalopram Outcome: 02 Y-BOCS SMD (fixed) SMD (fixed) Study Citalopram+CMI Citalopram or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Pallanti 1999 9 15.90(3.80) 7 25.60(4.80) -2.15 [-3.46, -0.84] Total (95% CI) -2.15 [-3.46, -0.84] Test for heterogeneity: not applicable Test for overall effect: Z = 3.22 (P = 0.001) Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison 02 Citalopram+Clomipramine vs Citalopram 03 Hamilton Depression Rating Scale Outcome: Study Citalopram+CMI Citalopram SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Pallanti 1999 9 5.60(2.60) 6.40(1.80) -0.33 [-1.33, 0.67] Total (95% CI) 7 -0.33 [-1.33, 0.67] Test for heterogeneity: not applicable Test for overall effect: Z = 0.65 (P = 0.52) Favours augmentation Favours non-aug OCD: augmentation strategies Review: Comparison: 03 Desipramine vs placebo Outcome: 01 Y-BOCS at 6 weeks Study SSRI+Placebo SMD (fixed) SSRI+Desipramine SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 SSRI+Desipramine v SSRI+Placebo -1.97 [-3.00, -0.93] -1.97 [-3.00, -0.93] Barr 1997 24.52(2.94) 18.52(2.94) 13 10 Subtotal (95% CI) 10 Test for heterogeneity: not applicable Test for overall effect: Z = 3.73 (P = 0.0002) Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 03 Desipramine vs placebo 02 Y-BOCS at 10 weeks Outcome: SMD (fixed) Study SSRI+Desipramine SSRI+Placebo SMD (fixed) N 95% CI or sub-category N Mean (SD) Mean (SD) 95% CI 01 SSRI+Desipramine v SSRI+Placebo Barr 1997 10 19.30(3.78) 13 22.43(3.78) -0.80 [-1.66, 0.06] Subtotal (95% CI) 10 13 -0.80 [-1.66, 0.06] Test for heterogeneity: not applicable Test for overall effect: Z = 1.81 (P = 0.07) Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 04 Haloperidol vs placebo Outcome: 01 Non-responders Study FLV+Haloperidol FLV+Placebo RR (fixed) RR (fixed) n/N n/Ν 95% CI 95% CI or sub-category 01 FLV+Haloperidol v FLV+Placebo 0.59 [0.40, 0.88] McDougle 1994a 10/17 17/17 Subtotal (95% CI) 17 0.59 [0.40, 0.88] Total events: 10 (FLV+Haloperidol), 17 (FLV+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 2.61 (P = 0.009) 0.2 0.5 5


Favours augmentation

Favours non-aug

Review: OCD: augmentation strategies 04 Haloperidol vs placebo 02 Y-BOCS Comparison: Outcome: Study FLV+Haloperidol or sub-category Ν 01 FLV+Haloperidol v FLV+Placebo McDougle 1994a Subtotal (95% CI) 17 Test for heterogeneity: not applicable Test for overall effect: Z = 4.94 (P < 0.00001)

Mean (SD)

18.53(2.71)



Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

Review: Comparison: OCD: augmentation strategies 05 Inositol vs placebo Outcome: 01 Y-BOCS

Of SRI+Inositol v SRI+Placebo Fux 1999 6 16.33 (9.46) 4 18.75 (8.85) -0.24 [-1.51, 1.04] Subtotal (95% Cl) 6 4 -0.24 [-1.51, 1.04] Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72)	Study or sub-category	N	SRI+Inositol Mean (SD)	N	SRI+Placebo Mean (SD)		MD (fixed) 95% Cl		SMD (fixed) 95% CI
Subtotal (95% CI) 6 4 -0.24 [-1.51, 1.04] Test for heterogeneity: not applicable	01 SRI+Inositol v SRI+Placebo								
Test for heterogeneity: not applicable	Fux 1999	6	16.33(9.46)	4	18.75(8.85)		_		-0.24 [-1.51, 1.04]
	Subtotal (95% CI)	6		4					-0.24 [-1.51, 1.04]
Test for overall effect: Z = 0.36 (P = 0.72)	Test for heterogeneity: not app	plicable					_		
	Test for overall effect: $Z = 0.3$	6 (P = 0.72)							

OCD: augmentation strategies Review: 06 Lithium vs placebo Comparison: Outcome: 01 Non-responders

Study or sub-category	FLV+Lithium n/N	FLV+Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 FLV+Lithium v FLV+Placel	bo at 2 weeks			
McDougle 1991 (1)	9/11	9/9		0.82 [0.62, 1.08]
Subtotal (95% CI)	11	9		0.82 [0.62, 1.08]
Total events: 9 (FLV+Lithium)), 9 (FLV+Placebo)			
Test for heterogeneity: not ap	oplicable			
Test for overall effect: Z = 1.	41 (P = 0.16)			
02 FLV+Lithium v FLV+Placel	bo at 4 weeks			
McDougle 1991 (2)	5/5	5/5		Not estimable
Subtotal (95% CI)	0	0		Not estimable
Total events: 0 (FLV+Lithium)), 0 (FLV+Placebo)			
Test for heterogeneity: not as	oplicable			
Test for overall effect; not ap	plicable			
Total (95% CI)	16	14		0.82 [0.62, 1.08]
Total events: 14 (FLV+Lithium	n), 14 (FLV+Placebo)			
Test for heterogeneity; not as				
Test for overall effect: Z = 1.	•			
		0.5	0.7 1 1.5	2


OCD: augmentation strategies 06 Lithium vs placebo Review: Comparison: Outcome: 02 Y-BOCS change score

Study or sub-category	N	FLV+Lithium Mean (SD)	N	FLV+Placebo Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 FLV+Lithium v FLV+Place	ebo at 2 weeks						
McDougle 1991 (1)	11	-4.00(5.23)	9	1.22(5.24)	_		-0.96 [-1.90, -0.01]
Subtotal (95% CI)	11		9		-		-0.96 [-1.90, -0.01]
Test for heterogeneity; not a	applicable					_	
Test for overall effect: Z = 1							
02 FLV+Lithium v FLV+Place	ebo at 4 weeks						
McDougle 1991 (2)	5	2.60(3.58)	5	-1.40(2.07)			1.24 [-0.19, 2.66]
Subtotal (95% CI)	5		5				1.24 [-0.19, 2.66]
Test for heterogeneity: not a	applicable						
Test for overall effect: Z = 1	.70 (P = 0.09)						
Total (95% CI)	16		14				-0.29 [-1.07, 0.50]
Test for heterogeneity: Chi ²	= 6.34, df = 1 (P	= 0.01), I ² = 84.2%				7	·
Test for overall effect: Z = 0	.72 (P = 0.47)	• •					
					-4 -2	0 2	4
					Favours augme	ntation Favours non-aug	1

Review: OCD: augmentation strategies

Comparison: 06 Lithium vs placebo

03 Hamilton Depression Scale change score Outcome:



Review: OCD: augmentation strategies

Comparison: 06 Lithium vs placebo Outcome:

04 Hamilton Anxiety Scale change score

Study or sub-category	N	FLV+Lithium Mean (SD)	N	FLV+Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 FLV+Lithium v FLV+Placel	oo at 2 weeks					
McDougle 1991 (1)	11	-0.73(4.67)	9	-1.11(3.26)		0.09 [-0.79, 0.97]
Subtotal (95% CI)	11		9			0.09 [-0.79, 0.97]
Fest for heterogeneity: not ap	oplicable				T	
est for overall effect: $Z = 0$.	20 (P = 0.84)					
02 FLV+Lithium v FLV+Placel	oo at 4 weeks					
McDougle 1991 (2)	5	1.40(3.51)	5	-3.20(3.27)	 	1.22 [-0.19, 2.64]
ubtotal (95% CI)	5		5			1.22 [-0.19, 2.64]
est for heterogeneity; not ap	oplicable					
est for overall effect: Z = 1.	69 (P = 0.09)					
Fotal (95% CI)	16		14		-	0.41 [-0.34, 1.15]
[est for heterogeneity: Chi² =	1.78, df = 1 (P	= 0.18), I ² = 43.8%				
Fest for overall effect: $Z = 1$.	06 (P = 0.29)					

Review: OCD: augmentation strategies Comparison:

07 Nortriptyline vs placebo 01 Y-BOCS

Outcome:

Study or sub-category	C N	MI+Nortriptyline Mean (SD)	N	CMI+Placebo Mean (SD)		S	MD (fixed 95% Cl)		SMD (fixed) 95% Cl
01 CMI+Nortriptyline v CMI+ Noorbala 1998 Subtotal (95% CI) Test for heterogeneity: not	15 15	8.33(5.56)	15 15	19.17(5.56)		<u></u>				-1.90 [-2.78, -1.02] -1.90 [-2.78, -1.02]
Test for overall effect: Z =					-			<u>.</u>	- :	
					-4 Favours	-2 augmentat	0 ion Fav	2 /ours non-	4 aug	

Favours augmentation Favours non-aug

OCD: augmentation strategies Review: Comparison: 08 Olanzapine vs placebo Outcome: 01 Leaving the study early

Study or sub-category	FLX+Olanzapine n/N	FLX+Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 FLX+Olanzapine v FLX+	-Placebo			
Shapira 2004	5/22	2/22		2.50 [0.54, 11.54]
Subtotal (95% CI)	22	22		2.50 [0.54, 11.54]
Total events: 5 (FLX+Olanz	rapine), 2 (FLX+Placebo)			
Test for heterogeneity; not	applicable			
Test for overall effect: Z =	1.17 (P = 0.24)			
		(0.01 0.1 1 10	100
		F	avours augmentation Favours non-aug	I


Review: OCD: augmentation strategies Comparison: 08 Olanzapine vs placebo Outcome: 02 Leaving the study early due to adverse effects FLX+Olanzapine FLX+Placebo RR (fixed) RR (fixed) Study or sub-category n/Ν nΝ 95% CI 95% CI 01 FLX+Olanzapine v FLX+Placebo Shapira 2004 2/22 2/22 1.00 [0.15, 6.48] Subtotal (95% CI) 22 1.00 [0.15, 6.48] Total events: 2 (FLX+Olanzapine), 2 (FLX+Placebo) Test for heterogeneity; not applicable Test for overall effect: Z = 0.00 (P = 1.00) 0.5 0.2 Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 08 Olanzapine vs placebo 03 Non-responders (Y-BOCS 25%) Outcome: Study FLX+Olanzapine FLX+Placebo RR (fixed) RR (fixed) or sub-category nNn/Ν 95% CI 95% CI 01 FLX+Olanzapine v FLX+Placebo 1.00 [0.61, 1.64] Shapira 2004 13/22 13/22 Subtotal (95% CI) 22 22 1.00 [0.61, 1.64] Total events: 13 (FLX+Olanzapine), 13 (FLX+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)0.5 0.7 1.5 Favours augmentation Favours non-aug OCD: augmentation strategies Review: Comparison: 08 Olanzapine vs placebo 04 Y-BOCS change score Outcome: SMD (fixed) FLX+Placebo Study FLX+Olanzapine SMD (fixed) N or sub-category N 95% CI 95% CI Mean (SD) Mean (SD) 01 FLX+Olanzapine v FLX+Placebo Shapira 2004 22 -5.10(4.90) 22 -3.80(3.80) -0.29 [-0.89, 0.30] Subtotal (95% CI) 22 22 -0.29 [-0.89, 0.30] Test for heterogeneity: not applicable Test for overall effect: Z = 0.96 (P = 0.34) -0.5 0.5 0 Favours augmentation Favours non-aug Review: OCD: augmentation strategies 09 Pindolol vs placebo Comparison: 01 Leaving the study early Outcome: Study Paroxetine+Pindolol Paroxetine+Placebo RR (fixed) RR (fixed) or sub-category 95% CI 95% CI nNnΝ 01 PAR+Pindolol v PAR+Placebo Dannon 2000 0/8 2/8 0.20 [0.01, 3.61] Subtotal (95% CI) 8 8 0.20 [0.01, 3.61] Total events: 0 (Paroxetine+Pindolol), 2 (Paroxetine+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 1.09 (P = 0.28)0.01 100 0.1 10 Favours augmentation Favours non-aug Review: OCD: augmentation strategies 09 Pindolol vs placebo Comparison: Outcome: 02 Leaving the study early due to adverse effects Paroxetine+Placebo Study Paroxetine+Pindolol RR (fixed) RR (fixed)

or sub-category n/N nΝ 95% CI 95% CI 01 PAR+Pindolol v PAR+Placebo 0.20 [0.01, 3.61] Dannon 2000 0/8 2/8 Subtotal (95% CI) 0.20 [0.01, 3.61] 8 Total events: 0 (Paroxetine+Pindolol), 2 (Paroxetine+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 1.09 (P = 0.28) 0.01 100 Favours augmentation Favours non-aug

Review: OCD: augmentation strategies 09 Pindolol vs placebo 03 Y-BOCS Comparison: Outcome: Paroxetine+Pindolol Study or sub-category N 01 PAR+Pindolol v PAR+Placebo Dannon 2000 Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.98 (P = 0.003)

Mean (SD)

21.40(3.70)



Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

OCD: augmentation strategies 09 Pindolol vs placebo Review: Comparison:

Outcome: 04 MADRS

Study or sub-category	P: N	aroxetine+Pindolol Mean (SD)	Pa N	roxetine+Placebo Mean (SD)		S	MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 PAR+Pindolol v PAR+Pl	acebo									
Dannon 2000	8	11.80(7.60)	6	11.50(4.90)		-	_			0.04 [-1.02, 1.10]
Subtotal (95% CI)	8		6			-	-			0.04 [-1.02, 1.10]
Test for heterogeneity: not	t applicable						T			
Test for overall effect: Z =	0.08 (P = 0.94)									
					-4	-2	-	2	4	

Review: OCD: augmentation strategies Comparison: 09 Pindolol vs placebo 05 Hamilton Anxiety Scale Outcome:

Study or sub-category	P N	aroxetine+Pindolol Mean (SD)	Par N	oxetine+Placebo Mean (SD)	SMD (fixed) 95% CI				SMD (fixed) 95% CI
01 PAR+Pindolol v PAR	8 8 t applicable	10.25(3.80)	6 6	11.70(5.20)		4	-		-0.31 [-1.37, 0.76] -0.31 [-1.37, 0.76]
					-4	-2	ò	2	4

OCD: augmentation strategies Review: Comparison: 10 Quetiapine vs placebo Outcome: 01 Adverse effects

Study or sub-category	SRI+Quetiapine n/N	SRI+placebo n/N	RR (fixed) 95% Cl				RR (fixed) 95% Cl			
01 SRI+Quetiapine v SRI+PI	acebo									
Atmaca 2002	9/14	4/13			+		_		2.09 [0.85	, 5.16]
Subtotal (95% CI)	14	13			-	<u> </u>	-		2.09 [0.85	, 5.16]
Total events: 9 (SRI+Quetia	pine), 4 (SRI+placebo)					_				
Test for heterogeneity: not	applicable									
Test for overall effect: Z =	1.60 (P = 0.11)									
		0.1	0.2	0.5	1	2	5	10		

Favours augmentation Favours non-aug OCD: augmentation strategies

Review: Comparison: 10 Quetiapine vs placebo Outcome: 02 Leaving the study early

Not estimable
Not estimable

Favours augmentation Favours non-aug

Review: OCD: augmentation strategies Comparison: 10 Quetiapine vs placebo 03 Non-responders (Y-BOCS 30%) Outcome: SRI+Quetiapine SRI+placebo RR (fixed) RR (fixed) Study or sub-category n/Ν n/Ν 95% CI 95% CI 01 SRI+Quetiapine v SRI+Placebo Atmaca 2002 4/14 13/13 0.29 [0.12, 0.65] Subtotal (95% CI) 13 0.29 [0.12, 0.65] Total events: 4 (SRI+Quetiapine), 13 (SRI+placebo) Test for heterogeneity; not applicable Test for overall effect: Z = 2.96 (P = 0.003) 0.2 0.5 Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 10 Quetiapine vs placebo Outcome: 04 Y-BOCS Study SRI+Quetiapine SRI+Placebo SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 SRI+Quetiapine v SRI+Placebo Atmaca 2002 13.40(3.20) 13 21.40(4.30) -2.06 [-3.02, -1.10] Subtotal (95% CI) 13 -2.06 [-3.02, -1.10] 14 Test for heterogeneity; not applicable Test for overall effect: Z = 4.20 (P < 0.0001)Favours augmentation Favours non-aug OCD: augmentation strategies Review: 10 Quetiapine vs placebo Comparison: Outcome: 05 CGI: severity of illness SRI+Placebo SMD (fixed) SMD (fixed) Study SRI+Quetiapine or sub-category Mean (SD) Mean (SD) 95% CI 01 SRI+Quetiapine v SRI+Placebo 3.76(1.40) -1.15 [-1.98, -0.33] -1.15 [-1.98, -0.33] Atmaca 2002 2.42(0.80) 13 Subtotal (95% CI) 13 14 Test for heterogeneity: not applicable Test for overall effect: Z = 2.74 (P = 0.006) Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 11 Risperidone vs placebo Outcome: 01 Adverse effects SRI+Risperidone SRI+Placebo RR (fixed) RR (fixed) Study or sub-category nΝ n/N 95% CI 95% CI 01 SRI+Risperidone v SRI+Placebo 1.20 [0.31, 4.69] 0.96 [0.79, 1.16] Hollander 2003e 2/6 4/10 McDougle 2000a 18/20 15/16 Subtotal (95% CI) 30 22 0.99 [0.77, 1.28] Total events: 22 (SRI+Risperidone), 17 (SRI+Placebo) Test for heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67), I2 = 0% Test for overall effect: Z = 0.07 (P = 0.95) 0.5 Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 11 Risperidone vs placebo Outcome: 02 Leaving the study early Study SRI+Risperidone SRI+Placebo RR (fixed) RR (fixed) or sub-category n/N 95% CI n/N 95% CI 01 SRI+Risperidone v SRI+Placebo Hollander 2003e 1/10 2/6 0.30 [0.03, 2.65] McDougle 2000a 2/20 1/16 1.60 [0.16, 16.10] Subtotal (95% CI) 22 0.70 [0.16, 3.01] 30 Total events: 3 (SRI+Risperidone), 3 (SRI+Placebo) Test for heterogeneity: $Chi^2 = 1.07$, df = 1 (P = 0.30), $I^2 = 6.9\%$ Test for overall effect: Z = 0.48 (P = 0.63)

0.01

0.1

Favours augmentation Favours non-aug

10

100

Comparison: 11 Risperidone vs placebo Outcome: 03 Leaving the study early due to adverse effects SRI+Risperidone SRI+Placebo RR (fixed) RR (fixed) Study or sub-category n/Ν nΝ 95% CI 95% CI 01 SRI+Risperidone v SRI+Placebo McDougle 2000a 1/20 0/16 2.43 [0.11, 55.89] Subtotal (95% CI) 20 16 2.43 [0.11, 55.89] Total events: 1 (SRI+Risperidone), 0 (SRI+Placebo) Test for heterogeneity; not applicable Test for overall effect: Z = 0.55 (P = 0.58) 0.01 100 0.110 Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 11 Risperidone vs placebo Outcome: 04 Non-responders SRI+Risperidone SRI+Placebo RR (fixed) Study RR (fixed) or sub-category nΝ n/N 95% CI 95% CI 01 SRI+Risperidone v SRI+Placebo: CGI much or very much improved, Y-BOCS>=35% reduction McDougle 2000a 16/16 0.80 [0.64, 1.00] 16/20 Subtotal (95% CI) 20 16 0.80 [0.64, 1.00] Total events: 16 (SRI+Risperidone), 16 (SRI+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 2.00 (P = 0.05) 02 SRI+Risperidone v SRI+Placebo: CGI much or very much improved, Y-BOCS>=25% reduction Hollander 2003e 0.60 [0.36, 1.00] 6/10 6/6 Subtotal (95% CI) 10 6 0.60 [0.36, 1.00] Total events: 6 (SRI+Risperidone), 6 (SRI+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 1.98 (P = 0.05) Total (95% Ch. 0.74 [0.60, 0.91] 30 22 Total events: 22 (SRI+Risperidone), 22 (SRI+Placebo) Test for heterogeneity: Chi² = 1.14, df = 1 (P = 0.29), l² = 12.3% Test for overall effect: Z = 2.81 (P = 0.005) 0.5Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 11 Risperidone vs placebo 05 Y-BOCS change score Study SRI+Risperidone SRI+Placebo SMD (fixed) SMD (fixed) Ν Mean (SD) 95% CI or sub-category Mean (SD) 01 SRI+Risperidone v SRI+Placebo Hollander 2003e 10 -6.10(8.18) 6 -1.33(3.14)-0.66 [-1.71, 0.38] McDougle 2000a 20 -8.00(7.32) 16 -0.25 [-0.91, 0.41] -6.60(0.97)30 -0.37 [-0.92, 0.19] Test for heterogeneity: $Chi^2 = 0.43$, df = 1 (P = 0.51), $I^2 = 0\%$ Test for overall effect: Z = 1.28 (P = 0.20) Favours augmentation Favours non-aug OCD: augmentation strategies Review: Comparison: 11 Risperidone vs placebo 06 Hamilton Depression Scale SRI+Placeho SMD (fixed) SMD (fixed) Study SRI+Risperidone N Ν Mean (SD) or sub-category Mean (SD) 95% CI 95% CI 01 SRI+Risperidone v SRI+Placebo

18

18

7.60(4.90)

15

15

15.20(8.70)

-4 -2 0 2
Favours augmentation Favours non-aug

-1.08 [-1.82, -0.34]

-1.08 [-1.82, -0.34]

McDougle 2000a


Test for heterogeneity: not applicable Test for overall effect: Z = 2.86 (P = 0.004)

Subtotal (95% CI)

Review:

OCD: augmentation strategies

Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 07 Hamilton Anxiety Scale



Review: OCD: augmentation strategies Comparison: 12 All antipsychotics v placebo

Outcome: 01 Adverse effects

Study or sub-category	Augmentation n/N	non-augmentation n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 SRI+Quetiapine v SRI+Pla	acebo			
Atmaca 2002	9/14	4/13	+	2.09 [0.85, 5.16]
Subtotal (95% CI)	14	13		2.09 [0.85, 5.16]
Total events: 9 (Augmentation	on), 4 (non-augmentation)		-	
Test for heterogeneity: not a	applicable			
Test for overall effect: $Z = 1$	I.60 (P = 0.11)			
02 SRI+Risperidone v SRI+P	lacebo			
Hollander 2003e	4/10	2/6		1.20 [0.31, 4.69]
McDougle 2000a	18/20	15/16	<u> </u>	0.96 [0.79, 1.16]
Subtotal (95% CI)	30	22	•	0.99 [0.77, 1.28]
Total events: 22 (Augmental	tion), 17 (non-augmentation)			
Test for heterogeneity: Chi²	$= 0.18$, df $= 1 (P = 0.67)$, $I^2 = 09$	6		
Test for overall effect: Z = 0	0.07 (P = 0.95)			
Total (95% CI)	44	35	•	1.19 [0.89, 1.58]
Total events: 31 (Augmental	tion), 21 (non-augmentation)			,
, -	$= 6.13$, df = 2 (P = 0.05), $l^2 = 67$	7.3%		
Test for overall effect: Z = 1				
		0.1	0.2 0.5 1 2 5	10
		Favou	ırs augmentation Favours non-a	ug

Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 02 Leaving the study early

Study or sub-category	Augmentation n/N	non-augmentation n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 FLX+Olanzapine v FLX+Pla	acebo			
Shapira 2004	5/22	2/22		2.50 [0.54, 11.54]
Subtotal (95% CI)	22	22		2.50 [0.54, 11.54]
Total events: 5 (Augmentation	i), 2 (non-augmentation)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 1.1$	17 (P = 0.24)			
02 SRI+Quetiapine v SRI+Plac	ebo			
Atmaca 2002	0/14	0/13		Not estimable
Subtotal (95% CI)	0	0		Not estimable
Total events: 0 (Augmentation	i), 0 (non-augmentation)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: not ap	plicable			
03 SRI+Risperidone v SRI+Pla	cebo			
Hollander 2003e	1/10	2/6		0.30 [0.03, 2.65]
McDougle 2000a	2/20	1/16		1.60 [0.16, 16.10]
Subtotal (95% CI)	30	22		0.70 [0.16, 3.01]
Total events: 3 (Augmentation	n), 3 (non-augmentation)		-	
Test for heterogeneity: Chi ² =	1.07 , $df = 1$ ($P = 0.30$), $I^2 = 6.9$	%		
Test for overall effect: Z = 0.4	48 (P = 0.63)			
Total (95% CI)	66	57	—	1.34 [0.49, 3.67]
Total events: 8 (Augmentation	n), 5 (non-augmentation)			·
Test for heterogeneity: Chi² =	2.48, df = 2 (P = 0.29), l2 = 19.	3%		
Test for overall effect: $Z = 0.5$	57 (P = 0.57)			
		0	.01 0.1 1 10	100
		F8	vours augmentation Favours non-aug	g

Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 03 Leaving the study early due to adverse effects

Study or sub-category	Augmentation n/N	non-augmentation n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
01 FLX+Olanzapine v FLX+Plac	ebo					
Shapira 2004	2/22	2/22		1.00 [0.15, 6.48]		
Subtotal (95% CI)	22	22		1.00 [0.15, 6.48]		
Total events: 2 (Augmentation), Test for heterogeneity: not appl Test for overall effect: Z = 0.00	icable					
02 SRI+Risperidone v SRI+Place	ebo					
McDougle 2000a	1/20	0/16		- 2.43 [0.11, 55.89]		
Subtotal (95% CI)	20	16				
Total events: 1 (Augmentation), Test for heterogeneity: not appl Test for overall effect: Z = 0.55	icable					
Total (95% CI) Total events: 3 (Augmentation), Test for heterogeneity: Chi² = 0 Test for overall effect: Z = 0.33	.23, df = 1 (P = 0.63), I^2 = 0	38		1.31 [0.27, 6.35]		
		0.01	0.1 1 10	100		
		Favo	urs augmentation Favours non-au	ug		


Review: OCD: augmentation strategies Comparison: 12 All antipsychotics v placebo

Outcome: 04 Non-responders

Study or sub-category	Augmentation n/N	non-augmentation n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 FLV+Haloperidol v FLV+Place	bo			
McDougle 1994a	10/17	17/17		0.59 [0.40, 0.88]
Subtotal (95% CI)	17	17	•	0.59 [0.40, 0.88]
Total events: 10 (Augmentation),				
Test for heterogeneity: not applic				
Test for overall effect: Z = 2.61 (P = 0.009)			
02 FLX+Olanzapine v FLX+Placel	bo			
Shapira 2004	13/22	13/22	-	1.00 [0.61, 1.64]
Subtotal (95% CI)	22	22	-	1.00 [0.61, 1.64]
Total events: 13 (Augmentation),	13 (non-augmentation)			
Test for heterogeneity: not applic				
Test for overall effect: Z = 0.00 (P = 1.00)			
03 SRI+Quetiapine v SRI+Placebo)			
Atmaca 2002	4/14	13/13		0.29 [0.12, 0.65]
Subtotal (95% CI)	14	13		0.29 [0.12, 0.65]
Total events: 4 (Augmentation), 1	, -			
Test for heterogeneity: not applic				
Test for overall effect: Z = 2.96 (P = 0.003)			
04 SRI+Risperidone v SRI+Placeb	00			
Hollander 2003e	6/10	6/6		0.60 [0.36, 1.00]
McDougle 2000a	16/20	16/16	-	0.80 [0.64, 1.00]
Subtotal (95% CI)	30	22	•	0.74 [0.60, 0.91]
Total events: 22 (Augmentation),	22 (non-augmentation)		`	
Test for heterogeneity: Chi² = 1.1		6		
Test for overall effect: Z = 2.81 (P = 0.005)			
Total (95% CI)	83	74	•	0.66 [0.54, 0.81]
Total events: 49 (Augmentation),	65 (non-augmentation)		*	• •
Test for heterogeneity: Chi² = 9.9	18 , df = 4 (P = 0.04), 1^2 = 59.9%	5		
Test for overall effect: $Z = 4.05$ (P < 0.0001)			
			0.1 0.2 0.5 1 2 5 10	0
			Favours augmentation Favours non-aug	

Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo

Outcome: 05 Y-BOCS



Favours augmentation Favours non-aug

SSRIs (OCD, children)

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 01 Adverse events


Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine				
Geller 2001	53/71	27/32		0 00 10 72 1 001
Liebowitz 2002	21/21	19/22	 _	0.88 [0.72, 1.08]
	92	·		1.16 [0.98, 1.37]
Subtotal (95% CI)		54		0.98 [0.85, 1.12]
Total events: 74 (SSRI), 46 (0.000		
Test for neterogeneity: Cni ² Test for overall effect: Z = 0	= 4.99, df = 1 (P = 0.03), l² = 80 1 34 (P = 0.73)	1.0%		
1031 101 0401 all 011001. 2 = 0	3.04 (1 = 0.10)			
02 Fluvoxamine				
Riddle 2001	48/57	48/63	 •	1.11 [0.93, 1.32]
Subtotal (95% CI)	57	63		1.11 [0.93, 1.32]
Total events: 48 (SSRI), 48 ((Placebo)		-	
Test for heterogeneity: not a	applicable			
Test for overall effect: $Z = 1$	I.10 (P = 0.27)			
03 Paroxetine				
Geller 2004	83/98	77/105		1.15 [1.00, 1.33]
Subtotal (95% CI)	98	105		1.15 [1.00, 1.33]
Total events: 83 (SSRI), 77 (200		1110 (1110), 1110,
Test for heterogeneity: not a				
Test for overall effect: Z = 1				
1000 101 01010111011000. 2 = 1	1.00 (1 = 0.00)			
Total (95% CI)	247	222	•	1.09 [0.99, 1.19]
Total events: 205 (SSRI), 17	1 (Placebo)		-	•
Test for heterogeneity: Chi²	$= 5.30$, df $= 3$ (P = 0.15), $I^2 = 43$	3.4%		
Test for overall effect: $Z = 1$	I.80 (P = 0.07)			
		0.5	0.7 1 1.5	2
		0.0	Favours SSRI Favours Placeb	_
			Tayouts sort Tayouts Flaces	···

Review: OCD children: SSRIs Comparison: 01 SSRI vs placebo (acute phase) Outcome: 02 Serious adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl	
01 Paroxetine					
Geller 2004	3/98	1/105	- 	3.21 [0.34, 30.39]	
Subtotal (95% CI)	98	105		3.21 [0.34, 30.39]	
Total events: 3 (SSRI), 1 (Placebo)			-		
Test for heterogeneity: not applicable					
Test for overall effect: $Z = 1.02$ (P = 0.31))				
Total (95% CI)	98	105		3.21 [0.34, 30.39]	
Total events: 3 (SSRI), 1 (Placebo) Test for heterogeneity: not applicable					
= ,					
Test for overall effect: Z = 1.02 (P = 0.31)	J				
		0.0	1 0.1 1 10 10	0	
			Favours SSRI Favours Placebo		

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 03 Leaving the study early



Comparison:

01 SSRI vs placebo (acute phase)
04 Leaving the study early due to adverse events Outcome:


34]
Le
.64]
10]
.98]
.98]
.16]
.64]
.48]
. 60]
.60]
•
001

OCD children: SSRIs Review:

Comparison: 01 SSRI vs placebo (acute phase) Outcome: 05 Non-responders (25% CY-BOCS)

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Riddle 2001	33/57	46/63		0.79 [0.61, 1.04]
Subtotal (95% CI)	57	63	•	0.79 [0.61, 1.04]
fotal events: 33 (SSRI), 46 (Place	bo)		-	
Test for heterogeneity: not applica	able			
Test for overall effect: $Z = 1.70$ (F	P = 0.09)			
02 Paroxetine				
Geller 2004	39/100	65/107		0.64 [0.48, 0.86]
Subtotal (95% CI)	100	107	◆	0.64 [0.48, 0.86]
Total events: 39 (SSRI), 65 (Place	:bo)		-	
Test for heterogeneity: not applica	able			
Test for overall effect: Z = 3.01 (F	P = 0.003)			
Total (95% CI)	157	170	•	0.70 [0.58, 0.86]
Total events: 72 (SSRI), 111 (Plac	ebo)		- T	
Test for heterogeneity: Chi² = 1.15	5, df = 1 (P = 0.28), l ² = 13	3.2%		
Test for overall effect: Z = 3.44 (F	P = 0.0006)			
		0.1	0.2 0.5 1 2 5	10
			Favours SSRI Favours Placel	bo

Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 06 Non-responders (40% CY-BOCS)



Favours SSRI Favours Placebo

Review: OCD children: SSRIs

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 07 Non-responders (all)

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
O1 Fluoxetine				
Geller 2001	36/71	24/32	-	0.68 [0.50, 0.92]
Subtotal (95% CI)	71	32	-	0.68 [0.50, 0.92]
otal events: 36 (SSRI), 24 (Placebo))		•	,,
est for heterogeneity: not applicable				
est for overall effect: Z = 2.52 (P = 0				
02 Fluvoxamine				
Riddle 2001	33/57	46/63		0.79 [0.61, 1.04]
Subtotal (95% CI)	57	63	◆	0.79 [0.61, 1.04]
Total events: 33 (SSRI), 46 (Placebo)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 1.70 (P = 0	0.09)			
03 Paroxetine				
Geller 2004	39/100	65/107		0.64 [0.48, 0.86]
Subtotal (95% CI)	100	107	◆	0.64 [0.48, 0.86]
Total events: 39 (SSRI), 65 (Placebo)				
Fest for heterogeneity: not applicable				
Fest for overall effect: Z = 3.01 (P = 0	0.003)			
Fotal (95% CI)	228	202	◆	0.70 [0.59, 0.83]
fotal events: 108 (SSRI), 135 (Placek	00)			
Fest for heterogeneity: Chi² = 1.24, d	, ,,			
Test for overall effect: $Z = 4.18 (P < 1)$	0.0001)			
		0.	1 0.2 0.5 1 2 5	10
OOD stillers COD			Favours SSRI Favours placet	00

Review: OCD children: SSRIs

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 08 Non-responders (CGI Global Improvement)

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
01 Paroxetine						
Geller 2004	55/100	72/107	-	0.82 [0.66, 1.02]		
Subtotal (95% CI)	100	107	•	0.82 [0.66, 1.02]		
Total events: 55 (SSRI), 72 (I	Placebo)		-			
Test for heterogeneity: not a	pplicable					
Test for overall effect: Z = 1	.79 (P = 0.07)					
			0.1 0.2 0.5 1 2 5	10		
			Favours SSRI Favours Placebo			

01 SSRI vs placebo (acute phase) 09 Remission (CY-BOCS < 11) Comparison: Outcome:

Study or sub-category	Sertraline n/N	Placebo n/N				(fixed 5% CI				RR (fixed) 95% Cl
01 Sertraline										
POTS 2004	22/28	27/28			-					0.81 [0.66, 1.00]
Subtotal (95% CI)	28	28								0.81 [0.66, 1.00]
Total events: 22 (Sertraline),	27 (Placebo)				•					•
Test for heterogeneity: not a	pplicable									
Test for overall effect: Z = 1	.95 (P = 0.05)									
			0.1	0.2	0.5	1	2	5	10	

Favours Sertraline Favours Placebo

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 10 CY-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
D1 Fluoxetine						
Geller 2001	71	-9.50(9.20)	32	-5.20(7.40)		-0.49 [-0.91, -0.07]
Liebowitz 2002	21	14.71(8.73)	22	18.55(11.44)	-	-0.37 [-0.97, 0.23]
Riddle 1992	7	13.60(5.70)	6	14.80(7.00)	•	-0.18 [-1.27, 0.92]
Subtotal (95% CI)	99		60			-0.43 [-0.76, -0.10]
rest for heterogeneity: Chi² =	0.33, df = 2 (P	= 0.85), I ² = 0%				•
Test for overall effect: $Z = 2.5$	53 (P = 0.01)					
02 Fluvoxamine						
Riddle 2001	57	18.20(8.60)	63	20.90(8.50)		-0.31 [-0.67, 0.05]
Subtotal (95% CI)	57		63			-0.31 [-0.67, 0.05]
Test for heterogeneity: not ap	oplicable					
Test for overall effect: $Z = 1.7$	71 (P = 0.09)					
03 Sertraline						
March 1998	92	-6.80(8.35)	95	-3.40(8.00)		-0.41 [-0.70, -0.12]
POTS 2004	28	16.50(9.10)	28	21.50(5.40)	-	-0.66 [-1.20, -0.12]
Subtotal (95% CI)	120		123		-	-0.47 [-0.72, -0.21]
Test for heterogeneity: Chi² =	0.61, df = 1 (P	= 0.43), I ² = 0%			_	
Test for overall effect: $Z = 3.6$	60 (P = 0.0003)					
04 Paroxetine						
Geller 2004	94	-8.78(7.65)	102	-5.34(7.78)		-0.44 [-0.73, -0.16]
Subtotal (95% CI)	94		102		-	-0.44 [-0.73, -0.16]
Test for heterogeneity: not ap						
Test for overall effect: Z = 3.0	07 (P = 0.002)					
Total (95% CI)	370		348		•	-0.43 [-0.58, -0.28]
Test for heterogeneity: Chi² =						
Test for overall effect: $Z = 5.5$	59 (P < 0.00001)				
					-1 -0.5 0 0.5	1
					Favours SSRI Favours Plac	eho

Review: OCD children: SSRIs

01 SSRI vs placebo (acute phase) 11 NIMH-OC Comparison:


Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine						
Geller 2001	71	-3.10(3.00)	32	-1.30(2.20)	←	-0.64 [-1.07, -0.22]
Liebowitz 2002	21	6.24(2.45)	22	7.18(2.75)	-	-0.35 [-0.96, 0.25]
Subtotal (95% CI)	92		54			-0.55 [-0.89, -0.20]
Test for heterogeneity: Chi ²	= 0.59, df = 1 (P	$= 0.44$), $I^2 = 0\%$				•
Test for overall effect: Z = 3	3.07 (P = 0.002)					
02 Fluvoxamine						
Riddle 2001	57	7.50(3.20)	63	8.30(2.60)		-0.27 [-0.63, 0.09]
Subtotal (95% CI)	57		63			-0.27 [-0.63, 0.09]
Test for heterogeneity: not a	applicable				_	
Test for overall effect: $Z = 1$	1.49 (P = 0.14)					
03 Sertraline						
March 1998	92	-2.20(2.78)	95	-1.30(2.63)		-0.33 [-0.62, -0.04]
Subtotal (95% CI)	92		95			-0.33 [-0.62, -0.04]
est for heterogeneity; not a	applicable				_	
Test for overall effect: Z = 2	2.25 (P = 0.02)					
Total (95% CI)	241		212		•	-0.38 [-0.57, -0.19]
Test for heterogeneity: Chi²	= 1.91, df = 3 (P	= 0.59), I ² = 0%			-	
Test for overall effect: Z = 3	3.93 (P < 0.0001)					
					-1 -0.5 0 0.5	1

Favours SSRI Favours Placebo

Comparison: 01 SSRI vs placebo (acute phase)

12 Child Obsessive Compulsive Impact Scale (Parent Version) Outcome:



OCD children: SSRIs Review:

01 SSRI vs placebo (acute phase) Comparison:

Outcome: 13 Leyton Obsessional Inventory (Child Version): interference

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			O (fixed) 5% Cl		SMD (fixed) 95% Cl	
01 Fluoxetine										
Riddle 1992	7	20.60(19.40)	6	21.00(19.30)			•		-0.02 [-1.11, 1.07]	
Subtotal (95% CI)	7		6						-0.02 [-1.11, 1.07]	
Test for heterogeneity: not	applicable						T			
Test for overall effect: Z =	0.03 (P = 0.97)									
					-4	-2	<u> </u>	2	4	

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Review: OCD children: SSRIs

Comparison: 01 SSRI vs placebo (acute phase)

14 Leyton Obsessional Inventory (Child Version): resistance Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	MD (fixed) 95% CI			SMD (fixed) 95% CI
01 Fluoxetine										
Riddle 1992	7	19.60(14.40)	6	22.00(23.10)		_	_			-0.12 [-1.21, 0.97]
Subtotal (95% CI)	7		6			-	-			-0.12 [-1.21, 0.97]
Test for heterogeneity: not	applicable						7			
Test for overall effect: Z =	0.21 (P = 0.83)									
					-4	-2	-	<u>;</u>	4	

OCD children: SSRIs Review:

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 15 Leyton Obsessional Inventory (Child Version): symptoms

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	SMD (fixed) 95% CI			SMD (fixed) 95% Cl
01 Fluoxetine Riddle 1992 Subtotal (95% CI) Test for heterogeneity: not	7 7	16.30(8.40)	6 6	13.80(12.10)			-	-		0.23 [-0.87, 1.32] 0.23 [-0.87, 1.32]
Test for overall effect: Z =										
					-4	-2	Ó	2	4	

Review: OCD children: SSRIs

Comparison:

01 SSRI vs placebo (acute phase) 16 Children's Depression Rating Scale (Revised Version) Outcome:

01 Fluvoxamine Riddle 2001 57 27.40(8.00) 63 27.10(8.00 Subtotal (95% CI) 57 63	0.04 [-0.32, 0.40]
	0.04 [-0.32 0.40]
Subtotal (95% CI) 57 63	
	0.04 [-0.32, 0.40]
Test for heterogeneity: not applicable	
Test for overall effect: Z = 0.20 (P = 0.84)	

OCD children: SSRIs Review:

Comparison: 01 SSRI vs placebo (acute phase) Outcome: 17 Hamilton Rating Scale for Depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		(fixed) % Cl	SMD (fixed) 95% CI
O1 Fluoxetine Liebowitz 2002 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		9.14(6.56)	22 22	7.09(7.39)		-	0.29 [-0.31, 0.89] 0.29 [-0.31, 0.89]
					-1 -0.5 Favours SSRI	0 0.5 1 Favours Placebo	

Comparison: 01 SSRI vs placebo (acute phase) Outcome: 18 Depression (CDRS; HRSD)

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		SMD (fixe 95% CI	d)	SMD (fixed) 95% Cl
01 Fluoxetine								
Liebowitz 2002	21	9.14(6.56)	22	7.09(7.39)				0.29 [-0.31, 0.89]
Subtotal (95% CI)	21		22					0.29 [-0.31, 0.89]
Test for heterogeneity: not	t applicable					-		
Test for overall effect: Z =	0.94 (P = 0.35)							
02 Fluvoxamine								
Riddle 2001	57	27.40(8.00)	63	27.10(8.00)				0.04 [-0.32, 0.40]
Subtotal (95% CI)	57		63			-		0.04 [-0.32, 0.40]
Test for heterogeneity: not	t applicable					T		
Test for overall effect: Z =	0.20 (P = 0.84)							
Total (95% CI)	78		85					0.10 [-0.20, 0.41]
Test for heterogeneity: Ch	i ² = 0.49, df = 1 (P	= 0.48), I ² = 0%					_	
Test for overall effect: Z =								
					-1 -0		0.5	
					-1 -0	i.5 U	0.5	1
					Favo	urs SSRI Fa	vours placebo	

Review: OCD children: SSRIs

Comparison:

01 SSRI vs placebo (acute phase) 19 Multidimensional Anxiety Scale for Children Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine Geller 2001 Subtotal (95% CI)	71 71	-9.00(18.60)	32 32	-4.50(16.50)	-	-0.25 [-0.67, 0.17] -0.25 [-0.67, 0.17]
Test for heterogeneity: not a Test for overall effect: Z = 1					1 -05 0 05	

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours placebo

OCD children: SSRIs 01 SSRI vs placebo (acute phase) Review: Comparison:

Outcome: 20 Revised Children's Manifest Anxiety Scale

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine							
Riddle 1992	6	45.70(13.30)	5	40.20(16.90)			0.34 [-0.86, 1.53]
Subtotal (95% CI)	6		5				0.34 [-0.86, 1.53]
Test for heterogeneity: not	: applicable					_	
Test for overall effect: Z =	0.55 (P = 0.58)						
					4	5 1 5	1

Review: OCD children: SSRIs

01 SSRI vs placebo (acute phase) 21 Anxiety (MASC; RCMAS) Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Fluoxetine										
Geller 2001	71	-9.00(18.60)	32	-4.50(16.50)			-			-0.25 [-0.67, 0.17]
Riddle 1992	6	45.70(13.30)	5	40.20(16.90)		-	ᢇ.			0.34 [-0.86, 1.53]
Subtotal (95% CI)	77		37				•			-0.19 [-0.58, 0.21]
Test for heterogeneity: Chi	i ² = 0.81, df = 1 (P	= 0.37), I ² = 0%					٦			•
Test for overall effect: Z =	0.92 (P = 0.36)									
-					-4	-2	_	÷ -	4	

OCD children: SSRIs

01 SSRI vs placebo (acute phase) 22 Children's Global Assessment Scale Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	SMD (fixed 95% CI)		SMD (fixed) 95% CI
O1 Fluoxetine Riddle 1992 Sulototal (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.		70.40(13.20)	6 6	62.00(8.40)			-	-		0.69 [-0.44, 1.83] 0.69 [-0.44, 1.83]
					-4	-2	ö	2	4	
						Favours S	SRI Fav	ours Place	ebo	

01 SSRI vs placebo (acute phase) 23 Systolic blood pressure - supine Comparison: Outcome:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Sertraline v Placebo (at 1 v	week)					
March 1998	92	108.50(12.50)	95	107.60(10.60)	<u>=</u>	0.08 [-0.21, 0.36]
Subtotal (95% CI)	92		95		∓	0.08 [-0.21, 0.36]
Test for heterogeneity: not ap	plicable					
Test for overall effect: $Z = 0.5$	3 (P = 0.60)					
02 Sertraline v Placebo (at 4 v	weeks)					
March 1998	92	108.10(12.10)	95	107.00(11.00)	<u> </u>	0.09 [-0.19, 0.38]
Subtotal (95% CI)	92		95			0.09 [-0.19, 0.38]
Test for heterogeneity: not ap	plicable				ſ	
Test for overall effect: $Z = 0.6$	65 (P = 0.52)					
03 Sertraline v Placebo (at 12	weeks)					
March 1998	92	107.00(11.00)	95	107.40(10.60)	<u> </u>	-0.04 [-0.32, 0.25]
Subtotal (95% CI)	92		95			-0.04 [-0.32, 0.25]
Test for heterogeneity: not ap	plicable					
Test for overall effect: $Z = 0.3$	25 (P = 0.80)					

Favours sertraline Favours placebo

Favours sertraline Favours placebo

Review:

OCD children: SSRIs 01 SSRI vs placebo (acute phase) 24 Systolic blood pressure - standing Comparison: Outcome:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Sertraline v Placebo (at 1	week)					
March 1998	92	108.40(11.00)	95	107.40(10.90)	<u>=</u>	0.09 [-0.20, 0.38]
Subtotal (95% CI)	92		95		T	0.09 [-0.20, 0.38]
Test for heterogeneity: not a	pplicable				ĺ	
Test for overall effect: $Z = 0$.62 (P = 0.53)					
02 Sertraline v Placebo (at 4	weeks)					
March 1998	92	106.20(11.40)	95	107.20(11.70)	<u> </u>	-0.09 [-0.37, 0.20]
Subtotal (95% CI)	92		95		▼	-0.09 [-0.37, 0.20]
Test for heterogeneity: not a	pplicable					
Test for overall effect: $Z = 0$.59 (P = 0.56)					
03 Sertraline v Placebo (at 1	2 weeks)					
March 1998	92	105.80(10.80)	95	107.10(10.90)	<u>=</u>	-0.12 [-0.41, 0.17]
Subtotal (95% CI)	92		95		₹	-0.12 [-0.41, 0.17]
Test for heterogeneity: not a	pplicable				1	•
Test for overall effect: $Z = 0$.81 (P = 0.42)					

Review: OCD children: SSRIs

Comparison: 01 SSRI vs placebo (acute phase) Outcome: 25 Diastolic blood pressure - supine

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)		:	SMD (fixed) 95% Cl	ı		SMD (fixed) 95% Cl
	k)									
March 1998	92	64.80(8.50)	95	64.40(10.20)						0.04 [-0.24, 0.33]
Subtotal (95% CI)	92		95				•			0.04 [-0.24, 0.33]
Test for heterogeneity: not applicate	able									
Test for overall effect: $Z = 0.29$ (F	P = 0.77)									
02 Sertraline v Placebo (at 4 wee	ks)									
March 1998	92	63.00(8.70)	95	63.80(9.40)						-0.09 [-0.37, 0.20]
Subtotal (95% CI)	92		95				- ▼			-0.09 [-0.37, 0.20]
Test for heterogeneity: not applica	able									
Test for overall effect: $Z = 0.60$ (F	P = 0.55)									
03 Sertraline v Placebo (at 12 we	eks)									
March 1998	92	63.70(10.90)	95	64.50(8.80)						-0.08 [-0.37, 0.21]
Subtotal (95% CI)	92		95				- ₹			-0.08 [-0.37, 0.21]
Test for heterogeneity: not applicate	able]			
Test for overall effect: $Z = 0.55$ (F	P = 0.58)									
					-10	-5	- 6	5	10	
					Favo	urs sertra	aline Fav	ours place	ebo	

01 SSRI vs placebo (acute phase) 26 Diastolic blood pressure - standing Comparison: Outcome:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Sertraline v Placebo (at 1	week)					
March 1998	92	67.60(9.40)	95	67.70(10.60)	<u> </u>	-0.01 [-0.30, 0.28]
Subtotal (95% CI)	92		95			-0.01 [-0.30, 0.28]
Test for heterogeneity: not a	applicable]	
Test for overall effect: $Z = 0$	0.07 (P = 0.95)					
02 Sertraline v Placebo (at 4	weeks)					
March 1998	92	67.20(10.60)	95	67.40(9.80)	<u> </u>	-0.02 [-0.31, 0.27]
Subtotal (95% CI)	92		95		▼	-0.02 [-0.31, 0.27]
Test for heterogeneity: not a	applicable					
Test for overall effect: $Z = 0$).13 (P = 0.89)					
03 Sertraline v Placebo (at 1	2 weeks)					
March 1998	92	67.10(9.20)	95	67.80(8.90)	<u> </u>	-0.08 [-0.36, 0.21]
Subtotal (95% CI)	92		95			-0.08 [-0.36, 0.21]
Test for heterogeneity: not a	applicable				Ī	•
Test for overall effect: $Z = 0$).53 (P = 0.60)					

Favours sertraline Favours placebo

Favours sertraline Favours placebo

Review:

OCD children: SSRIs 01 SSRI vs placebo (acute phase) 27 Heart rate - supine Comparison:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1	I week)					
March 1998	92	75.40(12.70)	95	77.80(13.00)	<u>=</u>	-0.19 [-0.47, 0.10]
Subtotal (95% CI)	92		95		∓	-0.19 [-0.47, 0.10]
Test for heterogeneity: not a	applicable					
Test for overall effect: $Z = 1$	1.27 (P = 0.20)					
02 Sertraline v Placebo (at 4	4 weeks)					
March 1998	92	76.90(11.50)	95	78.10(11.80)	<u>=</u>	-0.10 [-0.39, 0.18]
Subtotal (95% CI)	92		95			-0.10 [-0.39, 0.18]
Fest for heterogeneity: not a	applicable					
Test for overall effect: $Z = 0$	0.70 (P = 0.48)					
D3 Sertraline v Placebo (at 1	12 weeks)					
March 1998	92	77.30(9.80)	95	78.40(13.00)	<u>=</u>	-0.09 [-0.38, 0.19]
Subtotal (95% CI)	92		95			-0.09 [-0.38, 0.19]
Fest for heterogeneity: not a	applicable					,
Test for overall effect: Z = 0						

Review: OCD children: SSRIs 01 SSRI vs placebo (acute phase) 28 Heart rate - standing Comparison:

Outcome:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)		5	SMD (fixed) 95% CI)		SMD (fixed) 95% Cl
D1 Sertraline v Placebo (at 1	week)									
March 1998	92	81.40(13.90)	95	86.10(13.30)						-0.34 [-0.63, -0.06]
Subtotal (95% CI)	92		95				•			-0.34 [-0.63, -0.06]
Test for heterogeneity: not ap	pplicable						1			
Test for overall effect: $Z = 2$.	.34 (P = 0.02)									
02 Sertraline v Placebo (at 4	weeks)									
March 1998	92	83.90(13.80)	95	84.50(12.00)						-0.05 [-0.33, 0.24]
Subtotal (95% CI)	92		95				- ▼			-0.05 [-0.33, 0.24]
Test for heterogeneity: not ap	pplicable									
Test for overall effect: $Z = 0$.	.32 (P = 0.75)									
03 Sertraline v Placebo (at 10	2 weeks)									
March 1998	92	85.10(12.10)	95	86.20(15.30)						-0.08 [-0.37, 0.21]
Subtotal (95% CI)	92		95				- ▼			-0.08 [-0.37, 0.21]
Test for heterogeneity: not a	pplicable						1			
Test for overall effect: $Z = 0$.	.54 (P = 0.59)									
					-10	-5	6	5	10	
					Favou	ırs sentra	aline Fav	ours place	ebo	

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 29 Suicidality (Columbia reclassification - "Outcome 3: definitive suicidal behaviour/ ideation")

itudy r sub-category	Treatment n/N	Control n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
1 Fluoxetine				
Geller 2001	1/71	0/32		1.38 [0.06, 32.87]
Subtotal (95% CI)	71	32		1.38 [0.06, 32.87]
otal events: 1 (Treatment), 0 (Co				
est for heterogeneity: not applica est for overall effect: Z = 0.20 (P				
,	,			
2 Fluvoxamine Riddle 2001	2/57	0/63	_	→ 5.52 [0.27, 112.55]
ubtotal (95% CI)	2/57 57	63		- 5.52 [0.27, 112.55]
otal events: 2 (Treatment), 0 (Co		63		- 5.52 [0.27, 112.55]
est for heterogeneity: not applica				
est for overall effect: Z = 1.11 (P				
3 Paroxetine				
Seller 2004	1/99	0/107		3.24 [0.13, 78.62]
ubtotal (95% CI)	99	107		3.24 [0.13, 78.62]
otal events: 1 (Treatment), 0 (Co	ntrol)		T	, ,
est for heterogeneity: not applica				
est for overall effect: Z = 0.72 (P	P = 0.47)			
4 Sertraline				
farch 1998	0/92	1/95		0.34 [0.01, 8.34]
ubtotal (95% CI)	92	95		0.34 [0.01, 8.34]
otal events: 0 (Treatment), 1 (Co				
est for heterogeneity: not applica				
est for overall effect: Z = 0.66 (P	P = 0.51)			
otal (95% CI)	319	297		1.81 [0.46, 7.13]
otal events: 4 (Treatment), 1 (Co	ntrol)		1-	•
est for heterogeneity: Chi² = 1.72				
est for overall effect: Z = 0.84 (P) = 0.40)			
		0.0	1 0.1 1 10 1	100
			Favours treatment Favours control	

Review: OCD children: SSRIs

Comparison: 02 SSRI vs placebo (continuation phase)

Outcome: 01 Adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
01 Fluoxetine						
Liebowitz 2002	3/11	0/7		4.67 [0.28, 78.68]		
Subtotal (95% CI)	11	7		4.67 [0.28, 78.68]		
Total events: 3 (SSRI), 0 (Place	cebo)		- -			
Test for heterogeneity; not as	pplicable					
Test for overall effect: $Z = 1$.	07 (P = 0.29)					
			0.01 0.1 1 10 100			
			Favours SSRI Favours Placebo			

Review: OCD children: SSRIs


Comparison: 02 SSRI vs placebo (continuation phase)

Outcome: 02 Leaving study early

RR (fixed) 95% Cl
1.85 [0.09, 40.05] 1.85 [0.09, 40.05]

02 SSRI vs placebo (continuation phase) 03 CY-BOCS Comparison:

Outcome:



OCD children: SSRIs Review:

Comparison: 02 SSRI vs placebo (continuation phase)

Outcome: 04 NIMH-OC

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		s	MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Fluoxetine										
Liebowitz 2002	11	3.73(1.74)	7	5.43(3.10)			-			-0.69 [-1.67, 0.29]
Subtotal (95% CI)	11		7				•			-0.69 [-1.67, 0.29]
Test for heterogeneity: not	t applicable						1			
Test for overall effect: Z =	1.38 (P = 0.17)									
					-10	-5	-	5	10	

Review: OCD children: SSRIs

Comparison: 02 SSRI vs placebo (continuation phase)

05 Child Obsessive Compulsive Impact Scale (Parent version) Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	MD (fixed 95% CI	1)		SMD (fixed) 95% Cl
01 Fluoxetine										
Liebowitz 2002	11	23.00(20.57)	7	49.29(32.70)						-0.97 [-1.98, 0.04]
Subtotal (95% CI)	11		7				∓			-0.97 [-1.98, 0.04]
Test for heterogeneity: not	t applicable									
Test for overall effect: Z =	: 1.88 (P = 0.06)									
					-100	-50	-	50	100	

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

OCD children: SSRIs Review:

Comparison: 02 SSRI vs placebo (continuation phase) Outcome: 06 Hamilton Rating Scale for Depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		8	SMD (fixed 95% CI)		SMD (fixed) 95% Cl
01 Fluoxetine										
Liebowitz 2002	11	4.64(6.14)	7	7.14(5.24)			-			-0.41 [-1.37, 0.55]
Subtotal (95% CI)	11		7				•			-0.41 [-1.37, 0.55]
Test for heterogeneity: not	applicable						1			
Test for overall effect: Z =	0.84 (P = 0.40)									
					-10	-5	-	5	10	
						Favours S	SRI Fav	ours Plac	ebo	

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)

Outcome: 01 Adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl						
Carpenter 1999	73/95	80/98	-	0.94 [0.81, 1.09]						
Total (95% CI) Total events: 73 (Paroxetine Test for heterogeneity: not a Test for overall effect: Z = 0	applicable	98		0.94 [0.81, 1.09]						
		0.	.5 0.7 1 1.5	2						
	Favours Paroxetine Favours Placebo									

Comparison: 03 SSRIs vs placebo (discontinuation)

Outcome: 02 Serious adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% CI	RR (fixed) 95% Cl					
Carpenter 1999	2/95	2/98		1.03 [0.15, 7.18]					
Total (95% CI) Total events: 2 (Paroxetine), Test for heterogeneity: not a Test for overall effect: Z = 0	pplicable	98		1.03 [0.15, 7.18]					
			0.1 0.2 0.5 1 2 5 10)					
	Favours Paroxetine Favours Placebo								

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)

Outcome: 03 Leaving the study early

Study or sub-category	Paroxetine n/N	Placebo n/N		RR (fixed) 95% Cl		RR (fixed) 95% Cl
Carpenter 1999	54/96	65/98	-	+		0.85 [0.68, 1.06]
Total (95% CI) Total events: 54 (Paroxetine Test for heterogeneity: not a Test for overall effect: Z = 1	applicable	98	-	+		0.85 [0.68, 1.06]
		C	0.5 0.7	1 1.5	5 2	

Favours Paroxetine Favours Placebo

Favours Paroxetine Favours Placebo

Favours Paroxetine Favours Placebo

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)

Outcome: 04 Leaving the study early due to adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
Carpenter 1999	8/95	11/98		0.75 [0.32, 1.78]
Total (95% CI) Total events: 8 (Paroxetine), Test for heterogeneity: not a Test for overall effect: Z = 0	pplicable	98		0.75 [0.32, 1.78]
		0.	1 0.2 0.5 1 2 5	10

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 05 Non-responders (25% CY-BOCS)

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Carpenter 1999	72/96	85/98	-	0.86 [0.75, 0.99]
Total (95% CI) Total events: 72 (Paroxetine Test for heterogeneity: not a Test for overall effect: Z = 2	applicable	98	-	0.86 [0.75, 0.99]
		0	.5 0.7 1	1.5 2

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)


Outcome: 06 Non-responders (CGI Global Improvement < "much improved")

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl		RR (fixed) 95% Cl
Carpenter 1999	42/96	55/98			0.78 [0.59, 1.04]
Total (95% Cl) Total events: 42 (Paroxetine) Test for heterogeneity: not a Test for overall effect: Z = 1	pplicable	98			0.78 [0.59, 1.04]
			0.5 0.7 1	1.5 2	

OCD children: SSRIs Review:

03 SSRIs vs placebo (discontinuation) Comparison:

07 Relapse (CGI Global Improvement score increase) Outcome:



Favours Paroxetine Favours Placebo

Review:

OCD children: SSRIs 03 SSRIs vs placebo (discontinuation) 08 CY-BOCS Comparison: Outcome:

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)			(fixed) % Cl		SMD (fixed) 95% Cl
Carpenter 1999	92	3.60(8.82)	98	6.90(8.51)			•		-0.38 [-0.67, -0.09]
Total (95% CI) Test for heterogeneity: not			98				•		-0.38 [-0.67, -0.09]
Test for overall effect: Z =	2.59 (P = 0.010)				-10	- - 5	0	5	10

Favours treatment Favours control OCD children: SSRIs

Review:

Comparison: 03 SSRIs vs placebo (discontinuation) Outcome: 09 Hamilton Rating Scale for Depression

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% Cl
Carpenter 1999	92	1.90(4.80)	98	3.10(5.64)			•			-0.23 [-0.51, 0.06]
Total (95% CI) Test for heterogeneity: not	92 applicable		98				+			-0.23 [-0.51, 0.06]
Test for overall effect: Z =	1.56 (P = 0.12)									
					-10	-5	Ó	5	10	

Favours treatment Favours control

Review:

OCD children: SSRIs 03 SSRIs vs placebo (discontinuation) Comparison: Outcome: 10 Hamilton Rating Scale for Anxiety

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)) (fixed) 5% Cl			SMD (fixed) 95% Cl
Carpenter 1999	92	1.80(5.08)	98	3.10(5.74)						-0.24 [-0.52, 0.05]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.6			98				•			-0.24 [-0.52, 0.05]
					-10	-5	Ó	5	10	

Favours treatment Favours control


OCD children: SSRIs Review:

Comparison: 03 SSRIs vs placebo (discontinuation) Outcome: 11 Global Assessment of Functioning

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)		:	SMD (fixed 95% CI	1)		SMD (fixed) 95% CI
Carpenter 1999	93	-5.80(11.77)	98	-8.10(12.47)			-			0.19 [-0.10, 0.47]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			98				•			0.19 [-0.10, 0.47]
					-10	-5	0	5	10	

Clomipramine (OCD, children)

Review: OCD children: Clomipramine Comparison: 01 Clomipramine vs placebo 01 Leaving study early Outcome:



Review: OCD children: Clomipramine Comparison: 01 Clomipramine vs placebo

Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Clomipramine n/N	Placebo n/N		R (fixed) 95% Cl	RR (fixed) 95% Cl
DeVeaugh-Geiss 1992	2/31	0/29	_		— 4.69 [0.23, 93.70]
March 1990	1/8	0/8		-	3.00 [0.14, 64.26]
Total (95% CI)	39	37			3.86 [0.45, 32.80]
Total events: 3 (Clomipramine),	0 (Placebo)			- - -	
Test for heterogeneity: Chi ² = 0	.04, df = 1 (P = 0.84), I ² = 0%				
Test for overall effect: Z = 1.24	(P = 0.22)				
		0.0	1 0.1	1 10	100

Favours Clomipramine

Favours Placebo

Favours Clomipramine Favours Placebo

OCD children: Clomipramine Review: Comparison: 01 Clomipramine vs placebo

Outcome: 03 Y-BOCS

Study or sub-category	N	Clomipramine Mean (SD)	N	Placebo Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
March 1990	8	19.30(8.60)	8	25.60(2.40)		-	\vdash			-0.94 [-1.99, 0.11]
Total (95% Cl) Test for heterogeneity: not Test for overall effect: Z =			8			⋖				-0.94 [-1.99, 0.11]
					-4	-2	ö	2	4	

Review: OCD children: Clomipramine Comparison: Outcome: 01 Clomipramine vs placebo 04 NIMH-OC

Study or sub-category	N	Clomipramine Mean (SD)	N	Placebo Mean (SD)			(fixed) % Cl			SMD (fixed) 95% Cl
March 1990	8	7.20(2.70)	8	9.50(1.90)		-	-			-0.93 [-1.98, 0.12]
Total (95% Cl) Test for heterogeneity: not ap Test for overall effect: Z = 1.7			8			-	-			-0.93 [-1.98, 0.12]
					-4	-2	Ó	2	4	
					Favours	Clomipramine	Favou	urs Placel	00	

OCD children: Clomipramine Review:

02 Clomipramine continuation vs Desipramine substitution Comparison:


Outcome: 01 Leaving study early

Study or sub-category	Clomipramine n/N	Desipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Leonard 1991a	0/11	1/10		0.31 [0.01, 6.74]
Total (95% CI) Total events: 0 (Clomipramir Test for heterogeneity: not a Test for overall effect: Z = 0	applicable	10		0.31 [0.01, 6.74]
		(0.01 0.1 1 10	100
		F	avours Clomipramine Favours Desipra	mine

OCD children: Clomipramine Review:

Comparison: 02 Clomipramine continuation vs Desipramine substitution

02 Relapse (Physician's Relapse Scale) Outcome:



Favours Clomipramine Favours Desipramine

OCD children: Clomipramine Review:

Comparison: Outcome: 02 Clomipramine continuation vs Desipramine substitution

03 Comprehensive Psychopathological Rating Scale: obsessive-compulsive

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)		SMD (fixed 95% CI)	SMD (fixed) 95% CI
Leonard 1991a	11	5.20(4.00)	9	6.30(3.30)		-		-0.28 [-1.17, 0.60]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			9					-0.28 [-1.17, 0.60]
					_	'	$\overline{}$	4

Favours Clomipramine Favours Desipramine

Review: OCD children: Clomipramine

Comparison: 02 Clomipramine continuation vs Desipramine substitution

Outcome: 04 NIMH-OC

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)			D (fixed) 15% Cl			SMD (fixed) 95% Cl
Leonard 1991a	11	5.00(2.30)	9	5.80(0.40)		-	-			-0.44 [-1.34, 0.45]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z = I			9			- ◀				-0.44 [-1.34, 0.45]
					-4	-2	ò	2	4	

Favours Clomipramine Favours Desipramine

Pharmacological (BDD)

Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo Outcome: 01 Adverse effects

Study or sub-category	Fluoxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Phillips 2002b	28/34	21/33	-	1.29 [0.96, 1.75]
Total (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 1.68 (21/33		1.29 [0.96, 1.75]
		0.5	0.7 1 1.5	2

Favours Fluoxetine Favours Placebo

Favours Placebo

Favours Placebo

Favours Placebo

Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo Outcome: 02 Leaving study early

Study or sub-category	Fluoxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Phillips 2002b	3/34	5/33		0.58 [0.15, 2.24]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0		5/33		0.58 [0.15, 2.24]
			0.1 0.2 0.5 1 2 5	10

Favours Fluoxetine

Favours Fluoxetine

Favours Fluoxetine

Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo

Outcome: 03 Leaving study early due to adverse effects

Study or sub-category	Fluoxetine n/N	Placebo n/N	RR (fi 95%	,	RR (fixed) 95% Cl
Phillips 2002b	0/34	0/33			Not estimable
Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/0	0/0			Not estimable
		0.1	0.2 0.5 1	2 5 10	


Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo Outcome: 04 Non-responders

Study or sub-category	Fluoxetine n/N	Placebo n/N	,	fixed) % Cl	RR (fixed) 95% CI
Phillips 2002b	16/34	27/33	-		0.58 [0.39, 0.85]
Total (95% CI) Test for heterogeneity: not appl Test for overall effect: Z = 2.77		27/33	-		0.58 [0.39, 0.85]
		0	2 0.5	1 2	5

Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo

Outcome: 05 BDD-YBOCS



Review: BDD: pharmacological interventions 01 Fluoxetine vs placebo 06 BDD-NIMH Comparison:

Outcome:

Study or sub-category	N	Fluoxetine Mean (SD)	N	Placebo Mean (SD)		(fixed) % Cl	SMD (fixed) 95% CI
Phillips 2002b	34	6.60(3.00)	33	7.90(2.20)			-0.49 [-0.97, 0.00]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			33		-	-	-0.49 [-0.97, 0.00]
					-1 -0.5	0 0.5	i
					Favours Fluoxetine	Favours Placebo	

BDD: pharmacological interventions 01 Fluoxetine vs placebo 07 Hamilton Rating Scale for Depression Review:

Comparison:

Outcome:

tudy r sub-category	N	Fluoxetine Mean (SD)	N	Placebo Mean (SD)			(fixed) % Cl			SMD (fixed) 95% Cl	
Phillips 2002b	34	12.50(10.10)	33	19.50(10.50)		-				-0.67 [-1.16, -0.18]	
otal (95% Cl) est for heterogeneity: not a est for overall effect: Z = 2			33			•				-0.67 [-1.16, -0.18]	
et for overall effect: Z = Z	2.67 (P = 0.008)				-4	-2	<u> </u>	2	4		

Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo

08 Global Assessment of Functioning Scale Outcome:

Study or sub-category	N	Fluoxetine Mean (SD)	N	Placebo Mean (SD)		SMD (fi 95%		SMD (fixed) 95% Cl
Phillips 2002b	34	-68.90(15.70)	33	-57.00(12.30)		-		-0.83 [-1.33, -0.33]
Total (95% Cl) Test for heterogeneity: not Test for overall effect: Z =			33			•		-0.83 [-1.33, -0.33]
					-4	-2 0	2	1

Favours Fluoxetine Favours Placebo

Favours Fluoxetine Favours Placebo

BDD: pharmacological interventions Review:

Comparison: 01 Fluoxetine vs placebo

09 Social & Occupational Functioning Scale Outcome:

Study or sub-category	N	Fluoxetine Mean (SD)	N	Placebo Mean (SD)		S	MD (fixed 95% CI	d)		SMD (fixed) 95% CI
Phillips 2002b	34	-71.10(17.80)	33	-59.90(14.60)		+	-			-0.68 [-1.17, -0.19]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 2			33			•	•			-0.68 [-1.17, -0.19]
					-4	-2	ó	ż	4	
					Favo	urs Fluoxet	ine Fa	vours Place	ebo	

Review: BDD: pharmacological interventions 02 Clomipramine v Desipramine 01 BDD-YBOCS at 8 weeks Comparison: Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)			(fixed) 5% Cl			SMD (fixed) 95% CI
Hollander 1999	12	17.41(6.85)	11	23.14(7.86)		-	+			-0.75 [-1.60, 0.10]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.			11			-	•			-0.75 [-1.60, 0.10]
					-4	-2	ò	2	4	
						Favours CMI	Favo	ours DMI		

BDD: pharmacological interventions Review: Comparison: 02 Clomipramine v Desipramine Outcome: 02 NIMH-BDD at 8 weeks

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)			(fixed) % Cl		SMD (fixed) 95% Cl
Hollander 1999	12	5.92(1.83)	11	9.09(2.35)		-			-1.46 [-2.40, -0.52]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 3			11			•			-1.46 [-2.40, -0.52]
					-4	-2 Favours CMI	5 2 Favours DMI	4	

Review: BDD: pharmacological interventions 02 Clomipramine v Desipramine 03 HAM-D at 8 weeks Comparison:

Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% Cl	
Hollander 1999	12	9.42(7.89)	11	14.64(5.61)		-	\vdash			-0.73 [-1.58, 0.12]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1			11			- ◀				-0.73 [-1.58, 0.12]
					-4	-2	ó	2	4	

Favours CMI Favours DMI

Favours Pimozide Favours Placebo

Favours Pimozide Favours Placebo

Review: BDD: pharmacological interventions

Comparison: 03 Pimozide v Placebo

01 Non-responders (Y-BOCS 30%) Outcome:

Study or sub-category	Pimozide n/N	Placebo n/N	RR (fi) 95%			RR (fixed) 95% Cl
Phillips_in press	9/11	14/17	-	_		0.99 [0.70, 1.42]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 0.0	•	14/17	•	-		0.99 [0.70, 1.42]
		0.2	0.5 1	2	5	

Review: BDD: pharmacological interventions

03 Pimozide v Placebo Comparison:

Outcome: 02 Leaving the study early

Study or sub-category	Pimozide n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Phillips_in press	6/11	13/17		0.71 [0.39, 1.30]
Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 1.10 (P = 0.	6/11 27)	13/17		0.71 [0.39, 1.30]
		0	.2 0.5 1 2	-

BDD: pharmacological interventions Review:

Comparison: 03 Pimozide v Placebo

Outcome: 03 Y-BOCS

Study or sub-category	N	Pimozide Mean (SD)	N	Placebo Mean (SD)		random) % Cl
Phillips_in press	11	23.90(6.60)	17	28.00(7.80)	-4.10 [-9.4	8, 1.28]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			17		-4.10 [-9.4	8, 1.28]
					-10 -5 0 5 10	
					Favours Pimozide Favours Placebo	

Review:

BDD: pharmacological interventions 03 Pimozide v Placebo 04 Brown Assessment of Beliefs Scale Comparison: Outcome:

Study or sub-category	N	Pimozide Mean (SD)	N	Placebo Mean (SD)		WMD (random) 95% Cl			WMD (random) 95% Cl	
Phillips_in press	11	13.50(7.30)	17	17.20(6.00)	_	-	+			-3.70 [-8.87, 1.47]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z = 1			17							-3.70 [-8.87, 1.47]
					-10	-5	Ó	5	10	
					Fau	oure Dimoz	ida Fas	oure Place	aho	

Review: BDD: pharmacological interventions Comparison: 03 Pimozide v Placebo

Outcome: 05 Hamilton Depression Rating Scale

Study or sub-category	N	Pimozide Mean (SD)	N	Placebo Mean (SD)		VVMD (random) 95% Cl			VVMD (random) 95% Cl	
Phillips_in press	11	17.90(5.60)	17	16.90(7.70)		_	-			1.00 [-3.93, 5.93]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			17				_	- -	ı	1.00 [-3.93, 5.93]
					-10	-5	ó	5	10	

Favours Pimozide Favours Placebo

Review: Comparison: BDD: pharmacological interventions 03 Pimozide v Placebo 06 Brief Psychiatric Rating Scale

Outcome:

